Protocol  I7S-MC-HBEH(b)   
 
Effect of LY3154207 on Cognition in Mild-to -Moderate Dementia Due to Lewy Body Dementia  
(LBD) Associated  with Idiopathic Parkinson’s Disease (PD) or Dementia with Lewy Bodies (DLB) 
(The PRESENCE Study)  
 
 
[STUDY_ID_REMOVED] 
 
Approval Date: 25 -Jan-2019 
 
 
I7S-MC-HBEH(b) Clinical Protocol Page 1
LY3154207Protocol I7S -MC-HBEH(b)
Effect of LY3154207 on Cognition in Mild- to-Moderate 
Dementia Due toLewy Body Dementia (LBD) A ssociated 
with Idiopathic Parkinson’s Disease (PD) or Dementia with 
Lewy Bodies (DLB)
(The PRESENCE Study )
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_824304]3154207, unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.
Note to Regulatory Authorities :  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation rega rding release/redaction prior to any public release.  In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY3154207
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_229490] : [ADDRESS_1143123] 2017
Amendm ent (a) Electronically Signed and Approved by [CONTACT_229490] : 14 February 2018
Amendm ent (b) Electronically Signed and Approved by [CONTACT_82356].
Approval Date: 25-Jan-2019 GMT
I7S-MC-HBEH(b) Clinical Protocol Page 2
LY3154207Table of Contents
Section Page
Protocol I7S-MC-HBEH(b) Effect of LY3154207 on Cognition in 
Mild-to-Moderate Dement ia Due to Lewy Body Dement ia (LBD) 
Associated with Idiopathic Parkinson’s Disease (PD) or Dement ia 
with Lewy Bodi es (DLB) .................................................................................................... [ADDRESS_1143124] ivities....................................................................................................... 14
3.Introduction ...................................................................................................................... 21
3.1.Study Rationale............................................................................................................ 21
3.2.Background .................................................................................................................. 21
3.3.Benefit/Risk Assessment .............................................................................................. 22
4.Objectives and Endpoints.................................................................................................. 24
5.Study Design..................................................................................................................... 27
5.1.Overall Design ............................................................................................................. 27
5.1.1. Screening Period (Visit 1).................................................................................... 28
[IP_ADDRESS] Screening Procedures ............................................................................................ 28
[IP_ADDRESS].1. BP and Pulse Rate ..................................................................................... 29
[IP_ADDRESS].2. CDR-CBB................................................................................................ 29
[IP_ADDRESS].3. Modified Hoehn and Yahr Scale ............................................................... 29
[IP_ADDRESS].4. Clinical Diagnostic Criteria for PD and DLB ............................................ 29
[IP_ADDRESS].5. Montreal Cognit ive Assessment Scale ....................................................... 30
[IP_ADDRESS].6. Geriatric Depressio n Scale Short Form ..................................................... 30
[IP_ADDRESS].7. Columbia-Suicide Severit y Rating Scale –Children’s 
Version..................................................................................................... 30
5.1.2. Pretreatment Period (Visit 2)................................................................................ 31
[IP_ADDRESS] Blood Pressure and Pulse Rate Measures .............................................................. 31
[IP_ADDRESS] Cognitive, Motor, and Funct ional Assessments ............................................... 31
[IP_ADDRESS] Actigraphy  and iPAD Device ................................................................................ 32
[IP_ADDRESS] Home Blood Pressure Monitoring ......................................................................... 32
5.1.3. Double-Blind Peri od (Visit3 through Visit 11).................................................... 32
[IP_ADDRESS]. Orthostatic BP/Pulse Rate Measurements ....................................................... 33
[IP_ADDRESS]. PK Sample...................................................................................................... 34
[IP_ADDRESS]. Home Blood Pressure Moni toring................................................................... 34
[IP_ADDRESS]. Visit 4 to Visit 11........................................................................................... 35
5.1.4. Telephone Visit (Visit 111) .................................................................................. 35
I7S-MC-HBEH(b) Clinical Protocol Page 3
LY31542075.1.5. Follow-Up Period (Visit 801)............................................................................... [ADDRESS_1143125] ions.................................................................................................... 43
6.4.Screen Fail ures............................................................................................................. 43
7.Treatments ........................................................................................................................ 44
7.1.Treatment s Administered ............................................................................................. 44
7.1.1. Packaging and Labeling ....................................................................................... 44
7.2.Method of Treatment Assignment ................................................................................ 45
7.3.Blinding....................................................................................................................... 45
7.4.Dosage Modification .................................................................................................... 45
7.5.Preparation/Handling/Storage/Accountabilit y............................................................... [ADDRESS_1143126] to Follow -Up........................................................................................................ 50
9.Study Assessments and Procedures ................................................................................... 51
9.1.Efficacy Assessments ................................................................................................... 51
9.1.1.Primary Efficacy  Assessments ............................................................................. 51
9.1.2. Secondary  Efficacy Assessments .......................................................................... 53
[IP_ADDRESS]. Measures of Cognit ive Function and Related Outcomes .................................53
[IP_ADDRESS].1. Alzheimer’s Disease Cooperative Study  –Clinician 
Global Impression of Change Scale .......................................................... 53
[IP_ADDRESS].2. Power of Attention Co mposite Score from the 
CDR-CCB................................................................................................ 53
I7S-MC-HBEH(b) Clinical Protocol Page 4
LY31542079.[IP_ADDRESS]. Alzheimer’s Disease Assessment Scale – 13-Item 
Cognitive Subscale ................................................................................... 53
[IP_ADDRESS].4. Delis–Kaplan Execut ive Function System................................................. 54
[IP_ADDRESS].5. Montreal Cognit ive Assessment Scale ....................................................... 54
[IP_ADDRESS].6. Penn Parkinson’s Daily Act ivities Questionnaire-15.................................56
[IP_ADDRESS]. Measures of Parkinson’s Disease Severit y...................................................... 56
[IP_ADDRESS].1. Movement Disorder Society’s United Parkinson’s 
Disease Rating Scale ................................................................................. 56
[IP_ADDRESS]. Measures of Behavioral Symptoms .................................................................56
[IP_ADDRESS].1. Neuropsychiatric Inventor y....................................................................... 56
[IP_ADDRESS].2. Epworth Sleepi[INVESTIGATOR_7110] ......................................................................... 57
[IP_ADDRESS].3. Questionnaire for Impulsive -Compulsive Disorders 
in Parkinson’s Disease .............................................................................. 58
9.1.3. Appropriateness of Efficacy  Assessments ............................................................ 58
9.2.Adverse Events ............................................................................................................ 58
9.2.1. Serious Adverse Events ........................................................................................ 59
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 60
9.2.2. Complaint Handling ............................................................................................. 60
9.3.Treatment of Overdose .................................................................................................60
9.4.Safety........................................................................................................................... 61
9.4.1. Electrocardiograms .............................................................................................. 61
9.4.2. Vital Signs........................................................................................................... 62
9.4.3. Laboratory Tests.................................................................................................. 63
9.4.4. Columbia-Suicide Severit y Rating Scale –Children’s 
Version................................................................................................................ [ADDRESS_1143127] ........................................................................... 63
9.4.6. Safety Monitoring................................................................................................ 64
[IP_ADDRESS]. Hepatic Safety Monitoring.............................................................................. 64
9.4.7. Appropriateness of Safet y Assessments ................................................................ 64
9.5.Pharmacokinet ics......................................................................................................... 64
9.6.Pharmacodynamics ...................................................................................................... 65
9.7.Pharmacogeno mics...................................................................................................... 65
9.7.1. Whole Blood Sample for Pharmacogenet ic Research ........................................... 65
9.8.Biomarkers................................................................................................................... 66
9.8.1. Digital Biomarkers............................................................................................... 66
[IP_ADDRESS]. Lilly Trial Application.................................................................................... 66
[IP_ADDRESS]. Actigraphy...................................................................................................... 66
9.9.Medical Resource Utilizat ion and Healt h Economics ................................................... 67
10.Statistical Considerations .................................................................................................. 68
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143128] ical Considerat ions........................................................................ 69
[IP_ADDRESS]. Handling of Missing Items for Scales ............................................................. 69
10.3.2. Treatment Group Comparabilit y........................................................................... 69
[IP_ADDRESS]. Time to Study  Disposition/Discontinuation ..................................................... 69
[IP_ADDRESS]. Protocol Deviations........................................................................................ 70
[IP_ADDRESS]. Subject Characterist ics.................................................................................... 70
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 70
[IP_ADDRESS]. Treatment Compliance .................................................................................... 70
10.3.3. Efficacy Analyses ................................................................................................ 70
[IP_ADDRESS]. Primary Analyses ........................................................................................... 70
[IP_ADDRESS]. Secondary  Efficacy Analyses .......................................................................... 71
[IP_ADDRESS]. Tertiary/Exploratory  Efficacy Analyses .......................................................... 71
10.3.4. Safety Analyses.................................................................................................... 71
[IP_ADDRESS]. Adverse Events ............................................................................................... 72
[IP_ADDRESS].Suicidal Ideation and Behavior ....................................................................... 72
[IP_ADDRESS]. Vital Signs and Weight ................................................................................... 73
[IP_ADDRESS]. Laboratory  Analyses ....................................................................................... 74
[IP_ADDRESS]. Electrocardiograms ......................................................................................... 74
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 74
10.3.6. Other Analyses ..................................................................................................... 75
[IP_ADDRESS].Subgroup Analyses ......................................................................................... 75
10.3.7. Interim Analyses .................................................................................................. 75
11.References ........................................................................................................................ 76
12.Appendices ....................................................................................................................... 83
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143129] ivities for Protocol  I7S-MC-HBEH....................................... 15
TableHBEH.2. Objectives and Endpo ints............................................................................... 24
TableHBEH.3. Potentially Clinically Si gnificant Vi tal Sign Criteria...................................... 34
TableHBEH.4. Vital Sign Inclusi on Criteria [6] for Subj ects at Visit 1 and Visit 3 (time 
0)................................................................................................................... 34
TableHBEH.5. Treatment Regimens ...................................................................................... 44
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143130] of Figures
Figure Page
FigureHBEH.1. Illustration of study design for Clinical Protocol I7S -MC-HBEH(b). .............27
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143131] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 84
Appendix 2. Clinical Laboratory  Tests............................................................................... 88
Appendix 3. Study Governance Considerat ions.................................................................. 89
Appendix 4. Hepatic Monitoring Tests for Treatment -Emergent Abnormalit y.................... 93
Appendix 5. MDS Diagnostic Criteria for Parkinson’s Disease –Red Flags and 
Supportive Criteria ........................................................................................ 94
Appendix 6. DLB Diagnostic Criteria ................................................................................ 97
Appendix 7. Protocol Amendment Summary  I7S-MC-HBEH(b) Effect of 
LY3154207 on Cognit ion in Mild-to-Moderate Dement ia Due to Lewy 
Body Dementia(LBD) Associated with Idiopathic Parkinson’s Disease 
(PD) or Dement ia with Lewy Bodies (DLB) (The PRESENCE Study) ..........98
I7S-MC-HBEH(b) Clinical Protocol Page 9
LY31542071.Synopsis
Title of Study:
Effect of LY3154207 on c ognition in mild-to-moderate dementia due toLewy Body Dementia
(LBD)associated with idiopathic Parkinson’s di sease (PD) or dem entia with Lewy bodies 
(DLB).
Rationale: 
Eli Lilly and Company  (Lilly) is developi[INVESTIGATOR_90721]3154207, an orally available, selective posit ive 
allosteric modulator (PAM, also called “potentiator”) of the dopam ine D1receptor subt ype 
(D1PAM). By [CONTACT_395514] y of dopamine for the D1 receptor, a D1PAM is 
hypothesized to amplify response to en dogenous dopamine, thereby [CONTACT_30212] D1 tone at the 
site of dopamine release , and represents a novel mechanism o f action.  By [CONTACT_824337] (or administered levodopa) in subjects wi th 
insufficient physio logic dopamine such as those with LBD(PDD orDLB), a D1PAM should 
improve cognit ive performance.  In addit ion, a D1PAM should have a positive impact on other 
domains affected by  [CONTACT_824338](PDD orDLB)including motor deficit s, mood, apathy , and daytime 
sleepi[INVESTIGATOR_008].
LY3154207 has been investigated in healthy subjects and subjectswith Parkinson’s disease .  
Study I7S-MC-HBEH (HBEH) is a multicenter, rando mized, double -blind, parallel -group, 
placebo-controlled, fixed-dosage, Phase 2 study  comparing 3 dosages of L Y3154207 (10, 30, or 
75 mgadministered orally [or 50 mg based on interim analysis] once a day ) with placebo over 12 
weeks in subjects with mild -to-moderatedementia associated withLBD (PDD orDLB).  Study 
HBEH will test the hy pothesis that LY3154207 admi nistered at 10mg, 30mg,and/or 75mg
daily (or 50mg based on interim analysis) ( QD) oral dosing for [ADDRESS_1143132] s with mild-to-moderate LBD (PDD orDLB)
compared with placebo. Important secondary  outcomes will assess the effect of LY3154207 on 
function, parkinsonism, sleep and mood/behavior .
CCI
I7S-MC-HBEH(b) Clinical Protocol Page 10
LY3154207Objective(s)/Endpoints:
Objectives Endpoints
Primary
To test the hypothesis that LY3154207 administered at 
10mg, 30mg,and/or 75mgdaily (or 50mg based on 
interim analysis) ( QD) oral dosing for 12 weeks will 
result in a significant improvement in cognition in 
subjects with mild-to -moderate LBD (PDD orDLB)
compared with placebo.Change in the CoA composite score of the CDR-CCB
from baseline to Week 12.
Secondary
Efficacy:
To evaluate the global efficacy of LY3154207 ADCS-CGIC score from baseline to Week12
To evaluate the efficacy of LY3154207 on cognitive 
outcomesChange in the CDR-CCB PoA composite score from 
baseline to Week12
To evaluate the efficacy of LY3154207 on cognitive 
outcomesChange in the ADAS-Cog 13scorefrom baseline to 
Week12
To evaluate the efficacy of LY3154207 on cognitive 
outcomesChange in the MoCAscore from screening to Week [ADDRESS_1143133] of LY3154207 on PD motor signsChange in the MDS-UPDRS total score (sum of 
PartsI-III) from baseline to Week [ADDRESS_1143134] score from 
baseline to Week12
Safety:
To evaluate the effect of LY3154207 on acute changes 
of vital signs on the first day of dosingNumber of subjects who met the potentially clinically 
significant vital signs criteria at 3 consecutive time 
points at Visit 3 (Day1 stoppi[INVESTIGATOR_004]).
To evaluate the effect of LY3154207 on SBP on the first 
day of dosingChange in in -clinic SBP from [ADDRESS_1143135] of LY3154207 on pul se rate from 
baseline to Week 12Change in in -clinic mean pulse rate at baseline to mean 
pulse rate at Week 12
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143136] of LY3154207 on physical 
withdrawal symptoms Change in the PWC -20 total score from Week 12 to in-
clinic follow -up visit
Pharmacokinetics:
To assess the PK of LY3154207 in a population of 
subjects with mild-to -moderate dementia due to PDSteady-state trough plasma concentrations of 
LY3154207 at Week 12
Abbreviations: ADAS-Cog 13= 13-item Alzheimer’s Disease Assessment Scale –Cognitive subscale;
ADCS-CGIC = Alzheimer’s Disease Cooperative Study –Clinician Global Impression of Change;
CDR-CCB= Cognitive Drug Research –Computerized Cognition Battery; C oA = Continuity  of Attention; 
D-KEFS = Delis –Kaplan Executive Function System; DLB = dementia with Lewy bodies; ESS = Epworth 
Sleepi[INVESTIGATOR_7110]; LBD = Lewy Body Dementia ;MDS-UPDRS = Movement D isorder Society’s Unified 
Parkinson’s Disease Rating Scale; MoCA = Montreal Cognitive Assessment; NPI = Neuro psychiatric Inventory; 
PD = Parkinson’s disease ; PDD= Parkinson’s disease dementia; PDAQ-15 = Penn Parkinson’s Daily Activities 
Questionnaire -15; PK = pharmacokinetics; PoA = Power of Attention; PWC-20 = physician withdraw al 
checklist-20; QD = once a d ay; SBP = systolic blood pressure .
Summary of Study Design:   Study I7S-MC-HBEH (HBEH)is a multicenter, randomized, 
double-blind, parallel -group, placebo-controlled, fixed- dosage, Phase 2study comparing 
3 dosages of LY3154207 (10, or 30, or 75 mg adminis tered orally [or 50mg based on interim 
analysis]once a day[QD]) with placebo over 12 weeks in subjects with mild-to-moderate LBD
(PDD orDLB).  The study  includes a Screening Period (Visit s1 to 2) of a minimum of 7 days 
and up to 14 days, a Pretreatment Period of a minimum  of 11days and up to 17 days(Visits2 to 
3), a 12-week Treatment Period (Visits 3 to 11), and a 14 -day Safety Follow-Up Period 
(Visits11 to 801 or early terminat ion [ET]/discontinuation [DC]visit toVisit801)that includes 
one telephone visit (Visit 111).  Subjectswho meet entry criteria will be randomized in a 1:1:1:1 
ratio to LY3154207 (10 or 30 or 75 mg QD) or placebo. 
Treatment Arms and Duration:
Study HBEH involves a comparison of LY3154207 10 mg, 30mg,and 75mg (or 50 mg based 
on interim analysis) administered orally QDwith placebo over 12 weeks.
Number of subjects:   Approximately [ADDRESS_1143137] imated total of 85 evaluable subjects per treatment grou p.
Statistical Analysis:
Efficacy Analysis :
All subjects in the evaluable pat ient population (EPP) will be considered for the efficacy 
analysis.  The primary analysis on CoA will occur when all subjects complete 12 weeks of 
treatment.  The analysis o f CoA will utilize a Bayesian MMRM model.  The Bayesian analysis 
may use uninformat ive priors for all terms in the model. These will be diffuse Normal 
distributions centered on zero. Priors for vari ance will follow an inverse gamma distribut ion. 
Further detai ls of the Bayesian analysis will be provided in the SAP.  The MMRM model will 
account for longitudinal data assessed throughout the study , after 1, 2, 4, 6, 8, 10, and 12 weeks 
of dosing.  The change of CoA from the baseline to Week 12 will be the dependen t variable.  
I7S-MC-HBEH(b) Clinical Protocol Page 12
LY3154207The model will com prise fixed (baseline value, treatment, visit) and random effects (subject) and 
the interaction terms (treatment by  [CONTACT_765], baseline val ue by [CONTACT_765]).  Unstructured vari ance structure 
will be applied in the model, but if it fai ls to converge, other suitable structures will be 
investigated. The primary co mparison will be the contrast (difference in least squares mean) 
between treatments and placebo for the Week 12 change fro m baseline.
The secondary  efficacy outcom es: the change from baseline at 12-week time point of total 
scores (or composite values) of Alzheimer ’s Disease Cooperative Study  –Clinician Global 
Impression of Change (ADCS-CGIC), CDR-CCB Power of Attention (PoA), 13-item 
Alzheimer’s Disease Assessment Scal e –Cognitive subscale (ADAS-Cog13), Montreal 
Cognitive Assessment (MoCA), Neuropsy chiatric Inventory  (NPI), Epworth Sleepi[INVESTIGATOR_7110] 
(ESS), Movement Disorder Societ y’s Unified Parkinson’s Disease Rat ing Scale (MDS-UPDRS), 
Penn Parkinson’s Daily Act ivitiesQuestionnaire 15 (PDAQ-15),and Delis–Kaplan Executive 
Function System (D-KEFS)will follow the sam e analysis method as above.
Missing records in so me scales (e.g., ADAS-Cog) will be imputed as detailed in the statistical 
analysis plan .  Forthe scales where the imputation is not done, if any  item is missing, any total or 
sum involving that item will be considered missing.  No adjustment for mult iple comparisons 
will be made.
Safety Analysis :  Safety analyses are based on the safet y population and analys is will include 
listings and/or summaries of the fo llowing:  adverse events (AEs), serious adverse events 
(SAEs), treatment -emergent adverse events (TEAEs), laboratory  measures, vital signs, 
electrocardi ogram readings and number of subjects who met the pot entially clinically significant 
vital signs criteria at 3 consecut ive time points at Visit 3(Day 1 stoppi[INVESTIGATOR_004]). 
Mixed-model repeated m easuresanalysis will be used to compare the change in in -clinic blood 
pressure (BP) and pulse rate from pretreatmen t up to 8hours post dose measured on the first day 
of study drug dosing (V3).  Two baselines will be considered in the change from baseline 
analyses:  the V3 pretreatment value and the time -matched baselines fro m Visit2 (hourly value 0
to 6hours).  For the second baseline, the V3, 7 -and 8-hour time po ints will use the V2 6 -hour 
time point as their baseline value.  A separate change fro m baseline analysis will be completed 
for each baseline approach.  Mixed-model repeated measures analyses will also be u sed to 
compare change in in- clinic BPand pulse rate from V2 (daily  average 0 to 6hours) to 
Week6/Visit8 and Week12/Visit11 (daily average 0 to 6hours), to evaluate the change in BP 
and pulse rate over 12 weeks of dosing.
Withdrawal: Withdrawal symptom  analyses will be conducted on subjects who completed at 
least one pre -withdrawal and one post -withdrawal PWC-[ADDRESS_1143138].Week 12/Visit 11 will be 
considered baseline in the change fro m baseline analyses ; Visit [ADDRESS_1143139] 
baseline assessment. This will be examined using an analysis o f covariance (ANCOVA) m odel 
with treatment arm as an independent factor and baseline value as a covariate in the model .This 
will allow us to assess the withdrawal symptom s between tr eatments and groups.
Pharmacokinetics (PK):  Pharmacokinet icanalyses will be conducted on subjects who receive 
at least 1dose of the study drug and have 1measurable concentration.  A model -based approach 
I7S-MC-HBEH(b) Clinical Protocol Page 13
LY3154207may be implemented using nonlinear mixed effects modeling (NONMEM) or other appropriate 
software to estimate PK parameters.
Additional endpoints and bio marker data collected during the study  will be evaluated in an 
exploratory  manner.
Interim Analysis :  Safety interim analyses will be conducted on the nu mber of subjects on each 
treatment who m et the potentially clinically significant vital signs criteria ( TableHBEH.3) at 3 
consecutive time pointsat Visit3 (Day1 stoppi[INVESTIGATOR_37660]).  This will be done after 50, 100, and 
[ADDRESS_1143140] ments to 
doses may  be made for subsequently randomized subjects at the discretion of the Internal 
Assessment Committee (IAC).   Additional efficacy analyses may be conducted at the time of 
thesesafety interim analyses. A safety and efficacy interim analysis will be conducted when [ADDRESS_1143141] co mpletedVisit11 (Week 12) assessments and may also be conducted 
at other timepo intsprior to study  completion.  All potentialefficacy analysesmay be used for 
internal decision making, but arenot planned to stop the study .
CCI
I7S-MC-HBEH(b) Clinical Protocol Page 14
LY31542072.Schedule of A ctivities
I7S-MC-HBEH(b) Clinical Protocol Page 15
LY3154207TableHBEH.1. Schedule of A ctivities for Protocol I7S -MC-HBEH
Procedure aScreening Pretreatment Double-Blind Treatment Follow-upUnscheduled
VisitET/DC 
Visitd,t
Study DayMin 7 
days; 
max
14 days
prior to
V2Min 11 days; 
max 17 days 
prior to V37 
days14 
days21 
days28 
days42 
days56 
days70 
days84 
days2days 
after
V11u14 
days 
from 
V11or 
ET/DC
Tolerance Interval for 
Visit (Days)Baseline 
VisitRandomization ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 +1±3
eCRF Visit No.: V1b,dV2b,d V3bV4dV5 V6 V7 V8 b,dV9V10 V11 b,dV111dV801 V997 c
Informed Consent(s) 
Signed (before 
procedures/tests)X
Register subject in 
IWRS -Subject number 
assignedX
Complete IWRS X X X X X X X X X X X X X X
Demographics X
Prior/concomitant 
treatmentX X X X X X X X X X X X X X
Inclusion/exclusion 
criteriaX X X
Modified Hoehn and 
Yahr ScaleX
Medical History X
Physical Examination e X X X X X
Height X
Weight X X X X
Orthostatic BP/pulse rate fX X X X X X X X X X X X X X
In-clinic BP/Pulse rate 
monitoring gX X X X X
I7S-MC-HBEH(b) Clinical Protocol Page 16
LY3154207Procedure aScreening Pretreatment Double-Blind Treatment Follow-upUnscheduled
VisitET/DC 
Visitd,t
Study DayMin 7 
days; 
max
14 days
prior to
V2Min 11 days; 
max 17 days 
prior to V37 
days14 
days21 
days28 
days42 
days56 
days70 
days84 
days2days 
after
V11u14 
days 
from 
V11or 
ET/DC
Tolerance Interval for 
Visit (Days)Baseline 
VisitRandomization ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 +1±3
eCRF Visit No.: V1b,dV2b,d V3bV4dV5 V6 V7 V8 b,dV9V10 V11 b,dV111dV801 V997 c
Temperature X X X X X
12-Lead ECG X X X X X X X c X
Review HBPM
instructionshX X X X X X
HBPM device returned to 
siteX X
Hematology X X X X X X X c X
Urinalysis X X X X X X X c X
Clinical Chemistry X X X X X X X c X
Serum FSH i X
PGx sampling X
Collection of dose 
administration timing 
(date and time)X X X X X X X X X X
PK Sampling j Xj XjXj Xj Xj Xj
Randomization X
Study drug dosing at site X Xk Xk
Dispense Investigational 
ProductX X X X X X X X
Return Investigational 
ProductX X X X X X X X X
Adverse Events X X X X X X X X X X X X X
I7S-MC-HBEH(b) Clinical Protocol Page 17
LY3154207Procedure aScreening Pretreatment Double-Blind Treatment Follow-upUnscheduled
VisitET/DC 
Visitd,t
Study DayMin 7 
days; 
max
14 days
prior to
V2Min 11 days; 
max 17 days 
prior to V37 
days14 
days21 
days28 
days42 
days56 
days70 
days84 
days2days 
after
V11u14 
days 
from 
V11or 
ET/DC
Tolerance Interval for 
Visit (Days)Baseline 
VisitRandomization ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 +1±3
eCRF Visit No.: V1b,dV2b,d V3bV4dV5 V6 V7 V8 b,dV9V10 V11 b,dV111dV801 V997 c
Review Lilly Trial app (if
available) instructions lX X X X X X X X X X
Actigraphy  watch
provided to subjects (if 
available) mX X X
Return of Actigraphy 
watch (if available) nX X X
CDR-CCBo,p X X X X X X X X X X X X X
Alzheimer’s Disease 
Cooperative Study –
Structured Clinical 
Global Impression 
interview dX X X X
ADCS-CGICd X X X
ADAS-Cog 13p X X X X
D-KEFS p X X X X
MoCAp X X X X
PDAQ-15d X X X X
MDS-UPDRS d,p X X X X X
NPId X X X X
ESSd X X X X X X
QUIPd X X X X
GDS-Sd X X X
I7S-MC-HBEH(b) Clinical Protocol Page 18
LY3154207Procedure aScreening Pretreatment Double-Blind Treatment Follow-upUnscheduled
VisitET/DC 
Visitd,t
Study DayMin 7 
days; 
max
14 days
prior to
V2Min 11 days; 
max 17 days 
prior to V37 
days14 
days21 
days28 
days42 
days56 
days70 
days84 
days2days 
after
V11u14 
days 
from 
V11or 
ET/DC
Tolerance Interval for 
Visit (Days)Baseline 
VisitRandomization ±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3 +1±3
eCRF Visit No.: V1b,dV2b,d V3bV4dV5 V6 V7 V8 b,dV9V10 V11 b,dV111dV801 V997 c
PWC-20(Subject) XX X X
PWC-20d(Caregiver) XX X X
C-SSRS –Children’s 
Version and Self -Harm 
Supplement Form sXq Xr Xr XrXrXrXrXrXrXrXr Xr Xr Xr
Abbreviations:  ADAS -Cog13= Alzheimer’s Disease Assessment Scale –13-Item Cognitive Subscale; ADCS-CGIC = Alzheimer’s Disease Cooperative 
Study -Clinician Global Impression of Change ; BP = blood pressure; CDR-CCB= Cognitive Drug Research Computerized Cognition Battery ;
C-SSRS = Columbia -Suicide Severity Rating Scale; DC = discontinuation; D -KEFS= Delis–Kaplan Executive Function System; ECG = electrocardiogram; 
eCOA = electronic Clinical Outcome Assessment; eCRF = electronic case report form; ED = early discontinuation; ESS = Epworth Sleepi[INVESTIGATOR_7110] ;
ET=earlytermination; FSH = follicle -stimulating hormone; GDS -S = Geriatric Depression Scale –Short Form;HBPM = home blood pres sure monitoring; 
HCG = human chorionic gonadotropin; HEENT = head, ear, eye, nose, and throat; IWRS = interactive web -response sy stem; MDS-UPDRS = Movement 
Disorder Society’s Unified Parkinson’s Disease Rating Scale ; MoCA=Montreal Cognitive Assessment; N PI = Neuropsychiatric Inventory; PDAQ-15= Penn 
Parkinson Daily Activities Questionnaire -15; PGx =pharmacogenomic(s); PK = pharmacokinetic(s); PWC-20 = physician withdraw al checklist -20;
QUIP = Questionnaire for Impulsive -Compulsive Disorders in Parkinson’ s Disease; V = visit .
Note:  Be sure that the visit allowance period takes into account the required washout duration needed for medications that are not allowed by [CONTACT_760].
aEvery effort should be made for visits to occur on designated study days.  The overall treatment period in the protocol shoul d be maintained (visits should be 
scheduled based on the randomization visit).  Procedures and assessments shouldbe done in the or der described in the Operations Manual.
bVisit1 may be splitover2days.  In exceptional circumstances, if the clinical assessments cannot be completed within 1 day at V2, V3, V8,and/or V11, those 
clinical assessments may be completed the next day. The orthostatic blood pressure measurements, in -clinic blood pressure measurements, the CDR -CCB,
and the laboratory procedures including PK mustbe completed on Day1 of that visit. The visit interval will start from Day1.
cECGs or samples for clinical laboratory tests (hematology, clinical chemistry, and urinalysis) will only be collected if a retest is needed. All other procedures 
are required for each unscheduled visit.
I7S-MC-HBEH(b) Clinical Protocol Page 19
LY3154207dThe caregiver is required to attend Visit1 at the clinic to sign the informed consent and be informed about the study details.  Caregiver’s attendance will also 
be required at Visit2, Visit4, Visit8, Visit 11, Visit801, and the ET/DC visit to provide inputs for the PDAQ -15, ADCS-CGIC,GDS-S, MDS-UPDRS, NPI, 
ESS, and QUIP scales. The caregiver is required at Visit 11 ,Visit 111and Visit 80 1to provide input for the PWC-20.
eThe physical examination should include HEENT, cardiac, lung, abdomen, extremity, skin,and neurological examinations.
fOrthostatic BP/pulse rate will be measured as part of the vital sign assessments at every visit. At Visit2, Visit3, Visit 8, Visit11, and Visit 801, these
measurements will be collected at time 0 of the in-clinic BP/pulse rate monitoring .  Subjects will have 3BP/pulse rate measurement s taken in the seated 
position approximately 1minuteapart followed by 1BP/pulse rate measurement taken in the standing position . Subjects should be seated for at least 
5minutes and stand for at least [ADDRESS_1143142] feels unable to stand, vital signs only in the seated 
position will be recorded.
gIn-clinic BP a nd pulse rate monitoring will be done at Visit 2, Visit3, Visit8, Visit 11,and Visit 801.  The BP and pulse rate measurements will occur at 
time0 and approximately every 60minutes thereafter at Visit2, Visit8, and Visit 11, in-clinic BP and pulse rate will be monitored for up to 6 hours; at 
Visit3,  for up to 8 hours and at Visit 801 for up to 2hours..  The initial measurement , time0of the in-clinic BP and pulse rate monitoring, will be done as an 
orthostatic BP/pulse rate (refer to footnote fabove), and subsequent BP and pulse rate measurements will be done in the seated position only.  Time [ADDRESS_1143143] meets inclusion criteria [6].  
hThe subject should be given the HBPM device at Visit 2.  Home BP will be measured twice daily in the seated position using the HBPMequipment provided 
by [CONTACT_105410] (Lilly).  Home BP measurements shouldbe conducted for a minimum of 7 days between Visit 2 and Visit 3, for 3weeks between 
Visit3 and Visit 6, and for a minimum of 7 days between Visit 10 and Visit 11, and Visit 11 andVisit 801.  Home BP shouldbe measured twice in the 
morning (approximatel y 1minute apart) (e .g., 8AM) immediately following study medication dosing and twice in the evening, approximately 12 hours later 
(approximately 1 minute apart) (e .g., 8PM).
iRefer to inclusion criterion[12e] in Section6.1.
jPK sampling. At Visit3, a PK sample is to be collected within 1 to 3hoursafter the drug is administered at the site.  At Visit 4, Visit5, Visit 8,and ET/DC
visit, thePK sample can be collected at any time during the visit.  At Visit 11, the PK sample should be collected prior to the drug being administered at the 
site.  The date and time of the PK sample collection as well as the date and time of the dose administrati on immediately preceding the PK sampl ingshouldbe 
enteredin theeCRF.
kStudy drug dos etobe administered at the clinic on the morning of Visit 8 and Visit 11following the Time0 in-clinic BP/pulse rate measurement s.
lAn iPad®configured with the Lilly Trial application (Lilly Trial app) will be provided to the subjects at Visit 2 (if available).  Subjects shouldcomplete 
assessments from 2 weeks prior to dosing (starting the day following Visit2), throughout the dosing period , and for 2 weeks after the conclusion of the 
treatment period (until Visit 801).  This assessment shouldbe done up to twice daily. Subjects will self -select for this optional component of the protocol at 
Visit1.  Subjects can decide to opt out at any t ime during the study .In case of opt -out or ET, the subject should return the iPad to the site at the visit 
following the subject opt -out or at the E T/DCvisit.  For subjects who complete the Lilly trial application assessments throughout the study, the i Pad should be 
returned at Visit 801.  Refer to the Operations Manual for details about Opt -in and Opt -out process.
mThe actigraphy device (if available) shouldbe worn on the wrist, similar to a watch, beginning at Visit 2, for 3 separate 2 -week periods of time:  Visit 2to
Visit3, Visit8toVisit9,and Visit [ADDRESS_1143144] shouldbring the device back to the site at the next scheduled visit (Visit 3, Visit9,or Visit801).
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143145]-CCB:  At least 2training sessions are required at Visit 1. At each visit, the CDR -CCB should be assessedafter the study drug has been dosed. At 
Visit4, Visit5, Visit6, Visit 7, Visit9,and Visit 10, if a subject has not taken the study drug prior tothe study visit, the subject must take study drug at the 
site prior tothe CDR-CCB.
pThe CDR -CCB, MoCA, ADAS -Cog13, MDS-UPDRS (Part III) ,and D-KEFS scales shouldbe conducted in the practi cally defined medication “on” state at 
all visits.  The “on” state is defined as the individual best motor function as determined by [CONTACT_093] ,or at approximately [ADDRESS_1143146] these assessments in the “on” state.  In the exceptional circumstance that this is not possible, 
the assessments could be done in the “off” state.  The “on/off” state should be confirmed prior to completion of the respecti ve scales listed above.  This 
information will be collected in the eCOA or the eCRF. If any portion of an assessment is done in the “off” state, then that subject should be rated as in the 
“off” state for the whole assessment.   If the subject is not on dopaminergic therapy the assessme nt should be documented as “on”.
qThe C-SSRS “Baseline” version will be used at the Screening visit (Visit 1).
rThe C-SSRS “Since Last Visit” scale will be administered at each subsequent visit.
sIf, based on administration of the C -SSRS, it is determined that suicide -related behaviors have occurred, then the Lilly Self -Harm Follow -Up form will be 
used to collect additional information to allow for a more complete assessment of these behaviors.
tAll subjects who discontinue study treatment priortoa scheduled visit should have an ET/ DCvisit and procedures/assessments performed as soon as possible.
uIf the visit window falls on a weekend/holiday then the visit should be conducted at the next possible day.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143147] ivepositive allosteric modulator (PAM, also called 
“potentiator”) of the dopamine D1 receptor subtype (D1PAM). By [CONTACT_395514] y of the 
dopamine for the D1 receptor, a D1PAM should amplify the response to endogenous dopamine, 
increasing D1 tone when and where dopamine is released , and represents a novel mechanism o f 
action.  This mode of activity is in contrast to a D1 agonist, which should act ivate all D1 
receptors to which it has access for as long as it is present (Svensson et al. 2017).  In animal 
models of cognition and locomotor activit y, D1 agoni sts often show bell -shaped, dose –response 
relationships, which are probably due to overstimulat ion at higherdoses (Arnsten et al. 2017).  
Some D1 agonists also show rapid development of tolerance due to constant activation of the D1 
receptor (Gulwadi et al . 2001).  In contrast, because a D1PAM would be dependent on 
endogenous tone and thus subject to normal feedback control, it should have a much lower 
propensity for overstimulat ion.  Furtherm ore, since endogenous tone is intermittent, there should 
be less potential for development of tolerance.
3.2.Background
Lewy Body Dementia (LBD), including Parkinson’s disease dementia (PDD) and DLB,is a
progressive neurodegenerat ive disorder associated with alpha -synuclein deposit ion, Lewy body 
pathology, and degenerat ion of nigro -striatal dopaminergic neurons.  According to the 
Parkinson’s Disease Foundation, Parkinson’s disease ( PD)affects approximately 1million 
people in the [LOCATION_002] (U.S.) and 7 to 10million people worldwide (Statistics on 
Parkinson’s ).It is estimated that up to 78% of of patients with PD will develop dement ia (PDD) 
in their lifet ime(Aarsland et al. 2005).  DLB is the second most commo n dementia after 
Alzheimer’s disease ( AD)and affects 1.4 millio n individuals in the U .S., represent ing an 
estimated 15 -20% of all dementia cases worldwide (Lewy Body Dementia Associat ion 
[https://www.lbda.org/go/10- things-you-should-know-about-lbd).  
LBDispathologically characteri zed by [CONTACT_824339], a major component of which is misfo lded aggregated 
α-synuclein (Beyer et al . 2009).  Lewy body formation and propagati on is accom panied by 
[CONTACT_824340], particularly affect ing the dopaminergic and cho linergic 
neurons (Harding and Halliday  2001; Klein et al . 2010; Coll oby [CONTACT_2297]. 2012).  These
neuropathological findings are largely indist inguishable between DLB and PDD and have thus 
led the field to consider them the same disease.
The cognit ive impairments of PDD and DLB also overlap. Progressive executive dysfunct ion
andvisual-spatial abnormalit iesare noted in both, butmemory remains relat ively intact early in 
the course of disease (Lippa et al . 2007).Prodromal and non-motor features are similarfor both
conditions and incl udeREM sleep behavi or disorde r, hyposmia, prominent visual hallucinat ions, 
fluctuations in arousal, autonomic dysfunct ion, and depression/anxiet y. They share 
neuroimaging characteristics with overlappi[INVESTIGATOR_824305], glucose utilizat ion, and 
neurotransmitter changes ( cortical cholinergic deficits[Colloby [CONTACT_2297]. 2016] and striatal/cortical 
I7S-MC-HBEH(b) Clinical Protocol Page 22
LY3154207dopaminergic deficit s[Klein et al. 2010] ).  Although once considered as two separate entit ies,
the constellat ion of supportive pathological, clinical, imaging, and neurochemical data suggest 
PDD and DLB fall within a spectrum of the same disease (Berg et al . 2014; Gom perts 2016; 
Friedman 2018; Jellinger 2018; Jellinger and Korczyn 2018) . 
Because of the dopaminergic fronto -striatal dysfuncti on and cho linergic deficit s associated with 
LBD[Kleinet al. 2010],LY3154207 ,a D1PAM,is a hypothesized mechanism to treat cognit ive 
deficits of the disorder .LY3154207 increases the affinity of dopamine for the D1 receptor, thus 
amplifyingthe response to endogenous dopamine andincreasing D1 tone when a nd where 
dopamine is released.  By  [CONTACT_824341] (or 
administered L -DOPA), a D1PAM should improve cognit ive performance through enhancing 
frontal dopaminergic neurotransmissio n.  In addition to facilitating dopam ine neurotransmissio n, 
LY3154207 may be effect ive in improving cognit ive dysfunct ion through acti vation of cortical 
neurons, markers of synaptic plasticit y,and D1 medi ated enhanced acetylcholine 
neurotransmitter release .  Other potential effects such as r educed day time sleepi[INVESTIGATOR_008], enhanced 
motor function, improved mood, and goal-directedbehaviors leading to reduced apathy  (via 
activation of cortical and striatal D1receptors) would also be beneficial in LBD.  
3.3.Benefit/Risk Assessment
 
 
 
 
 Study HBEH is a proof -of-concept study , and no benefit 
for participation should be antici pated.
Subjects participat ing in Study HBEH may experience  
 
 
 
 
 
CCI
CCI
CCI
I7S-MC-HBEH(b) Clinical Protocol Page 23
LY3154207The development and reproductive risk sof LY3154207 adminis tration are unknown and 
therefore women of child -bearing potenti al (WOCBP) have been excluded fro m participation in 
Study HBEH.
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) ,
and reasonably ant icipated adverse events (AEs) of LY3154207 are to be found in the IB.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143148] the hypothesis that LY3154207 administered at 
10mg, 30mg,and/or 75mgdaily (or 50mg based on 
interim analysis) (QD)oral dosing for 12 weeks will 
result in a significant improvement in cognition in 
subjects with mild-to -moderate LBD(PDD orDLB)
compared with placebo .Change in the CoA composite score of theCDR-CCB
from baselineto Week12
Secondary
Efficacy:
To evaluate the global efficacy of LY3154207 ADCS-CGIC score from baseline to Week12
To evaluate the efficacy of LY3154207 on cognitive 
outcomesChange in the CDR-CCBPoA composite score from 
baseline to Week [ADDRESS_1143149] of LY3154207 on Parkinson’s 
disease severityChange in the MDS-UPDRS total score (sum of parts 
I-III) from baseline to Week [ADDRESS_1143150] score from 
baseline to Week12
Change in MDS-motor exam (Part III)from baseline to 
Week12
I7S-MC-HBEH(b) Clinical Protocol Page 25
LY3154207Objectives Endpoints
Safety:
To evaluate the effect of LY3154207 on home blood 
pressure monitoring (HBPM) of SBP
To evaluate the effect of LY3154207 HBPM of pulse 
rate
To evaluate the effect of LY3154207 on physical 
withdrawal symptoms 
To evaluate the effect of LY3154207 on acute changes 
of vital signs on the first day of dosingChange in HBPM SBP from baseline to Week 12
Change in HBPM of pulse rate from baseline to 
Week12
Change in the PWC-20 total score from Week 12 to in -
clinic follow -up visit
Number of subjects who met the potentially clinically 
significant vital signs criteria  at 3 consecutive time 
points at Visit 3 (Day1 stoppi[INVESTIGATOR_004])
To evaluate the effect of LY3154207 on BP on the first 
day of dosingChange in in -clinic BP from [ADDRESS_1143151] day of study drug dosing
Change in in -clinic mean BP at baseline to mean BP at 
Week12
Change in in -clinic mean pulse rate at baseline to mean 
pulse rate at Week 12
Pharmacokinetics:
To assess the PK of LY3154207 Steady-state trough plasma concentrations of 
LY3154207 at Week12
Tertiary/Exploratory
Efficacy
To evaluate the efficacy of LY3154207 on cognitive 
outcomesChange in total score of the ADAS-Cog 11from baseline
to Week12
To evaluate the efficacy of LY3154207 on cognitive 
outcomesChange in the CDR-CCB Cognitive reaction time
composite score, Reaction Time Variability composite 
score, and Speed Score composite scores from baseline
to Week12
Change in the CDR -CCB individual task outcomes from 
baseline to Week [ADDRESS_1143152] of LY3154207 on mood Change in GDS -S score from screening to Week 12
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143153] of LY3154207 on impulse controlChange in NPI [INVESTIGATOR_32005] (Part D Depression/Dysphoria) 
from baseline to Week 12
Change in QUIP score from baseline to Week 12
Digital biomarkers
To evaluate the feasibility of using the Lilly Trial 
application (Lilly Trial app) to evaluate the effect of 
LY3154207 on motor tasks or cognitive outcomes in a 
subset of subjectsTo explore trends, utilizations, and changes in 
quantitative motor and cognitive outcomes as measured 
by [CONTACT_824342] 12weeks
To explore the feasibility of using actigraphy to evaluate 
the effect of LY3154207 on various sleep parameters 
and day time activity  including but not limited to sleep 
latency, duration of sle ep, sleep–wake cycles, sleep 
architecture, and sleep disruptionChange in actigraphy measured sleep parameters as 
measured by [CONTACT_824343] 12 weeks
Pharmacogenomic
To evaluate genetic interactions with study treatment 
response or safety if appropriate/as warrantedExplore relationships between pharmacogenomic 
variations and relevant clinical outcomes.
Abbreviations: ADAS-Cog 11= 11-item Alzheimer’s Disease Assessment Scale –Cognitive subscale;
ADAS-Cog 13= 13-item Alzheimer’s Disease Assessment Scale –Cognitive subscale; CDR -CCB = Cognitive 
Drug Research Computerized Cognition Battery; ADCS –-CGIC = Alzheimer’s Disease Cooperative Study –
Clinician Global Impression of Change; CoA = Continuity of Attention; D -KEFS = Delis–Kaplan Executive 
Function System ; DLB = dementia with Lewy bodies; ESS = Epworth Sleepi[INVESTIGATOR_7110]; LBD = Lewy Body 
Dementia ;HBPM = home blood pressure monitoring; MDS -UPDRS = Movement Disorder Society’s Unified 
Parkinson’s Disease Rating Scale; MoCA = Montreal Cognitive Assessment; NPI = Neuropsychiatric Inventory; 
PDD= Parkinson’s disease dementia; PDAQ-15 = Penn Parkinson’s Daily Activities Questionnaire -15;
PK = pharmacokinetics; PoA = Power of Attention; PWC-20 = physician withdraw al checklist -20; QD = once a 
day; QUIP = Questionnaire for ’Impulsive -Compulsive Disorders in Parkinson’s Disease ; SBP = sy stolic blood 
pressure.
I7S-MC-HBEH(b) Clinical Protocol Page 27
LY31542075.Study Design
5.1.OverallDesign
Study HBEHis a multicenter, randomized, double -blind, parallel-group, placebo-controlled , 
fixed-dosage, Phase2study comparing 3 dosages of LY3154207 (10, 30, or 75 mg administered 
orally [or 50mg based on interim analysis ]once a day[QD]) with placebo over12weeksin 
subjects with mild-to-moderate dementia associated withLBD(PDD and DLB) .  The study  
includes a Screening Period (Visits1 to 2)of a minimum o f 7daysand up to 14days, a 
Pretreatment Period of a minimum of 11days and up to 17 days(Visits2 to 3), a 12-week 
Treatment Peri od(Visits3 to 11), and a 14-daySafety Follow-Up Periodincluding a telephone 
visit (Visit 11 + 2 day s) and Visit801or early terminat ion [ET]/discontinuation [DC].Subjects 
who meet entry  criteria will be rando mized in a 1:1:1:1 ratio to LY3154207 ( 10 or 30or 75mg 
QD) or placebo.  The primary objective of this study is to test the hypothesis that LY3154207 
administration for 12 weeks will result in a significant improvement in cognit ion as measured by  
[CONTACT_735514] m baseline to Week 12 on the Continuit y of Attention (CoA) com posite score of 
the Cognitive Drug Research Computerized Cognition Battery (CDR -CCB), in subjects wi th 
mild-to-moderate dementia associated withLBD(PDD and DLB) , compared to pl acebo.  
(Wesnes et al. 2005; Rowan et al . 2007, McKeith et al 2000).
FigureHBEH.1illustrates the study design.
FigureHBEH.1 .Illustration of study design for Clinical Protocol I7S-MC-HBEH(b).

I7S-MC-HBEH(b) Clinical Protocol Page 28
LY3154207Abbreviat ions and definit ions are provided in Appendix 1 ; clinical laboratory  tests are described 
in Appendix 2 ; study governance considerations are described in detail in Appendix 3 ; and
hepatic monitoring tests for treatment -emergent abnormalit y are provi ded in Appendix 4 .
5.1.1.Screening Period (Visit 1)
At or prior toVisit1, the study  will be explained to the subject(and his or her legal 
representative, if applicable) and caregiver.  Informed consent of the subject and caregiver must 
be obtained prior toany study procedures conducted.  The screening period length is of a 
minimum o f 7days to a maximum of 14days between Visit 1 and Visit2.  See the Schedule o f 
Activities (Section 2)for the timing of events and the measures to be assessed during the 
screening period.
Current or planned use of conco mitant medications, the effects of vacat ions or absences on 
protocol compliance, and general compliance wit h the protocol should be discussed at Visit 1.  
Subjects must meet applicable eligibility criteria (Section6.1andSection6.2) to continue to 
Visit2. Refer toSection6.4for more informat ion about rescreening criteria.
Visit1 is expected to be of a duration of approximately 3to 5hoursand maybe splitover 1 to 
2days.
[IP_ADDRESS] Screening Procedures
Screening, entry  and administrative procedures, cognit ive and physical assessments, vitals, safety 
assessments, and laboratory  assessments (see Schedule of Activities) are to be perform ed at 
Visit 1.For subjects treated with dopaminergic treatment for parkinsonism symptoms, t he
CDR-CCB and MoCAshouldbe conducted in the practically defined medicat ion “on” state.  
The “on” state is defined as the individual ’sbest motor funct ion as determined by [CONTACT_824344] [ADDRESS_1143154] these assessment sin the “on” state. Inthe exceptional circumstance 
that this isnot possible, the asse ssmentscould be done in the “off” state.   The “on/o ff” state 
should be confirmed pri or to com pletion of the respective scales listed above.   This informat ion 
will be co llected in the electronic Clinical Outcome Assessment (eCOA)or the electronic case 
report form (eCRF).  If any portion of an assessment is done in the “o ff” state, then that subject 
should be rated as in the “off” state for the whole assessment. Subjects NOT on dopamine rgic 
therapy shouldbe recorded as being in the “on” state for the purpose of analysis.
Medical history  should include thediagnosis, whether PDD or DLB , and thetiming of onset of 
dementiaand Parkinson’s symptoms anddate of diagnosis if applicable. Additionally,the 
relationship of the onset of dementia relat ive tomotor symptoms will be assessed. Subjects 
without motor symptoms shoul d report thei r dementia as occurring prior to motor symptoms.
The physical examinat ion should include head, ear, ey e, nose, and throat (HEENT), cardiac, 
lung, abdo men, extremit y, skin, and neurological examinat ions.
I7S-MC-HBEH(b) Clinical Protocol Page 29
LY31542075.[IP_ADDRESS]. BP and Pulse Rate
Subjects should have a BP or pul se rate at Visit 1 and Visit 3(time 0), as determined by  
3sequential BP/pulse rate measurements in theseated posit ion:
Subjects <60 years old:
oa mean systolic blood pressure (SBP) less than or equal to 
140mmHg, a mean diastolic BP less than or equal to 90 mmHg,
and a mean pulse rate less than or equal to 90beats/min in the
seated posit ion.
oeach of the [ADDRESS_1143155] be less than 180 mmHg.
Subjects ≥60years old:
oa mean SBP less than or equal to 150 mmHg, a mean diastolic BP 
less than or equal to 90 mmHg,and a mean pulse rate less than or 
equal to 90beats/min in theseated posit ion.
oeach of the [ADDRESS_1143156] be less than 180 mmHg.
[IP_ADDRESS].2. CDR-CBB
At Visit 1, two training sessions of the CDR-CBB will be administered to familiarize subjects 
with the instrum ent and to minimize practice effects. Subjects must be able to complete both 
training sessions in order to be considered eligible for HBEH.  Scores on the CDR -CCB at V1 
will not be included in the analysis unless the baseline (V2) scores are inco mplete or missing and 
then V1 scores may  be usedfor calculation of the baseline . 
[IP_ADDRESS].3. Modified Hoehn and Yahr Scale
The Hoehn and Yahr Scale (Hoehn and Yahr 1967) is used to describe the symptom progression 
of PD. The scale was originally described in 1967 and included Stages 1 through 5.  It has since 
been modified wi th the addition of Stages1.5 and 2.5 to account for the intermediate course of 
PD. The modifiedHoehn and Yahr scale is as fo llows:
Stage 0: No signs of disease
Stage 1:  U nilateral disease
Stage 1.5: Unilateral plusaxial invo lvement
Stage 2: Bilateral disease,without impairment of balance
Stage 2.5: Mild bilateral disease ,with recovery on pull test
Stage 3: Mild-to-moderate bilateral disease; so me postural instabilit y; physically 
independent
Stage 4: Severe disabilit y; still able to walk or stand unassisted
Stage 5: Wheelchair bound or bedridden unless aided
[IP_ADDRESS].4. Clinical Diagnostic Criteria for PD and DLB
Subjects must meet diagnost ic criteria for either PD or DLB.
PDCriteria:Subjectsshould meet MDS criteria for clinically probable PD (Postuma et al .
2015)as detailed in Appendix [ADDRESS_1143157] parkinsonism as defined by [CONTACT_46917]
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143158] tremor and/or ri gidity. Subjectsmust not have any  absolute 
exclusion criteria.  Subjects must not have greater than 2 red flags ;if 1red flag is present thenit 
must be offset by  1supportive cri terionandif 2red flags are present it must be offset by  [ADDRESS_1143159] of absolute exclusio n 
criteria, red flags and supportive criteria .
DLBCriteria:Subjects should meet the Fourth consensus report of the DLB Consortium 
diagnostic criteria for probable DLB (McKeith et al. 2017) as detailed in Appendix [ADDRESS_1143160] 2 or more of the 4 core clinical features of DLB 
(fluctuation in cognit ion, visual hallucinat ions, REM sleep behavior disorder and/or 
parkinsonism). Subjects with [ADDRESS_1143161] of core features and indicative bio markers.
[IP_ADDRESS].5. Montreal Cognitive Assessment Scale
The MoCA will be administ ered to subj ects in Visit [ADDRESS_1143162] ion9.[IP_ADDRESS].
[IP_ADDRESS].6. Geriatric Depression Scale Short Form
The GDS i s a site-administered questionnaire of depression in older adults (Yesavage et al. 
1983).  Users respond in a “Yes/No” format.  Originally developed as a 30 -item scale (Long 
Form), it has since been shortened to a 15 -item scale (Short Form ), which can be com pleted in 
approximately  5 to 7minutes (Sheikh and Yesavage 1986).  Of the 15 items, 10 are indicative of 
depressio n when answered “Yes” and 5 are indicative of depressio n when answered “No.”
Caregiver’s input maybe needed at Visit1 for the GeriatricDepressio n Scale –Short form 
(GDS-S).
[IP_ADDRESS].7. Columbia -Suicide Severity Rating Scale –Children’s Version
The C-SSRS is a scale that captures the occurrence, severit y, and frequency  of suicide-related 
thoughts and behaviors during the corresponding assessment period.  The C-SSRS, included here 
as a screening assessment, is described in detail in Section 9.4.4.  The C-SSRS “Baseline” 
version will be used at screening , and the findings will const itute the baseline assessment.
The C-SSRS will be administered to the patient with the study  partner/study  informant present or 
available by  [CONTACT_756], after the cognit ive and functional assessments. Responses from both the 
study partner/study  informant and patient will be considered when administering the scale. Ifa 
suicide-related though t or behavio r is identified at any time dur ing the study , a thorough
evaluation will be perfo rmed by a study  physician, and appropriate med ical care will be
provided.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143163] additional inf ormation 
to allow for a more complete assessment of these behaviors.
5.1.2.Pretreatment Period (Visit 2)
See the Schedule o f Activities (Section2)for the timing of events and the measures to be 
assessedat Visit 2.  
Visit [ADDRESS_1143164]-CCB,and the laboratory  procedures including pharmacokinetics ( PK)mustbe completed 
on Day1 of that visit. The visit interval will start from Day1.
Subjects must continue to meet applicable eligibility  criteria (Section6.1andSection6.2) to 
continue to Vis it3.  Subject s who do not m eet all inclusion criteria or who meet any  exclusion 
criteria will be discontinued fro m the study.
[IP_ADDRESS] Blood Pressure and Pulse Rate Measures
Orthostatic BP/pulse rate m easurements will be collected at time 0 of the in-clinic BP/pulse rate 
monitoring.  Subjects will have 3BP/pulse rate m easurements taken in the seated posit ion 
approximately  1minuteapart followed by 1BP/pulse rate measurement taken in the standing 
position.  Subjects shoul d be seated for at least [ADDRESS_1143165] feels unable to stand, vital signs only in the 
seated position will be recorded.
In-clinic BPand pulse rate measurements will occur at time 0 and every  60minutes thereafter up 
to 6hours. The initial measurement, time 0 of the in-clinic BPand pulse rate m onitoring, will  be 
done as an orthostatic BP/pulse rate (refer to orthostatic BP/pulse rate above), and subsequent BP
and pulse rate measurements will be done in theseated posit ion only.
[IP_ADDRESS] Cognitive, Motor, and Functional Assessments
For subjects treated with dopaminergic therapyfor parkinsonism symptoms, CDR-CCB, 
Alzheimer’s Disease Assessment Scale – 13-Item Cognitive Subscale [ADAS-Cog13], 
Movement Disorder Society’s Unified Parkinson’s Disease Rat ing Scale [MDS-UPDRS] 
[PartIII])and Delis–Kaplan Execut ive Function System (D-KEFS) assessments shouldbe 
conducted in the practically defined medicat ion “on” state.  The “on” state is defined as the 
individual ’sbest motor function as determined by [CONTACT_824345] [ADDRESS_1143166] these assessment s
in the “on” state.  In the except ional circum stance that this isnot possible, the asse ssmentscould 
be done in the “off” state.   The “on/o ff” state should be confirmed prior to complet ion of the 
respective scales listed above.   This informat ion will be collected in the eCOA or the eCRF.If 
any portion of an assess ment is done in the “off” state, then that subject should be rated as in the 
I7S-MC-HBEH(b) Clinical Protocol Page 32
LY3154207“off” state for the who le assessment. Subjects NOT on dopaminergic therapy shouldbe recorded 
as being in the “on” state for the purpose of analysis.
Caregiver’s input will be needed at Visit [ADDRESS_1143167] ivities 
Questionnaire-15 (PDAQ-15), Alzheimer’s Disease Cooperative Study  –Clinician Glo bal 
Impression interview, MDS-UPDRS, Neuropsy chiatric Inventory (NPI), Epworth Sleepi[INVESTIGATOR_7109] (ESS), andQuestionna ire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
(QUIP) scales.
The C-SSRS “Since Last Visit” scale will be assessed.  If, based on assessment of the C-SSRS, it 
is determined that suicide -related behaviors have occurred, then the Lilly Self- Harm Follow-Up 
form will be used to collect addit ional information to allow for a more complete assessment of 
these behaviors.
[IP_ADDRESS] Actigraphy and iPAD Device
The actigraphy device , similar to a watch ,will be placed on the wri st of the subject at Visit 2(if 
available and if consented ) for the 2-week period of t imeuntilVisit 3 (see Section 9.8.1.2and 
the Operations Manual) .
An iPad configured wi th the Lilly Tri al application (Lilly Tri al app) will  be provided to the 
subjects (if available and if consented )(see Section 9.8.1.1and the Operations Manual) .  
Subjects shouldcomplete assessments starting the day  following Visi t2, throughout the dosing 
period, and for 2 weeks after the conclusion of the treatm ent period (until Visit801).  Thi s 
assessment should be done up to twice daily.
[IP_ADDRESS] Home Blood Pressure Monitoring
The subject should be given the ho me blood pressure monitoring (HBPM) device at Visit 2 and 
instructed to measure Hom e BPtwice daily in the seated posit ion using the HBPM equipment 
provided by [CONTACT_242936] a minimum of 7 days between Visit 2 and Visit 3.  Home BP shouldbe 
measured twice in the morning (approximately 1 minute apart) (e .g., 8AM) immediately 
following study medication dosing and twice in the evening, approximately 12 hours later 
(approximately 1 minute apart) (e .g., 8PM).
5.1.3.Double-Blind Period (Visit 3through Visit 11)
See the Schedule o f Activities (Section2)for the timing of events and the measures to be 
assessedduring the double -blind period.
Estimated length o f study visits:
Visit 3: approximately 8 hours
Visit4, Visit5, Visit6, Visit7, Visit 9,and Visit 10: approximately 2 hours
Visit8 and Visit 11: approximately 6 hours
All study procedures for the respective visits should be completed within 1 day.In exceptional 
circumstances, if the clinical assessments cannot be completed within 1day at V3, V8 ,and/or 
V11,those clinical assessments may be completed the next day . The orthostatic blood pressure 
measurements, in -clinic blood pressure measurements, the CDR -CCB,and the laboratory  
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143168] day  of visit.
Visit3 (Day1 of dosing)   
[IP_ADDRESS]. Orthostatic BP/Pulse Rate Measurements
Prior to dosing, o rthostatic BP/pulse rate m easurements will be collected at time 0 of the in-clinic 
BP/pulse rate monitoring.  Subjects will have 3BP/pulse rate measurements taken in the seated 
position approximately 1 minuteapart followed by 1BP/pulse rate measurement taken in the 
standing posit ion.  Subjects shoul d be seated for at least [ADDRESS_1143169] feels unable to stand, vital 
signs only in the seated posit ion will be recorded.
The mean should be calculated from the 3 initial in-clinic BP/pulse rate measurements taken in 
the seated posit ion, andmust meet inclusion criteria [6] in order to proceed with dosing
(TableHBEH.4).  At Visit 3, s ubjects not fulfilling inclusio n criteria [6] at their time 0 BP/pulse 
rate measurements can have their BP/pulse rate re -evaluated within 3 days.  If inclusio n criteria 
[6] is subsequent ly met (within 3days of Visit3), subject may proceed with dosing.  If inclusi on 
criteria [6] is subsequent ly not met (within 3days of Visit3), the subject must be discont inued.  
Subjects who continue to meet entry criteria will be randomized to LY3154207 (10, 30, or 75mg 
QD) or placebo immediately fo llowing confirmat ion that subject meet sinclusion criteria [6] .  
Subjects should be dosed immediately after randomizat ion.
The time 0 mean BP and pulse rate will be used for the baseline measurement to assess the 
change thresho ld for the development of potentially clinically significant BP/pulse rate
(TableHBEH.3).
After time 0, in-clinic BPand pulse rate measurements will be takenevery 60minutes in the 
seated posit ion only for up to 8 hours.Subjects who meet potentially clinically significant 
BP/pulse rate measurement (TableHBEH.3)at 3 consecut ive timepo ints(Day 1 stoppi[INVESTIGATOR_37660]) 
should be discont inuedfrom the study.
I7S-MC-HBEH(b) Clinical Protocol Page 34
LY3154207TableHBEH.3 .Potentially Clinically Significant Vital Sign Criteria
TableHBEH.4
. Vital Sign Inclusion Criteria [6]for Subjects at Visit1 and Visit 3
(time 0)
Subjects <60 Years Subjects ≥60 Years
Mean Systolic BPa(mm Hg) ≤140 ≤150
Mean Diastolic BP (mm Hg) ≤90 ≤90
Mean Pulse Rate (bpm) ≤90 ≤[ADDRESS_1143170] be less than 180 mmHg
[IP_ADDRESS]. PK Sample
APK sample is to be collected within [ADDRESS_1143171] ingwill be recorded.
[IP_ADDRESS]. Home Blood Pressure Monitoring
Home BP measurements shouldbe conducted for a minimum o f 7days between Visit 2 and 
Visit3, for approximately 3weeks between Visit 3 and Visit 6, and for a minimum o f 7days 
between Visit 10 and Visit 11, and Visit 11 andVisit 801.  Hom e BP shouldbe measured twi ce 
in the morning (approximately 1 minute apart) (e .g., 8AM) immediately fo llowing study  
medication dosing and twice in the evening, appr oximately 12 hours later (approximately 
1minute apart) (e .g., 8PM).

I7S-MC-HBEH(b) Clinical Protocol Page 35
LY31542075.1.3.4. Visit 4 to Visit 11
Visits will occur at weekly  intervals (7days ± 1day) for Visit 4through Visit 7, and will occur 
at biweekly  intervals (14 days ± 3days) for Visit8 through Vi sit 11.
Study drug is to be administered at the clinic on the morning of Visit 8 and Visit 11 following 
the Time0in-clinic BP/pulse rate m easurements.
In-clinic BP/pulse rate monitoring at Visit [ADDRESS_1143172]-CCB assessment .  
MoCA, ADAS -Cog13, MDS -UPDRS [Part III], and D -KEFS will be performed according to the 
Study Schedule.  
Caregiver’s inputs will be needed at Visit 4,Visit8, Visit11, or ET/ D Cfor the PDAQ-15, 
Alzheimer’s Disease Cooperative Study  –Clinician Global Impressio n of Change 
(ADCS-CGIC), MDS-UPDRS, NPI, ESS, GDS-S,and/orQUIPscales.  Caregiver’s input , 
separate from the subject, will be needed at Visit 11 , Visit 111 and Visi t 801for the PWC -20
early termination.
5.1.4.Telephone Visit ( Visit 111)
A telephone visit will be conducted [ADDRESS_1143173] and caregiver , separately, at this telephone visit.
5.1.5.Follow-Up Period (Visit 801)
A follow-up visit will be perform ed at Visi t801, which will occur 14 days ± 3daysfollowing 
the subject’s last dose of study  medication.
Visit 801 is expected to be of a duration of approximately 2 hours.
Caregiver’s inputs will be needed at Visit 801for MDS-UPDRS, PWC-20, and ESS.
See the Schedule o f Activities (Section2)for the timing of events a nd the measures to be 
assessedduring the fo llow-up period.
5.2.Number of Subjects
Approximately  750subjects will be screened to achieve 340randomized and evaluable subjects 
for an estimated total o f [ADDRESS_1143174] ivities
(Section2) for the last subject.
I7S-MC-HBEH(b) Clinical Protocol Page 36
LY31542075.4.Scientific Rationale for Study Design
StudyHBEH will include subjects who meet the revised MDS criteria for PD (Postuma et al. 
2015) or those who meet the revised criteria for DLB , and all who have mild-to-moderate 
dementiaas defined by a decline in cognit ive function, which in the opi[INVESTIGATOR_3078] n of the invest igator 
has resulted in funct ional impairment and a MoCA score between 10 and 23 (Trzepacz et al. 
2015).  The inclusio n of LBD(PDD orDLB)inHBEH meets current thinking about LBDthat, 
apart from the timing of cognit ive impairment, PDD and DLB are clinically and pathologically 
indistinguishable and would likely respond to similar therapeutic approaches ( Aarsland et al. 
2004; Ballard et al. 2006).
Placebo is included as the control, in a blinded manner for investigator and site staff and 
subjects, to allow for an unbiased assessment of the safet y data generated, which will allo w for a 
more robust com parison between LY3154207 and placebo data. Comparisonof 3 dosage levels 
of LY3154207 was chosen to evaluate dosage exposure response for safet y and efficacy.  Init ial 
visits (Visit3 to Visit 7) were selected to occur at a weekly interval to provide a detailed 
evaluation of the efficacy and safet y of LY3154207 during the init ial treatment.  A dosing
duration of 12weeks was selected ,as it is est imated to be the minimum durat ion in which a 
beneficial effect on cognit ion may be observed.
5.5.Justification for Dose
Three fixed dosages of LY3154207 (10, 30, or 75mg administered orally  [or 50mgQD, see 
Section 10.3.7, Interim Analysis])were selected based on current preclinical pharmaco logy and 
toxicology data, and clinical PK, p harmacodynamic and safety data.
The key considerations regarding the dose se lection were to:
ensure a broad exposure exploration around the effective concentration 25 (EC25) 
defined as the drug concentration at which25% of the maximal response has been 
achieved.  

explore the possibilit y of an inverted U -shaped pharmacodynamic effect on cognit ion
explore wheth er different dosages of LY3154207 have different ial efficacy on domains 
of PD(cognition, motor, wakefulness).
In StudyHBEA, CSF samples were collected in healthy  subjects, and the peak m ean CSF 
concentrations of LY3154207 fo llowing a  
Given that LY3154207 PK is dose linear, the proposed dosages of 10, 30, and 75 mg 
LY3154207 are expected to encompass  
 
 
 
CCI
CCI
CCI
CCI
CCI
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143175] on cognition (Cools and D’Esposito2011).  
Although there i s no evidence of an inverted U -shaped response in the Phase [ADDRESS_1143176] range of pharmacodyna mic effects, 
may identify an invertedU-shaped dose –response rel ationship if such effect exists, minimize the 
risk of either under -or overdosing , and explore differential effect son relevant clinical do mains 
(cognition, motor, wakefulness) .
CCI
CCI
CCI
CCI
I7S-MC-HBEH(b) Clinical Protocol Page 38
LY31542076.Study Populati on
Prospective approval o f protocol deviations to recrui tment and enro llment criteria, also known as 
protocol waivers or exempt ions, are not permitted.
6.1.Inclusion Criteria
Subjects are eligible to be included in the study  only if they meet all of the following criteria
(note that inclusio n criteria [6] must be metat additional visit s):
Type of Subjectand Disease Characteristi cs
[1]Male and female subjects aged 40 to 85 years (inclusive).
[45]Meet diagnostic criteria for PD (Postuma et al. 2015) or DLB (McKeit h et al. 
2017) (See Appendix 5 and 6)
[2]Inclusion criterion2 removed with Amendment b
[3]Have dementia as defined by a decline in cognit ive function, which in the 
opi[INVESTIGATOR_824306].
[4]Have a MoCA score of 10 to 23 
[5]Are Modified Hoehn and Yahr Stages 0 to 4.
[6]Have a BP or pulse rate at Visit 1 and Visit 3 (time 0) , as determined by 3
sequential BP/pulse rate measurements in theseated posit ion:
Subjects <60 years old:
oa mean systolic blood pressure (SBP) less than or equal to 
140mmHg, a mean diasto lic BP less than or equal to 90 mmHg,
and a mean pulse rate less than or equal to 90beats/min in the
seated posit ion.
oeach of the [ADDRESS_1143177] be less than 180 mmHg.
Subjects ≥60years old:
oa mean SBP less than or equal to [ADDRESS_1143178] olic BP 
less than or equal to 90 mmHg,and a mean pulse rate less than or 
equal to 90beats/min in theseated posit ion.
oeach of the [ADDRESS_1143179] be less than 180 mmHg.
[7]If onanti-parkinsonian agents , subjects m ust be on stable dosage for at least 
3weeks prior to Visit 1, andshould remain on stable doses duringthe course 
of the study.
[8]If on medications affect ing cognit ion (rivastigmine, galantamine, donepezil, 
memantine), subjects m ust be on stabledosagefor at least 3 weeks prior to 
Visit 1and shouldremain ata stable dosageduring the course of the study .
I7S-MC-HBEH(b) Clinical Protocol Page 39
LY3154207[9]If on antidepressant medicat ions, subjects m ustbe on stabledosagefor at least 
3 weeks prior to Visit1and shouldremain at a stable dosage during the 
course of the study .
[10]If on clozapi[INVESTIGATOR_050], queti api[INVESTIGATOR_050],and pi[INVESTIGATOR_824307]- induced or 
disease-related psy chosis, subjects must be on stabledosagefor 3weeks prior 
to Visit1and shouldremain at a stabl edosage during the course of the study .
[11]If on antihypertensive medications, subjects must be on stable dosage for at 
least 3weeksprior to Visit 1
SubjectCharacteristics
[12]Contraception.
[12a]Male subjects, regardless of their fertilit y status, with nonpregnant WOCBP 
partners must agree to either remain abstinent (if this is their preferred and 
usual lifestyle) or use condoms as well as 1additional highly effective (l ess 
than 1% failure rate) method of contraception (such as co mbinationoral 
contraceptives, implanted c ontraceptives ,or intrauterine devices) or effect ive 
method of contraception (such as diaphragms wit h spermicide or cervical 
sponges) for the durationof the study and until their plasma concentrations are 
below the level that couldresult in a relevant potenti al exposure to a possible 
fetus, predicted to be 90days following the last dose of study  drug (bel ow the 
no-observed-adverse-effect-level [NOAEL]/10) plus 90 days.
[12b]Men and their partners may  choose to use a double –barrier method of 
contraception.   (Barrier protection methods without concomitant use of a 
spermicide are not an effect ive or acceptable method of contraception. Thus, 
each barrier method must include use of a spermicide. It should be noted,
however,thatthe use ofmale and female condoms as a double barrier method 
is not considered acceptable due to the high failure rate when these barrier
methods are combined).
[12c]Men with pregnant partners should use condoms during intercourse for the
duration ofthe study and unt il 93daysfollowing the last dose of study  drug.
[12d]Men should refrain fro m sperm donation for the durati on of the study  anduntil 
theirplasma concentrations are below the level that could result in a relevant
potentialexposure to a possibl e fetus, predi cted to be 93daysfollowing the last 
dose of study  drug.
[12e]Female subjects not of childbearing potential may  participate and include those 
who are:
infertile due to surgical sterilizat ion (hysterectomy, bilateral
oophorectomy , or tubal ligation), congenital ano maly such as 
Mullerian agenesis; or
I7S-MC-HBEH(b) Clinical Protocol Page 40
LY3154207post-menopausal –defined as :
oA woman at least 40years of age with an intact uterus, not on 
hormone therapy , who has had at l east 1year of spontaneous 
amenorrhea wi th a follicle-stimulating hormone level 
>40mIU/mL; or
oA woman [ADDRESS_1143180] 6months of spontaneous amenorrhea; or
oA woman at least 55years of age with a diagnosis of 
menopause prior to start of hormone replacement th erapy.
[13]In the invest igator’s opi[INVESTIGATOR_3078] n is able to comply wit h all appo intments for clinic
visits,tests, and procedures, including venipuncture, computerized 
assessments and examinat ions required by [CONTACT_760].
[14] Are able to swallow capsules.
[15] Have a level o f understanding such that the subjectcan communicate with the 
site study personnel, understand the study  requirements.
[16]All subjectsmust have a reliable caregiver who is in frequent contact [CONTACT_824346](defined as at least 10 hours per week) and will acco mpany the subject
toVisit1, Visit2, Visit4, Visit8, Visit11, Visit 111 (telephone only) and 
Visit 801.
[17]The caregiver must be able to communicate with site personnel and be willing 
to comply with protocol requirements , and in the investigator’s opi[INVESTIGATOR_824308] -specified quest ionnaires.
[18]Agree not to post any  personal medical data related to the study or 
information related to the study  on any websi te or social media site(e.g., 
Facebook, Twitter, LinkedIn, Google+, etc.).
Informed Consent
[19]Provision of signed and dated informed consent form (ICF) fro m subject and 
caregiver prior to any  study-specific procedures being performed.
6.2.Exclusion Criteria
Subjects will be excl uded from  study enrollment if they meet any o f the following:
Medical Conditions
[20]Are WOCBP.
[21]Have significant central nervous system or psychiatric disease, other than PD
or DLB, that in the invest igator’s opi[INVESTIGATOR_3078] n may affect cognition or the abili ty to 
complete the study .
[22]Have a history  in the last 6months of transient ischemic attacks or ischemic 
stroke.
I7S-MC-HBEH(b) Clinical Protocol Page 41
LY3154207[23]Have a history  of intra-cerebral h emorrhagedue to hypertension.
[24]Have a history  of hypertensive encephalopathy .
[25]Have atypi[INVESTIGATOR_824309] (e .g., antipsychotics) or 
disease (such as progressive supranuclear palsy, essential tremor, mult iple 
system atrophy [e.g., striatonigral degenerat ion, olivopontocerebellar 
atrophy], or postencephalit ic parkinsonism).
[26]Have a current implantable intracranial st imulator or hi story of intracranial 
ablation surgery (e.g., subthalamic, globus pallidus -internal segment).
[27]Exclusion criterion27 removed with Amendment b
[28]Exclusion criterion28 removed with Amendment b
[29]Exclusion criterion29 removed with Amendment b
[30]Have a history  of substance abuse within the past 1 year (drug categories 
defined by [CONTACT_824347], 5 th
Edition, and/or substance dependence within the past 1 year, not including 
caffeine and nicotine).
[31]Exclusion criterion31 removed with Amendment b
[32] Have a serious or unstable medical illness, other than LBD(PDD orDLB),
including cardiovascular, hepat ic, respi[INVESTIGATOR_696] , hematologic, endocrinologic,
neurologic, or renal  disease, or clinically significant laboratory  or 
electrocardi ogram (ECG) abnormalit y as determined by  [CONTACT_3170].
have a history  in the last 6 m onths of exerti onal angina, unstable angina, 
myocardial infarction, and acute coronary  syndrome
have a history  of heart failure of eit her [LOCATION_001] Heart Associat ion 
ClassIII or IV
have a history  of additional risk factors for Torsades de Pointes (e .g., 
chronic hypokalemia, family history  of Long QT Syndro me)
[33]Subjects with acute liver disease (e .g., acute viral hepatit is, alcoho lic 
hepatitis); subjects with a known chronic liver disease (e .g., hepatitisB, C, 
alcoholic liver disease, cirrhosis); alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) equal to or higher than 2X upper limit of normal 
(ULN); total bilirubin (TBL) equal to or higher than 1.5X ULN; (except for 
subjects with Gilbert’s syndrome); or alkaline phosphatase ( ALP)equal toor 
higherthan 2X ULN .
I7S-MC-HBEH(b) Clinical Protocol Page 42
LY3154207[34] Subjects have answered “yes”to either Question4 (Active Suicidal Ideat ion 
with Some Intent to Act, Without Specific Plan) or Question 5 (Active 
Suicidal Ideation with Specific Pl an and Intent) on the “Suicidal Ideati on”
portion of the C-SSRS -Children’s versio n, or answer “yes”to any of the 
suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, 
preparatory  act or behavior) on the “Suicidal Behavior”portion of the 
C-SSRS; and the ideation or behavior occurred within the past month.
Prior/Concomitant Therapy
[35]Have used ant ipsychotic medications, with the excepti on of clozapi[INVESTIGATOR_050], 
quetiapi[INVESTIGATOR_050], pi[INVESTIGATOR_824310] 6 months prior to screening (Visit 1) and at 
any time during the course of the study .
[36]Have used anticholinergics trihexyphenidyl and ben ztropi[INVESTIGATOR_231423] 4weeks 
prior toscreening (Visit 1) and at any  time during the course of the study .
[37]Have motor condit ions for which the ant iparkinsonian treatment is expected to 
change during the course of the study, as well as unpredictable motor 
fluctuations that in the invest igator’s opi[INVESTIGATOR_3078] n would interfere with conduct ing 
assessments.
[38]Are taking any medicat ions or food, herbal or dietary  supplements that are 
inhibitors (e .g., ketoconazole, grapefruit juice), or strong/moderate inducers of 
cytochrome P450 3A4 (CYP3A4) (e.g ., rifampi[INVESTIGATOR_2513]) orare unable or unwilling 
to discont inue usage of them 4 weeks prior to Visit 3. If subjects are willing 
and able to discont inue use o f CYP3A4 inhibitors or strong/moderate inducers 
at least [ADDRESS_1143181] of inhibitors and inducers of CYP3A4.
Prior/Concurrent Clinical Trial Experience
[39]Are current ly enrolled in any other clinical study  involving an invest igational 
product or any  other type of medical research judged not to be scient ifically or 
medically co mpatible with this study.
[40]Have part icipated, within the last [ADDRESS_1143182] or device.
[41]Have previously been exposed to LY3154207.
Other Exclusions
[42]Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted.
[43]Are Lilly employees, employees of IQVIA, or employees of a thi rd party 
organization involved in the conduct of the study .
[44]Exclusion criterion44 removed with Amendment b
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143183] performance on 
cognitive tasks and influence the interpretation of other clinically relevant outcomes.
CNS diseases and o ther neuropsy chiatric disorders (e .g., active psychosis, substance abuse) that 
can affect performance on cognit ive tasks and compliance wit h the protocol are also excluded.
Medications that negatively affect cognit ion (e.g., certain anticholinergics, exclusio n criterion
#36) and motor function (e.g., certain antipsychotics, exclusio n criterion#35) will be excluded, 
given the potential of these medicat ions to confound clinically  relevant outcom es.
 
 
 
In addition, WOCBP have been excluded because n onclinical studi es of development and 
reproducti on with LY3154207 have not been conducted.
6.3.Lifestyle Restrictions
Subjects should be instructed not to donate blood or blood products during t he study or for 
93days following the l ast dose of LY3154207 .  Male subjects shoul d be instructed to not donate 
sperm during the study  for 93days following the last dose of LY3154207 .
6.4.Screen Failures
Individuals who do not meet the criteria for participat ion in this study  (screen failure) m aybe 
rescreened once.  The interval between the initial screening and the re screen should be at least 
4weeks.  When the subject is rescreened, the subject must sign a new ICF , be assigned a new 
subject identification number, and undergo all screening procedures .
CCI
CCI
I7S-MC-HBEH(b) Clinical Protocol Page 44
LY31542077.Treatment s
7.1.Treatments Administered
This study  involves a comparison of LY3154207 75mg(or 50mg, see Section 10.3.7, Interim 
Analyses), 30mg,and 10mg administered orally QDwith placebo.TableHBEH.5.shows the 
treatment regimens.
TableHBEH.5. Treatment Regimens
Regimen Dose
LY Dose Group 110mg LY
(25-mg caps and 1placebo caps)
LY Dose Group 230mg LY
(125 -mg caps, 1 x 5 mg caps and 1placebo caps)
LY Dose Group 375mg LY
(325-mg caps)
Or50 mg LY
(2 x 25-mg caps and 1 placebo caps)
Placebo 3 placebo caps
Abbreviations :  caps = capsule ; LY = LY3154207.
The invest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the investigational agent(s) to the subjectand/or legal 
representative
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection
at the end of the study  returning all unused medication to Lilly ,or its designee,unless 
the sponsor and sites have agreed all unused medication is to be destroy ed by [CONTACT_779], as 
allowed by  [CONTACT_1769].
7.1.1.Packaging and Labeling
The drug product is s upplied for clinical trial use as capsules for oral administration.
Capsules: Each capsule is composed of LY3154207 with no inactive ingredients other than the
hypromellose capsule shell. Each capsule contains LY3154207 4- Hydroxybenzo ic acid
equivalent to 5mgor 25mg of the LY3154207 drug substance. The drug product should be 
stored according to instructions on the label.
Clinical trial materials will be labeled according to the country ’s regulatory requirements.
I7S-MC-HBEH(b) Clinical Protocol Page 45
LY31542077.2.Method of Treatment Assignment
Subjects whomeet all criteria for enrollment will be randomized to double -blind treatment at 
Visit3.  Subjects will be rando mized in a blinded fashio n to the 4treatment arms (Pl acebo;
LY3154207 10 mg;LY3154207 30 mg; LY3154207 75 mg [or 50mg based on interi m analysis 
–refer to Section 10.3.7]) at 1:1:1:[ADDRESS_1143184] igator site and the currentuse of AChEIs (Yes, No) using an 
interactive web-response system (IWRS).
The IWRS will be used to assign blister packs containing double -blind invest igational product to 
each subject. Oneblisterpack will be dispensed for each week of dosing,for example, for 
14-day study intervals,[ADDRESS_1143185] blister packs by [CONTACT_45342] a confirmat ion number found 
on the blister packs into the IWRS.
Selection and Timing of Doses
The doses shouldbe administered at approximately the same time each day in the morning.  At 
Visit3, Visit8, and Visit 11, the dose will be administered at the clinic.   The actual date and time 
of thedose administrations on theday of Visit3, Visit4, Visit5, Visit8, Visit11, and ET/ DC
visit will be recorded in the subject’s eCRF.
7.3.Blinding
This is a double -blind study .  To preserve the blinding of the study , a minim alnumber of Lilly  
personnel will see the rando mization table and treatm ent assignments prior tostudy completion.  
The efficacy and safet y interimanalyseswill be completed by  [CONTACT_824348] (IAC) who will be unblinded.  An additional group not direct ly involved 
in this study  will review unblinded digital bio marker data at prespecified interim analyses.
Emergency  unblinding for AEs m ay be perform ed through the IWRS, which m ay supplement or 
take the place of emergency  codes generated by  a computer drug -labeling system.  This option 
may be used ONLY if the subject’s well-being requi res knowl edge ofthe subject’s treatment 
assignment.  All calls result ing in an unblinding event are recorded and reported by  [CONTACT_8784].
If an invest igator, site personnel performing assessments, or subjectisunblinded, the subject
must be discont inued from thestudy.  
In case of an emergency , the invest igator has the sole responsibilit y ofdetermining if unblinding 
of a subject’s treatment assignment is warranted for medical management of the event.  The 
subject’s safet y must always be the first consideratio n in making such a determinat ion.Every 
effort should be made to notify  Lilly Medical  representati ve prior to unblinding if feasible.   If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
promptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
7.4.Dosage Modification
Investigator-initiated dosage modificat ions are not allowed in this study.
I7S-MC-HBEH(b) Clinical Protocol Page 46
LY31542077.5.Preparation/Handling/Storage/Accountabil ity
The invest igator or his/her designee is responsible for the fo llowing:
confirming appropriate temperature condit ions have been maintained during transit for all 
study treatment received and any  discrepancies are reported and resolved prior touse of 
the study treatment.
ensuring that only subjects enrolled in the study  may receive study  treatment and only 
authorized site staff may  supply or administer study  treatment. All study treatments must 
be stored in a secure, environmentally  controlled , and monitored (manual or autom ated) 
area in accordance with the labeled storage condit ions with access limited to the 
investigator and authorized site staff.
The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatment accountabilit y, reconciliat ion, and record maintenance (such as 
receipt, reconciliat ion,and final disposit ion records).
7.6.Treatment Compliance
Subjectcompliancewith study medication will be assessed at each visit.  Compliance w ill be 
assessed by  [CONTACT_433676].   Capsules dispen sed and returned should be recorded in 
theCRF.
Compliance is defined as having taken ≥80% to <120% of the prescribed amount of medicat ion.
7.7.Concomitant Therapy
Concomitant medicat ions to treat the underlying PD (known as ant iparkinsonian agents) are 
permitted, provided the subjecthas been on a stable dos ageregimen for at least 3weeks prior to
Visit 1, and shouldremain on a stabl e dosage for the duration of the study .  Routine medications 
taken PRN are allowed.  However, if in the investigator ’s opi[INVESTIGATOR_824311] ,the reason for change in 
medication should be recorded as an AE and the concomitant medicat ion eCRF page updated 
accordingly. In addition, the study  sponsor shoul d be notified as soon as feasible and a 
notification generated.
In addition to medications for PD, drugs for common conditions in an older population, such as 
hypertension,hypercholesterolemia, and ischemic heart disease ,are acceptable. Specifically, 
antihypertensive medicat ions should be stable for 3 weeks prior to V 1.During the course of the 
study, antihypertensive medications may be adjusted for medical need. The conco mitant 
medication eCRF page should be updated accordingly and if applicable the reason for change in 
medication should be recorded as an AE.
Drugs and supplements that areknown inhibitors or inducers of CYP3A4, as well  as
trihexyphenidyl and benztropi[INVESTIGATOR_050] ,are specifically excluded .
If subjects are taking atorvastatin, they  should be instructed to take atorvastatin in the evening 
(approximately 12 hours after study  drug dosing).
I7S-MC-HBEH(b) Clinical Protocol Page 47
LY3154207Concomitant medicat ions to treat cognition ( rivastigmine, galantam ine, donepezil, memantine )
and depression are permitted ,if subjects havebeen on a stable dosage regimen for at least 
3weeks prior to Visit 1and shouldremain on a stable dosage for the duration of the study .  
Concomitant medicat ions to treat psy chosis (clozapi[INVESTIGATOR_050], queti api[INVESTIGATOR_050],and pi[INVESTIGATOR_4256]) are 
permitted, provided the subject has been on a stable dosage regimen for at least 3weeks prior to 
Visit 1and shouldremain on a stable dosage for the duration of the study .  However, if in the 
investigators op inion cognitive and antipsychotic medicat ions need to be adjusted during the 
course of the study to address a clinical change ,the reason for change in medicat ion should be 
recorded as an AE and the concomitant medication eCRF page updated accordi ngly.  Inaddition, 
the Lilly CRP or designee must be contact[CONTACT_112073] t o determine whether the subject
should continue in the study .
If the need for concomitant medicat ion arises, inclusi on or continuat ion of the subject may be at 
the discretion of the investigator after consultation with the Lilly CRP or designee.  All 
concomitant medicat ionstaken during the study  must be recorded on the concomitant medication 
eCRFpage.
Subjects and their caregiver shouldbe instructed to consult withthe appropriate study personnel 
at the site prior toinitiation of any new medicat ions orsupplements and prior tochanging dose 
or discontinuing fro mconcomitant medications or supplements.
Additional information about concomitant medicatio ns is provided in the Opera tions Manual .
7.8.Treatment after the End of the Stu dy
7.8.1.Treatment after Study Completion
Study completion will occur fo llowing thefinal analysis o f primary and secondary  objectives, as 
determined by [CONTACT_11007].Investigators will cont inue to fo llow Schedule of Ac tivities (Section2) for 
all subjects until notified by [CONTACT_824349].
LY3154207 will not be made available after conclusion of the study  to subjects.
I7S-MC-HBEH(b) Clinical Protocol Page 48
LY31542078.Discontinuation Criteria
8.1.Disconti nuation from Study Treatment
8.1.1.Permanent Discontinuation from Study Treatment
Possible reasons leading to permanent discontinuatio n of study  treatment:
Subject Decisio n
othe subject or the subject’s designee , for example, legal guardian ,requests to 
discontinue the investigational product.
Day 1 stoppi[INVESTIGATOR_004] -Discontinuation due to change in acute vital signs on Day1 
(Visit3) 
If during Day 1 (Visit3) and following study drug dosing, any  of the potenti ally 
clinically significant vital signs criteria (TableHBEH.3)are met at [ADDRESS_1143186] should be discont inued from 
the study drug.The relative value of the potentially clinically significant vital sign 
criteria is calculated by  [CONTACT_824350] 3 seated b lood pressure and pulse 
rate at Time0 of Visit 3(baseline) .
oFor vital sign measurements that meet the criteria for potentially  clinically 
significant vi tal signs (TableHBEH.3)after Visit3, management will be left to 
the discretion of the invest igator and may include discontinuat ion of study  drug.  
Theinvestigator should consult with the Lilly  CRPor designee.
Discontinuati on due to a hepati c event or liver test abnormalit y
Subjects who are discontinued from the studydue to a hepatic event or liver test 
abnormality should have addi tional hepatic safet y data collected via eCRF.
Discontinuati on of the invest igational product for abnormal liver tests should be 
considered by [CONTACT_82378] a subject meets 1of the following condi tions after 
consultation wit h the Lilly -designated m edical monitor:
oALT or AST >8X ULN
oALT or AST >5X ULN for more than [ADDRESS_1143187] >[ADDRESS_1143188] and TBL >2X ULN or internat ional normalized 
ratio >1.[ADDRESS_1143189] >3X ULN with the ap pearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
oALP >3X ULN
oALP >2.5X ULN and TBL >2X ULN
oALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right 
quadrant pain or tenderne ss, fever, rash, and/or eosinophilia (>5%)
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143190] in the fo llowing 
circumstances:
Mean Fredericia ’s corrected QT interval on the ECG (QTcF)>500millisecondsoran 
absolute change >60 millisecondswhen compared with baseline
Subjects discont inuing fro m the study treatment prem aturely for any reason shoul d complete an 
early termination visit and safet y follow-up (V801) to com plete AEand other fo llow-up 
procedures per Section 2(Schedule of Act ivities), Section 9.2(Adverse Events) and Section 9.4
(Safety).
8.1.2.Temporary Discontinuation from Study Tr eatment
Temporary discontinuation from study drug treatment is allowed if a short -term treatment of an 
excluded medicat ion is necessary, secondary  to hospi[INVESTIGATOR_059], personal  circumstances ,or to 
evaluate the study  drug impact on an uncertain AE. Study drug may be restarted at the 
investigator’s discret ion. If temporary discontinuation is due to an AE, it should be reported to 
the LillyCRP or their representative .Temporary treatment discont inuation and restarting should 
be docum entedin the eCRF . Restarting treatment after a discont inuation period that is greater 
than [ADDRESS_1143191] should complete an early terminat ion 
visit and safety follow-up (V801) to complete safety follow-up as outlined in Sect ion2
(Schedule of Act ivities), Section9.2(Adverse Events) ,and Section 9.4(Safety).
8.2.Discontinuation from the Study
Subjects will be discont inued in the fo llowing circumstances:
enrollment in any other clinical study invo lving an invest igational product or enrollmen t 
in any other type of medical research judged not to be scient ifically or medically 
compatible with this study
participation in the study needs to be stopped for medical, safet y, regulatory, or other 
reasons consistent with applicable laws, regulations, a nd good clinical pract ice (GCP)
investigator decisio n
othe investigator decides that the subject should be discontinued from the study
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143192], for any reason, requi res treatment with another therapeutic agent 
that has been demo nstrated to be effective for treatment of the study  indication, 
discontinuat ion from the study occurs pri or to introducti on of the new agent
subject decisio n
othe subjector thesubject’s legal representative requests to be withdrawn fro m the 
study
Subjects discontinuing from the study prematurely for any  reason should complete an early 
termination visit and safet y follow-up (V801) ,to completeAEand other safet y follow-up per 
Section2(Schedule of Act ivities), Section9.2(Adverse Events) ,and Section 9.4(Safety).
8.3.Lost to Follow -Up
A subjectwillbe considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by [CONTACT_4145].  Site personnel are expected to make 
diligent attempts to contact [CONTACT_105416] a scheduled visit or were otherwise 
unable to be fo llowed up by  [CONTACT_779].
Site personnel, or an independent third party, will attempt to collect the vital status of the subject 
within legal and ethical  boundaries for all subjects randomized, including those who did not get 
investigat ional product.  Public sources may  be searched for vi tal status information.  If vital 
status is determined, this will be documented and the subject will not be considered lost to 
follow-up.
Neither Lilly personnel  nor Lilly Third Party  vendors will be involved in any attempts to collect 
vital status inform ation.
I7S-MC-HBEH(b) Clinical Protocol Page 51
LY31542079.StudyAssessments and Procedures
Study assessments and procedures and their timing (including tolerance limits for timing) are 
summarized in Section2(Schedule of Act ivities).
Appendix [ADDRESS_1143193] resul ts.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1.Efficacy Assessments
Screening measures used for diagnosis and establishment of study  eligibility are described 
elsewhere (Section 2and Section5.1.1).
To assess the efficacy of LY3154207, which targets attentional and executive funct ion pathways, 
a set of cognit ive tests has been selected as primary and secondary endpoints in Study HBEH.  
Cognitive and funct ional testing for each subject s houldbe perform ed in the same order as 
outlined in the Operations Manual to reduce potential variabilit y.  Ifpossible, each assessment 
should be perform ed on a given subject by  [CONTACT_477871].  The principal invest igator 
has the responsibilit y of selecting who will administer the instruments at the site, as long as all 
training requirements (see the Operations Manual )have been met by  [CONTACT_511162].
The following is a brief descript ion of the assessments that will be used in this study .
9.1.1.Primary Efficacy Assessments
Continuity of Attention Composite Score from the Cognitive Drug Research Computerized 
Cognition Battery:   The CoA component of the CDR -CCB has been selected as the primary 
endpoint for this study because it measures the ability to sustain concentration and has 
demonstrated a si gnificant treatm ent effect in previous trials in subjectswith LBD(PDD or
DLB)within the time frame ofthe current study (Wesnes et al . 2005;Rowan et al .2007).  The 
battery is a simple “yes/no”computerized assessment that is feasible across a range of PD motor 
impairment ,and as the CoA score is based on accuracy  but not speed of response, it is resistant 
to confounding due to motor impairment (Wesnes et al . 2002).The CDR -CCB isnot dependent 
on skill of a rater,and hence there i s less inter -rater variability;learning effects can be minimized 
with training and it targets domains relevant to subjects with LBD.Treatment effects with
acetylcho linesterase inhibitors in LBDsubjects have been demo nstrated using the CDR (Wesnes 
et al. 2005;Rowan et al. 2007, McKeith et al 2000 ).  The CoA is calculated from the CDR -CCB 
by [CONTACT_824351] .
The CDR -CCB system  includes tests of attention (simple and cho ice reaction t ime, digit 
vigilance), working memory  (spatial and numeric) and epi[INVESTIGATOR_39751] c memory (word recogni tion, 
pi[INVESTIGATOR_824312]) (Wesnes 2008), from which CoA, Power of Attention (PoA), and cogni tive 
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143194] -CCB is com puter controlled, with info rmation 
presented on high reso lution monitors and responses recorded via a response module containing 
2buttons, 1marked “no” and the other “ yes”(Wesnes et al . 2002; Rowan et al. 2007 ).  The 
CDR-CCB assessment including the tasks listed below will be co mpleted at each visit :
Word presentation: 12 words are presented on the monitor at the rate of 1 every 3 secondsfor 
the subjectto remember.
Pi[INVESTIGATOR_337615]: Aseries of 14 pi[INVESTIGATOR_824313] 1 every 
3seconds.
Simple reaction time:   The subject is instructed to press the “yes”response button as quickly as 
possible every  time the word “y es”is presented on the monitor.  Twentystimuli are presented 
with a varying interstimulus interval.
Digit vigilance task:   Atarget digit is randomly selected and then constant ly displayed to the 
right of the m onitor screen.  A series of digits are then presented in the center of the screen at the 
rate of 80/min and the subject is required to press the “yes” button as quickly as possible every  
time the digit in the series matched the target digit.  There are 15 targets.  The task lasts for 
approximately  2minutes in total.
Choice reaction time:   Either the word “no” or the word “y es” are presented on the monitor, and 
the subject is instructed to press the corresponding button as quickly as possible.  There are [ADDRESS_1143195] is chosen randomly wit h equal probabilit y and there is a 
varying interstimulus interval.
Spatial working memory:   Api[INVESTIGATOR_510] a house is presented on the screen with [ADDRESS_1143196] their response by 
[CONTACT_117775] “yes” or “no” response button as appropriate.
Numeric working memory:   Aseries of [ADDRESS_1143197] has to decide 
whether or not it was in the original series and press the “yes” or “no” response button as 
appropriate.
Word recognition:   The original words plus [ADDRESS_1143198] of words by  [CONTACT_117775] “yes” or “no” button as 
appropriate.
Pi[INVESTIGATOR_824314]:   The original pi[INVESTIGATOR_1103] s plus [ADDRESS_1143199] is required to indicate whether or not they 
recognized it as being from  the original series by [CONTACT_117775] “yes” or “no” button as 
appropriate.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143200] Sleepi[INVESTIGATOR_7110] (Hoddes et al. 1973):  The subject rates his or her alertness at the 
present time using a scale of [ADDRESS_1143201] asleep. 
9.1.2.Secondary Efficacy Assessments
The following assessments shouldbe administered in the same order at specified visit s (refer to 
the Operations Manual for information about the procedural order).  Measures should be 
administered by  [CONTACT_824352] y.  To minimize missing data, the 
rater should go through each measure orally with the subject or caregiver (as designated in the 
instructions), recordi ng responses appropriately.  The same caregiver shoul d be used as the 
informant at all visits.
[IP_ADDRESS]. Measures of Cognitive Function and Related Outcomes
The following assessments will serve as measures to assess cognit ive functioning and related 
outcome:
[IP_ADDRESS].1. Alzheimer’s Disease Cooperative Study –Clinician Global Impression 
of Change Scale
The ADCS-CGIC is a 7- point, categorical scale that provides a single g lobal rating of change 
from baseline (Schneider et al. 1997) and includes a baseline interview to set subject -specific 
probes for the fo llow-up assessments.  A score of 1 indicates marked improvement; a score of 2, 
moderate improvement; a score of 3, minim al improvem ent; a score of 4, no change; a score of 
5, minimal worsening; a score of 6, moderate worsening; and a score of 7, marked worsening.  
Minimal changes were predefined as clinically detectable changes that did not affect a subject’s 
clinical statu s; moderate changes as definite, detectable changes that had a corresponding effect 
on clinical status; and marked changes as those that had a dramatic effect on clinical status.
[IP_ADDRESS].2. Power of Attention Composite Score from the CDR-CCB
The PoA is a composite score derived fro m the CDR-CCB that measures the intensit y of 
concentration (ability to focus attenti on): the faster the responses, the more processes are being 
brought to bear upon the task.  The PoA composite score will be calculated by [CONTACT_824353], simple react ion time,and digit vigilance reaction t ime scores.
[IP_ADDRESS].3. Alzheimer’s Disease Assessment Scale –13-Item Cognitive Subscale
Cognitive function will be assessed by  [CONTACT_2329] a 13 -item versio n of ADAS -Cog.  This version is 
composed of the original 11-item ADAS-Cog, which measures memory , language ,and praxis
(Rosen et al . 1984).In addition, it includes Delayed Recall (epi[INVESTIGATOR_10682]) and Number 
Cancellat ion(attention)itemsthat havebeen shown asreliable and sensit ive measures f or 
assessing a wide range of dement ia severity(Mohs et al .1997).
The ADAS -Cog has been designed to evaluate the cognit ive impairment characterist ic of 
mild-to-moderate AD dement ia.In a placebo -controlled registration study  of rivastigmine in 
PDD, the A DAS-Cog11was used to measure a significant treatment effect over 24 weeks (Emre 
et al. 2004).  ADAS-Cog11has frequently been used in drug studies in mild-to-moderate AD and 
to date is the only cognition measure used as a primary  endpoint in a registration trial for a 
product approved for PDD .  The 2 addit ional items in the ADAS -Cog13, number cancellat ion 
I7S-MC-HBEH(b) Clinical Protocol Page 54
LY3154207and delayed recall, offer the opportunit y for a more comprehensive assessment of cognit ion in 
LBDthan the ADAS -Cog11.
The primary  cognitive functions tested include components of memory , language, praxis , and 
attention. Memory is evaluated by  [CONTACT_584916]: Word Recall (immediate and delayed) , 
Orientation, Word Recogni tion, and Remembering Test Instructions (based on the Word 
Recognition task). Language is evaluated by [CONTACT_584916]: Spoken Language Abilit y, 
Comprehension of Spoken Language, Word- finding Difficult y, Commands, and Naming Objects 
and Fingers. Praxis is evaluated by [CONTACT_824354]. 
Attention is eval uated by [CONTACT_824355].  The assessment is expected to take 
approximately  [ADDRESS_1143202] item scores are based on the number of words not 
recalled or the number of errors: Word Recall, Commands, Constructional Praxis, Delayed 
Word Recall, Naming, Ideational Praxis, Orientation ,and Word Recognition.  Remembering 
Test Instructions is r ated based on the number of reminders during the Word Recognit ion task. 
Spoken Language Abilit y, Comprehensio n of Spoken Language, and Word- finding Difficult y are 
rated on a scale o f severity of dysfunction ranging fro m 0 to 5, where 0 = no impairment, 1 = 
very mild, 2 = mild, 3 = moderate, 4 = m oderately severe, and 5 = severe. The score for the 
Number Cancellat ion item ranges from  0 to 5, based on ranges o f numbers of target items 
correctly crossed off by [CONTACT_824356] ; the fewer cor rect responses, the higher 
the score.
[IP_ADDRESS].4. Delis–Kaplan Executive Function System
The D-KEFS Verbal Fluency test requires subjects to produce as many words per minute as they  
can, starting wit h a particular letter, wi th higher scores indicat ing better performance (Delis et al.
2001).
The D-KEFSverbal fluency has shown a significant response (p<.001) to rivastigminetherapy in 
a 24-week randomized controlled trial in subjects with PDD (Em re et al. 2004).  The D-KEFS 
verbal fluency test is preferred as a measure of executive funct ion in PDD because it is not 
confounded by [CONTACT_542699] .  This specific measure of execut ive function, a domain commonly 
affected in LBD, will complement other m easures of cognit ion included in Study  HBEH thatdo 
not adequately assess this domain.
[IP_ADDRESS].5. Montreal Cognitive Assessment Scale
The MoCA (available at www.mocatest.org) was developed as a brief screening instrument for 
mild cognit ive impairment and mild AD to address limitat ions of the Mini-Mental State 
Examinat ion (MMSE)(Nasreddine et al. 2005).  The MoCA has been ident ified as a suitable 
screening instrument for the detection of cognit ive impairment in PD (Hoops et al. 2009) and 
DLB (McKeith et al. 2017).  Since development, it has been increasingly ut ilized to detect 
cognitive impairment in subjects with PD.The MoCA is divided into 7 subscores (maximum
possible subscore):
I7S-MC-HBEH(b) Clinical Protocol Page 55
LY3154207visuospat ial/executive (5 points)
naming (3 poi nts)
memory (5 points for del ayed recall)
attention (6 points)
language (3 points)
abstraction (2 points)
orientation to time and place (6 points)
Visuospatial abilities are assessed using a clock -drawing task and a [ADDRESS_1143203]. Language is 
assessed using a 3- item confrontati on naming task wi th low-familiarity animals (lion, camel, and 
rhinoceros), repetition of [ADDRESS_1143204] has <12 years of educat ion.  The MoCA has a 
maximum possible total score of 30 points, with higher scores indicat ing better cognitive 
performance.  A score of greater than 26 is co nsidered norm al (Nasreddine et al .2005; Hoops et 
al. 2009).
Use of MoCA in the context of PD to screen for subjects with cognit ive impairment is consistent 
with the Parkinson Study  Group (PSG) Cogni tive/Psychiatric Working Group and MDS 
recommendat ions; although, due to limitat ions of data for the MoCA on change over time or 
change with treatment, the PSG only reviewed the scale in the context of trials where execut ive 
functioning was not a primary outcome (Chou et al. 2010; Litvan et al. 2012).  The MoCA has 
consistent ly demonstrated higher sensit ivity than the MMSE for the detection of mild cognit ive 
impairment in various subjectpopulations including PD and DLB (Nasreddine et al. 2005; Smith 
et al. 2007, Zadi koff et al. 2008; Ol son et al. 2011; Frei tas et al. 2012; Biundoet al. 2016; Wang 
et al. 2013).  Using a cut -off score of less than or equal to 26 as a predictor of cognit ive 
impairment, results fro m the MoCA i dentified from 52% to 83% of subjects with PD who had 
already been i dentified as having mil d cognitive impairment (Smith et al. 2007; Hoops et al. 
2009; Nazem et al. 2009).  A MoCA score of 26 or less has also provided excellent 
discriminat ion between subjects who had mild cognit ive impairment and those who did not 
(receiver operating characteri stic curve analyses 78% to 90%; sensit ivity 90%; specificit y 75% 
(Dalrymple-Alford et al . 2010).  Sati sfactory test–retest reliabilit y and inter-rater reliabilit y have 
been demo nstrated (interclass correlat ion coefficients 0.79 and 0.81, respectively ) (Gill et al. 
2008).  Addit ionally, good correl ation between the MoCA and a neuropsycho logical battery  
(assessing the domains of memory  and execut ive function) was observed (coefficient of 0.72 )
(Gill et al. 2008).
I7S-MC-HBEH(b) Clinical Protocol Page 56
LY31542079.[IP_ADDRESS]. Penn Parkinson’s Daily Activities Questionnaire -[ADDRESS_1143205] ivities of daily living (IADL) that is 
impacted by  [CONTACT_824357].  The PDAQ -[ADDRESS_1143206] –retest reliability, construct validit y, 
sensitivity,and specifi city to PD cogni tive impairment (Brennan et al. 2016a , 2016b), and the 
questionnaire iscompleted by [CONTACT_18629]. The score range is [ADDRESS_1143207]–retest reliabilit y and construct validit y,and is both sensit ive and specific in PD cognit ive 
impairment.  The PDAQ -15 demonstrates abili ty to discriminate between cognit ively normal, 
mildcognitive impairment ,and dement ia in PD, and correlateswith global measures of 
cognition (dementia rating scale) and perfor mance-based funct ional measures.The PDAQ -[ADDRESS_1143208] of LY 3154207 on cognitive IADL in 
order to understand the relationship between change in cognit ion and change in IADL in PDD
and DLB.
[IP_ADDRESS]. Measures of Parkinson’s Disease Severity
[IP_ADDRESS].1. Movement Disorder Society ’sUnited Parkinson’s Disease Rating Scale
The MDS -UPDRS Part I (non-motor aspects of experiences of daily living) assesses a wide 
spectrum of non -motor symptom s of PD and will be used to assess the impact on non -motor 
features wi th special interest in apathy , fatigue,and depressi on.  PartII (motor aspects of 
experience of daily living), Part III (motor examination) ,and PartIV (motor complicat ions) will 
be used to assess Par kinson’s– related motor function as well as potential impact on motor 
complications (dyskinesias and motor fluctuations).  In general, each item o f the scale is scored 
from0to4 using the fo llowing clinical descriptors (Goetz et al. 2007):
0 =normal
1 =slight; refers to symptoms/signs with sufficiently low frequency or intensit y to cause 
no impact on funct ion
2 =mild; refers to symptoms/signs of frequency  or intensi ty sufficient to cause a modest 
impact on funct ion
3 =moderate; refers to symptoms/signs sufficient ly frequent or intense to impact 
considerably, but not prevent, funct ion
4 =severe; refers to symptoms/signs that prevent funct ion.
Thetotal MDS-UPDRS is a sum of Parts I, II, and III and ranges from 0 (no impairment) to 263 
(maximum impairment).
[IP_ADDRESS]. Measures of Behavioral Symptoms 
The following measures will serve as tools to assess the impact of LY3154207 on behavioral 
symptoms associated with LBDas well as the effects on motor funct ions.
[IP_ADDRESS].1. Neuropsychiatric Inventory
The NPI [CONTACT_832] a well- validated clinical rating instrument designed specifically to assess a wide 
range of abnormal behaviors encountered in dement ia subjects (Cummings et al . 1994; 
Cummings 1997).  The NPI [INVESTIGATOR_824315] -based interview that utilizes scripted questions to 
I7S-MC-HBEH(b) Clinical Protocol Page 57
LY3154207explore 12 different symptom domains: delusions, hallucinat ions, agitation/aggressio n, 
dysphoria, anxiety, euphoria, apathy, disinhibit ion, irritability/lability, aberrant m otor activit y, 
night-time behavioral disturbances, and appet ite and eating abnormalit ies.  For each domain, the 
caregiver is asked a screening quest ion to determine whether the abnormal behavior has been 
present within the previous 4weeks and represents a change in the subjectsince the onset of 
illness.  If the behavior has been present, then a series of subquest ions are asked to obtain more 
detailed informat ion about the specific features of the behavioral disturbance.  F or any behavior 
that has been present in the past 4 weeks, the caregiver is asked to rate the frequency o f the 
behavior on a 4- point scale (Rarely –less than once per week; Somet imes –about once per 
week; Often –several times per week but less than ever y day; Very  often –once or m ore per day  
or continuously present), and the severit y of the behavior on a 3 -point scale (Mild –produces 
little distress in the subject; Moderate –more disturbing to the subjectbut can be redirected by 
[CONTACT_18629]; Severe –very disturbing to the subjectand difficult to redirect).
A total score for each symptom is calculated by  [CONTACT_824358].  The total NPI [INVESTIGATOR_824316] o f all symptom  scores and has a possible range of 0 to 
144, with higher scores indicat ing a greater degree of symptomatology.
The NPI [INVESTIGATOR_824317] a Caregiver Distress Scale (NPI -D) that was designed to quantitate the 
distress experienced by [CONTACT_50633], as it relates specifically  to the individual symptom s assessed 
in the subjectby [CONTACT_183245].  For each symptom deemed to be present in the past 4 weeks, the 
caregiver is asked to rate the distress the symptom has caused him or her on a 6 -point scale 
(based on response to the question “How emotionally  distressing do you find this behavior?”): 0 
= not at all, 1 = minimally, 2 = mildly, 3 = moderately, 4 = severely, 5 = very severely or 
extremely.  The maximum score for the Caregiver Distress Scale is 60.
[IP_ADDRESS].2. Epworth Sleepi[INVESTIGATOR_824318] a subject ive measure of a subject’s 
sleepi[INVESTIGATOR_008].  It is an 8-item questionnaire that measures one’s chances of “dozing off” in different 
daytime situations over the past week; scores range fro m 0 to 24,with scores ≥10 indicat ing 
excessive daytime sleepi[INVESTIGATOR_008] ( Johns 1991 ).  This scal e is easily administered, widely used, and 
deemed “Recommended” by  [CONTACT_824359] (Högl et al. 2010).  For the purposes of Study  HBEH, the ESS 
will be assessedby [CONTACT_18629].  The ESS scores correlated significant ly with MMSEscores 
and also wi th cognitive domain scores for attention/working memory, execut ive function, 
memory, and visuospati al function (Goldman et al . 2013).  Day time sleepi[INVESTIGATOR_824319], especially in the setting of dementia, and 
attention/working memory , executive function, memory, and visuospati al deficits (Goldman et 
al. 2013).
I7S-MC-HBEH(b) Clinical Protocol Page 58
LY31542079.[IP_ADDRESS]. Questionnaire for Impulsive -Compulsive Disorders in Parkinson’s 
Disease
The QUIP is a subject -and/or informant -reported screening quest ionnaire for impulse control 
disorders (ICD s) and com pulsive behaviors in PD.  It assesses behaviors across 3 domains: 
1.ICD including gambling, sexual, buying and eating; 
2.other compulsive behaviors such as punding andhobby[CONTACT_128053], and wandering; 
3.compulsive medicat ion use.
Scores for each ICD and related disorder range from 0 to 16, with a higher score indicating 
greater severit y (i.e. frequency) of symptom s.Thetotal QUIP rating scale score for all ICDs and 
related disorders combined ranges fro m [ADDRESS_1143209] –retest reliabilit y 
and has d emonstrated responsiveness to change in a treatment study  of ICD in PD (Weintraub et 
al. 2009; Weintraub et al. 2012).  As medicat ions that enhance dopaminergic tone have been 
associated with the development of ICD in PD, the sy stematic evaluat ion of this potential 
complication is critical (Weintraub et al. 2006).
9.1.3.Appropriateness of Efficacy Assessments
Efficacy:   As previously stated, the CoA has demonstrated a significant treatment effect in 
similar populat ions (Wesnes et al. 2005; Rowan et al.2007).  The CoA is a parameter calculated 
using the CDR-CCB,which has been widely  used in dementia research for more than [ADDRESS_1143210] demonstrated an abilit y to minimize learning effects 
up to 8weeks (Wesnes, personal co mmunicat ion).  The CDR -CCB system also has a large 
normative database of over [ADDRESS_1143211] of treatment on cognit ive changes (Wesnes 2008).
The secondary  efficacy measures described in Sectio n9.1.2are also established measures of 
cognitive function and related outcom es, as well as behavioral symptoms associated with PD 
dementiaand DLB, and considered appr opriate assessments for this populati on.
9.2.Adverse Events
Investigators are responsible for monitoring the safety of subjects who have entered this study 
and for al erting Lilly  or its designee aboutany event that seems unusual, even if this event may 
be considered an unanticipated benefit to the subject.
The invest igator is responsible for the appropriate medical care of subjects during the study.
Investigators must document their review of each lab oratory safety report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the subjects to discontinue the invest igational product prior 
tostudycompletion.  The subject should be followed until the event resolves, stabilizes with 
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143212]’s preexist ing condit ions, including clinically significant signs and symptoms of the 
disease under treatment in the study .  In addition, site personnel  will record any  change in the 
condition(s) and any  new condi tions as AEs. Investigators shoul d record thei r assessment of the 
potential relatedness of each AE to invest igational product and/or protocol procedure via eCRF.
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
ofbeing related to study  treatment, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment, or pathologies.
A “reasonable possibilit y” means that there is a cause -and-effect relationship between the 
investigat ional produc t, study device and/or study  procedure ,and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the c ourse of the study .
If a subject’s invest igational product is discont inued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via eCRF, clarifying if possible the circumstances leading 
to any dosage m odifications, or disco ntinuations of treatment.
9.2.1.Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1of the following outcom es:
death
initial or prolonged in patienthospi[INVESTIGATOR_3094]
a life-threatening experience ( i.e.immediate risk of dying)
persistent or s ignificant disabilit y/incapacity
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_824320] 1of the other outcomes listed in the definit ion above.  Examples of 
such medical events include allergic bronchospasm requiring intensive treatment 
in an emergency room  or at hom e, blood dyscrasias or convulsions that do not 
result in inpatienthospi[INVESTIGATOR_059], or thedevelopment of drug dependency  or drug 
abuse.
All AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious 
criteria.  The submissio n of SAE reports to the sponsor begins after the subject has signed the 
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143213], the SAE report should be submitted to the sponsor 
as per SAE reporting requirements and timelines (see Section 9.2) if it is considered reasonably 
possibly related to study  procedure.
Study site personnel  must alert Lilly or i ts designee of any SAE within [ADDRESS_1143214] addi tional data collected using the 
eCRF.
Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the 
definition of an AE.  However, to fulfill regulatory requirements any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the patient’s final study  dispositionCRF has been 
completed).  However, if the investigator learns of any SAE, including a dea th, at any time after 
a subject has been discharged fro m the study, and he/she considers the event reasonably possibly  
related to the study  treatment or study  participation, the invest igator must prompt ly notify Lilly.
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
[LOCATION_002] 21 CFR 312.32 and E uropean Unio n Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory requirements in participat ing countries 
require the reporting of S[LOCATION_003]Rs.  Lilly has procedures that will be followed for the 
identification, recording ,and expedit ed reporting of S[LOCATION_003]Rs that are consistent with global 
regulations and the associated detailed guidances.
9.2.2.Complaint Handling
Lilly collects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safety of subjects, m onitor quality, and to facilitate process 
and product improvements.
Subjects will be instructed to contact [CONTACT_17074] a 
complaint or probl em with the invest igational product so that the s ituation can be assessed.
9.3.Treatment of Overdose
For this study, any dose of invest igational product greater than twice participant’s assigned daily  
dose within a 24-hour time period will be considered an overdose.
In the event of an overdose, the invest igator or treating physician shoulduse supportive therapy  
as necessary  and contact [CONTACT_824360] (or designee) immediately .
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143215], 12-lead digital ECGs will  be collected as tri plicates according to the Schedule 
of Activities (Section2).  Subjects must be supi[INVESTIGATOR_17044]  10minutes prior toECG 
collection and rem ain supi[INVESTIGATOR_246639].
Consecutive replicate ECGs will be obtained at approximately [ADDRESS_1143216] iograms may be obtained at addi tional times, when deemed clinically necessary .  
Collection of more ECGs (more replicates) than expected at a particular time point is allowed 
when needed to ensure high -quality records.
Electrocard iogramswillinitiallybe interpreted by  a qualified healthcare provider (the 
investigator or qualified designee) at the site as soon after the time of ECG collect ion as possible, 
and ideally  while the subjectis still present to determine whether the subjectmeets entry criteria
atthe relevant visit(s) and for immediate subjectmanagement, should any clinically rel evant 
findings be ident ified.
Any clinically  significant findings from ECGs that result in a diagnosis and that occur after the 
subjectreceives the first dose o f the investigationaltreatment should be reported to Lilly  or its 
designee as an AE via eCRF.
If aclinically significant quantitative or qualitat ive change fro m baselineis identified after 
enrollment, the investigator will assess the subject for symptoms (e.g., palpi[INVESTIGATOR_814], near 
syncope, syncope) to determine whether the subject can continue in the study.   The invest igator 
or qualified designee is responsible for determining if any change in subject management is 
needed and must d ocument his/her review of the ECG printed at the time of evaluat ion from at 
least [ADDRESS_1143217] a full over -readon 1 of the replicates 
(including all intervals).  A report based on data from this over-read will be issued to the 
investigat ive site.  For each set of replicates, the cardiologist will determine the RR and QT 
intervals, QRS duration, and pulserate on the ECGs that were not fullyover-read.  These data 
are not routi nely reported back to the invest igative site.  However, any  clinically  significant 
finding that was not present on the fully over -read ECG will be r eported to the invest igator and 
to Lilly.  All data from the over-reads will be placed in the Lilly database for analyt ical and study  
report purposes.
When there are differences in ECG interpretationbetween the invest igator (or qualified 
designee) and the cardio logist at thecentral ECG laboratory , the investigator’s (or qualified 
designee’s) interpretation will be used for study  entry and immediate subjectmanagement.  
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143218] at the central  ECG laboratory  will be used for data analysis 
and report writ ing purposes.
The investigator (or qualified designee )must document his/her review of 1of the replicate ECGs 
printed at the time of co llection, the final over -read ECG re port issued by [CONTACT_242304] ,and any alert reports .
9.4.2.Vital Signs
Vital signsincluding pulse rate, orthostatic BP, temperature, and weight will be measured as
detailed in the Schedule of Activities (Section2).
Orthostatic Blood Pressure Monitoring: For orthostatic BPmonitoring, subjects will have 3 
BP/pulse rate measurements taken in the seated posit ion approximately 1minute apart fo llowed 
by 1 BP/pulse rate measurement taken in the standing position.  For orthostatic BPmonitoring, 
subjects should be seatedfor at least 5minutes and stand for at least [ADDRESS_1143219] feels unable to stand, vital signs only in the seated 
position will be recorded.
Orthostatic BP/pulse rate will be measured as part of the vital sign assessments at every visit. At 
Visit2, Visit3, Visit 8, Visit 11,and Visit 801, these measureme nts will be co llected at time 0 of 
the in-clinic BP/pulse rate m onitoring.Unscheduled orthostatic vital signs should be assessed, if 
possible, during any AE of dizziness or posture -induced symptoms.  Addit ional vital signs may  
be measured during each stu dy period if warranted and agreed upon between the sponsor and 
investigator. (TableHBEH.3)
In-clinic Blood Pressure and Pulse Rate Monitoring:   In-clinic BPand pulse rate monitoring 
will be done at Visit2, Visit3, Visit8, Visit11,and Visit801.  The BPand pulse rate will be 
measuredat time0 and every  60minutes thereafter. The initial measurement, at time 0 of the 
in-clinic BP and pulse rat e monitoring, will  be done as an orthostatic BP/pulse rate (refer to 
Orthostatic Blood Pressure Monitoring above), and subsequent BP and pulse rate measurements 
will be taken in the seated posit ion only. Time0 at Visit 3,Visit8 and Visit [ADDRESS_1143220] met inclusio n criteria [6].  At Visit 2, Visit8, and Visit11, in-clinic BP 
and pulse rate will be monitored for up to 6 hours,  At Visit3, for up to 8 hours and at Visit 801 
for up to 2hours(TableHBEH.4).
Home Blood Pressure Monitoring:   Home BPmeasurements will be co llected in this study .  
Blood pressure m easurements shouldbe taken twice daily in the seated posit ion using the HBPM
equipment provi ded by [CONTACT_11007].  The subject shoul d be given the HBPM device at Visit 2.Home 
BPmeasurements shouldbe conducted for a minimum o f 7days between Visits2 and 3, for 
3weeks between Visit s3 and 6, and a minimum of 7 days between Visit s 10 and 11, and 
Visits11 and 801.  Home BP should be taken twice in the morning (approximately 1 minute 
apart) (e.g., 8AM) immediately fo llowing study medication dosing and twice in the evening, 
approximately  12hours later (approximately 1 minute apart) (e .g., 8PM).
All HBPM data will be electronically transmitted to a designated HBPM data processing vendor.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143221], lab oratory tests detailed in ( Appendix 2 ) should be conducted according to the 
Schedule of Act ivities (Section 2).
With the exception o f laboratory test resul ts that may  unblind the study , Lilly or i ts designee will 
provide the invest igator with the results of laboratory  tests analyzed by  a central vendor, if a 
central vendor is used for the clinical trial.
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the subjectreceives the first dose of investigational product should be reported to Lilly or 
its designee as an AE via eCRF.
9.4.4.Columbia -Suicide Severity Rating Scale –Children’s Version
Consistent with Food and Drug Administration (FDA) regulatory  guidance (FDA 2012), any  
occurrence of suicide -related thoughts and behavio rs will be asse ssed as indicated in the Study 
Schedule ( Section2).  The C-SSRS is a scale that captures the occurrence, severit y, and 
frequency  of suicide-relatedthoughts and behaviors during the corresponding assessment period.  
The scale includes suggested questions to elicit the ty pe of information needed to determine if a 
suicide-related though t or behavior occurred.
The C-SSRS is available in an adult’s and a children’s version.  There is no versio n of the 
C-SSRS desi gned for use in a cognit ively impaired population such as subjects with PD 
dementia; therefore, the children’s versio n will be used.  Terms captured by  [CONTACT_179708] 
C-SSRS children’s versio n canbe mapped to Columbia Classification Algorithm for Suicide 
Assessment (Posner et al. 2007), to facilitate future pooling of data.
The first time the scale is assessed in thi s study, the C-SSRS “Baseline” versio n will be used, and 
the findings will const itute the baseline assessment.  The C -SSRS “Since Last Visit” scal e will 
be used for all subsequent assessments.
The C-SSRS will be assessedafter the cogni tive and funct ional assessments.  Responses fro m 
subjectwill beconsidered when assessing the scale. If a suicide -related thought or behavior is 
identified at any  time during the study , a thorough evaluat ion will be performed by a study  
physician, and appropriate medical care will be provided.
If, based on assessment of the C-SSRS, it is determined that suicide-related behaviors have 
occurred, then the Lilly S elf-Harm Follow-Upform will be used to collect additional information 
to allow for a mor e complete assessment of these behaviors.
9.4.5.Physician Withdrawal Checklist
The Penn Physician Wit hdrawal Checklist (PWC -20) is a 20-item checklist that will be used to 
assess the presence and severit y of withdrawal symptom s.  The PWC -[ADDRESS_1143222] and caregiver ,separately. The scale was originally developed to assess the severit y 
of withdrawal symptom sin anxiolytic medication discontinuat ion (Rickels et al . 2008).The 
PWC-[ADDRESS_1143223] ive drug 
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143224] ( Schweizer et al. 1990; Rickels et al. 1990).  
The [ADDRESS_1143225]’s level of symptoms on a variety of withdrawalsymptoms since 
last visit.  Each of the 20 items are scored as 0 (not present), 1 (mild), 2 (moderate), 3 (severe) .
9.4.6.Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data within the study  by [CONTACT_81132].
In the event that safet y monitoring uncovers an issue that needs to be addressed by [CONTACT_129219], only members of the IAC(an advisory  group for this study  formed to protect the 
integrity of data; refer to Section10.3.7) can conduct additional analyses of the safet y data.
[IP_ADDRESS]. Hepatic Safety Monitoring
If a subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL ≥2X ULN, 
testsfor hepatic parameters (Appendix 4 ) should be repeated within [ADDRESS_1143226], TBL, and ALP should 
continue until levels normalize or return to approximate baseline levels.
Hepatic Safety Data Collection
Additional safety data should be co llected via the eCRF if 1or more of the fo llowing condit ions 
occur:
1.Elevation of serum ALT to ≥5X ULN on 2 or more consecutive blood tests.
2. Elevated serum TBL to ≥2X ULN (except for cases of known Gilbert’s syndro me).
3.Elevation of serum ALP to ≥2X ULN on [ADDRESS_1143227] discontinued from treatment due to a hepatic event or abnormalit y of liver tests.
5.Hepatic event consi dered to be an SAE.
9.4.7.Appropriateness of Safety Assessments
The clinical safet y measurements (AE reporting, physical examinat ions, vital signs, HBPM, 
ECGs, and clinical safet y laboratory  tests; Secti on9.2and Section 9.4) are well-established 
methods in drug development research and are standard procedures for clinical trials.
9.5.Pharmacokinetics
At the visits and times specified in the Schedule of Act ivities(Section2),venous blood samples
will be collected to determine the plasma concentrations of LY3154207.  Instructions for the 
collection and handling of blood samples will be provided by [CONTACT_456] .  At Visit3, a PK 
sample is to be collected within 1 to 3 hours after the drug is administered at the site.  At Visit 4, 
Visit5, Visit 8,and ET/DC, the PK sample can be collected at any t ime during the visit.  At 
Visit11, the PK sample should be collected prior to the drug being administered at the site.  The 
I7S-MC-HBEH(b) Clinical Protocol Page 65
LY3154207date and time (24-hour clock time ) of the PK sample collect ion as well as the da te and time of 
the dose administration immediately preceding the PK sampl ingwill be recorded.
Drug concentration informat ion that may unblindthe study will not be reported to invest igative 
sites or blinded personnel unt il the study has been unblinded.
Bioanalytical samples collected to m easure invest igational product concentration and 
metabolism and/or protein binding will be retained for a maximum o f 2years following last 
subject visit for the study .
The PK analyses will be based on validated bioanalyt ical assays and will use convent ional PK 
analysis methods.
9.6.Pharmacodynamics
Not applicable.
9.7.Pharmacogenomics
9.7.1.Whole Blood Sample for Pharmacogenetic Research
A whole blood sample will be co llected for pharmacogenet ic analysis as specified in the 
Schedule of Activities (Section 2) where local regulations allow.
The collection and storage of samples for genetic studies (including samples for 
pharmacogenet ic studies) is to continue our ongoing efforts to understand the correlation 
between the clinical outcome wit h the drug(s) under study  in the clinical trial and the genet ic 
makeup of the subject.  DNA extracted from the who le blood samples co llected fro m the subjects 
may be used to generate genetic data on a genome geno typi[INVESTIGATOR_362337] . The genoty pe data maybe 
used to perform a targeted genetic analysis of the genes of interest to understand potential safet y 
and efficacy  concerns shoul d they arise either during this tri al, future trials for thi s drug, or if the 
drug is launched and on the market. For example, genet ic variations in well-known 
drug-metabolizing enzymes, such as cytochro me P450 (CYP), including CYP3A4, could be a 
potential set of genes of interest to answer any safety  concerns.
Samples will notbe used to con duct unspecified disease or populat ion genetic research either 
now or in the future.  Samples maybe used to investigate variable response to LY3154207 and to 
investigate genet ic variants though t to play a role in LBD.  Assessment of variable response may  
include evaluat ion of AEs or differences in efficacy.
All samples will be coded with the subject number.  These samples and any  data generated can 
be linked back to the subject only by [CONTACT_82394].
Samples will be retained at a facilit yselected by  [CONTACT_134115] a m aximum of 15years 
after the last subject visit for the study , or for a shorter peri od if local regulations and/or ethical 
review boards (ERBs) impose shorter time limits.  This retention period enables use of new 
technologies, response to regulatory  questions, and invest igation of variable response that may 
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143228] ion.
9.8.Biomarkers
9.8.1.Digital Biomarkers
[IP_ADDRESS]. Lilly Trial Application
The Lilly Trial app lication (Lilly Trial app), if available, will be used to assess the feasibilityof 
collecting clinical research domains such as cognitive and motor funct ioning under real world 
conditions using a niPad-enabled application (see Operations Manual).  In addit ion, the abilit y of 
the Lilly Trial app to m easure the effect of LY3154207 on m otor and cogni tive outcom es in a 
subset of subjects will be explored.  The app uses a series of tasks that activate iPad sensors to 
collect and track data from the subjects.  These measures include a variet y of potential tests 
measuring motor funct ions andcognition (e.g., tappi[INVESTIGATOR_824321]).  An iPad configured 
with the Lilly Tri al app will be provided to the subjects at Vi sit2 (if available).  Subjects will 
complete assessments fro m 2weeks prior to dosing (starting day  following Visi t2), through out 
the dosing period, and for 2 weeks after the conclusion of the treatment period (until Visit 801).  
Subjects will self -select for thi s optional component of the protocol at Visit 1.  If subject 
consents to participate, sites should capture this informa tion in IWRS at Visit [ADDRESS_1143229]-treatment phases of the study  to validate findings fro m the Phase1 studies using thi s app 
and to determine its utilit y for future studi es in this population.
These data are exploratory  data and will be used for exploratory  purposes.
[IP_ADDRESS]. Actigraphy
As an increase in mean sleep latency  in sleep-deprived subjects was identified as a drug- response 
indicator, a wearable device capable of detecting and characterizing changes in various sleep 
parameters including but not l imited to sleep latency , duration of sleep, sleep –wake cycles, and 
sleep disruption may  be employed, in a subset of subjects, if available.  We will explore the 
feasibility of using act igraphy to evaluate the effect of LY3154207 on various sleep parameters
and day time activity.  If available, the acti graphy device will  be worn on the wri st, similar to a 
watch, beginning at Visit 2, for 3 separate 2 -week periods of time:  Visit 2 to Visit 3, Visit8 to 
Visit9, and Visit 11 to Visit801.  The si te will prov ide the device to the subjects at Visits 2, 8, 
and 11; and fo llowing 14days of wearing the device, the subject will bring the device to the site 
I7S-MC-HBEH(b) Clinical Protocol Page 67
LY3154207at the regularly  scheduled visi t at the end of the 14 -day period (Visit3, Visit9, or Visit801), 
whereupon t he site will mail it to the vendor using previously addressed mailing materials (see 
Operations Manual ).  These data are exploratory  data and will be used for exploratory  purposes.
9.9.Medical Resource Utilization and Health Economics
Medical Resource Utilization and Healt h Economics parameters will not be evaluated in this 
study.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143230] 
size for LY3154207 relat ive to placebo on the CoA is 0.4 with the sample size of 340there will 
be over80% probabilit y of passing this criterion. A 20% di scontinuation rate by [CONTACT_10585]12 has 
been accounted for in the sample size determinat ion.
Sample size was estimated based on the work of Wesnes et al. (2005) where the difference in 
mean chan ge from baseline for rivast igmine compared to pl acebo and the pooled standard 
deviation (SD) for CoA were estimated as 5.[ADDRESS_1143231] corresponding to a reduction in the deficit of subjects compared to age -matched healt hy 
volunteers is approximately 45%.  Based on this, the effect size of 0.4 in this study  corresponds 
to a mean difference of 7.2 units (approximately 57% reduction in the deficit).
This sample size will allow for assessment ofthe in-clinic BP and pulse rate on the first day  of 
dosing in order to evaluate any  changes after the first dose of treatment that wereobserved in 
Phase1.  If the SD of the in -clinic SBP is assumed to be 15 mmHg, then the difference from the 
mean to the upper limit of a 95% confidence interval (CI) of the change from baseline o f SBP 
relative to placebo is expected to be <4.7 mmHg.  If there is any init ial rise in BP or pulse rate , 
the in-clinic 6-and 12-week assessments along wit h the HBPM measure will be used to assess if 
the rise acco mmodates.  The difference from the mean to the upper limit of a 95% CI of the 
change in average SBP measured at each of these visit s relative to placebo is expected to be 
<3.5mmHg.  This assumes an SD of 10 mmHg and a 20% discont inuation rate.
10.2.Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Description
Entered All subjects who sign informed consent
Evaluable Patient Population 
(EPP)All randomized subjectswho received at least [ADDRESS_1143232] completed all study procedures ,including 
follow-upand/or ET/DC visit.
Safety population All randomized subjects who take at least [ADDRESS_1143233] one measurable concentration
Abbreviations :  DC = discontinuation; ET = early termination; PK = pharmacokinetic.
CCI
I7S-MC-HBEH(b) Clinical Protocol Page 69
LY315420710.3.Statistical Analyses
10.3.1.General Statistical Considerations
Statistical analysis for this study will be the responsibilit y of Lilly or its designee.
Unless otherwise specified, all efficacy analyses will be conducted on the evaluable pat ient 
population(EPP). This includes all data from all rando mized subjectswho received at least [ADDRESS_1143234] ification for making the change, will be described 
in the clinical study  report(CSR). Additional exploratory analyses of the data will be conducted, 
as deemed appropri ate. However, these analyses may not be included in the CSR.
Thestatistical analyses specified in the protocol will be detailed in the statist ical analysis plan 
(SAP).  However, some of the exploratory  analysis suggested by  [CONTACT_824361].
[IP_ADDRESS]. Handling of Missing Items for Scales
Thetotal and subscale scores will be derived fro m individual items. If any of the individual 
items are missing or unknown, ev ery effort will be made to obtain the score for the missing item 
or items. However, failing to gather missing informat ion,some scales (e.g., ADAS-Cog) will be 
imputed as appropriate. The scales for which imputation is adopted will be detailed in the SAP .
For the scaleswhere imputati on is not done , if any item is missing, any  total or sum involving 
that item will be considered missing.
10.3.2.Treatment Group Comparability
[IP_ADDRESS]. Time to Study Disposition/Discontinuation
The reasons for discont inuation and the t ime in days-to-study disposit ion will be summarized by 
[CONTACT_824362].  A corresponding list ing will also be produced.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143235]’s participat ion in the study  
endsand will be sum marized as frequency  and percentage by [CONTACT_824363].
[IP_ADDRESS]. Protocol Deviations
Listings of subjects with significant protocol deviationswill be provi ded based on the safet y 
population. Protocol deviat ionswill be summarized using frequencies and percentages.
[IP_ADDRESS]. SubjectCharacteristics
Baseline characterist ics will be summarized for the EPP and per -protocol populat ions by 
[CONTACT_6654]. Summaries will include descript ive statist ics for continuous 
measures and frequencie s and percentage for categorical measures.  Comparability between 
treatment groups will be evaluated based on the point est imates and the associated variabilit y.
[IP_ADDRESS]. Concomitant Therapy
Prior medicat ions are defined as those that stop before randomizat ion (Visit3). Concomitant
medications are defined as those being taken on or after randomizat ion (Visit 3).  A summary  of
concomitant medicat ions will be presented as frequencies and percentages for each treatment
group. If the start or stop dates of therapi[INVESTIGATOR_824322], the therapy will 
be deemed conco mitant.
Summary  tables will  also be provided for PD concomitant medications and cognit ive enhancing
medications.
Prior and concomitant m edications will also be listed.
Medications will be coded using the World Health Organizat ion drug dictionary .
[IP_ADDRESS]. Treatment Compliance
Treatment compliance informat ion for each treatment arm will be collected through capsule
counts at each visit,and the number of capsulestaken relative to the number expected to be taken 
will besummarized.
10.3.3.Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The primary  analysis on CoA will occur when all subjects complete 12 weeks of treatment.  The 
analysis of CoA will ut ilize a Bayesian MMRM model .  The Bayesian analysis may use 
uninformative priors for all terms in the model. These will be diffuse Normal distributions 
centered on zero. Priors for variance will fo llow an inverse gamma distribut ion.  Further details 
of the Bayesian analysis will be provided in the SAP.  The MMRM model will account for 
longitudinal data assessed throughout the study , after 1, 2, 4, 6, 8, 10 ,and 12weeks of dosing.  
The change of CoA fro m the baseline to Week 12 will be the dependent variable.  The model 
will comprise fixed (baseline value, treatment, visit) and random effects (subject) and the 
interaction terms (treatment by [CONTACT_765], baseline value by  [CONTACT_765]). Unstructured variance structure 
will be applied in the model, but if it fails to converge ,other suitable structures will be 
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143236] (difference in least squares mean) 
between treatments and placebo for the Week12 change fro m baseline.
[IP_ADDRESS]. Secondary Efficacy Analyses
The secondary efficacy outcom es (ADCS-CGIC, PDAQ- 15, ADAS -Cog13, CDR-CCB PoA, 
D-KEFS, MoCA, NPI, ESS, and MDS -UPDRS[total and Part III] ) will be assessed at the 
12-week time po int.  Each of these secondary endpoints will be analyzed using a nMMRM 
model,which will include terms for: baseline value, treatment, visit, and the relevant interaction 
terms.  Further covariates may be included such as age, site, and the severit y of PD motor 
function as well as severit y of dementia at baseline as appropriate.  The change of the score from 
baseline will be the dependent variable.  If subscores for a particular scale are deemed clinically  
relevant to analysis, it will be completed as an exploratory  analysis.
[IP_ADDRESS]. Tertiary/Exploratory Efficacy Analyses
The following exploratory  efficacy endpoints will be analyzed using MMRM model.
Change in the total score for the ADAS -Cog11from baseline to Week 12 (as a subset 
of ADAS-Cog13)
Change in the CDR elements (Cognitive react ion time composite score, Reaction 
Time Variabilit y composite score, Speed Score composite scores, Simple React ion 
Time outcomes, Cho ice Reaction t ime task outcomes, Digit Vigilance outcomes, 
Numeric Working Memory  outcomes, Spatial Working Mem ory Outcomes, Verbal  
Memory outcomes, Visual Me mory outcomes) from baseline to Week 12
Change in MDS -UPDRS individual subscales – non-motor experiences o f daily living 
(PartI), motor experi ences of daily living ( PartII), and motor complicat ions 
(Part IV) subscales fro m baseline to Week 12
Change in MDS-UPDRS PartIA score from baseline to Week 12
Change in GDS -S score from  screening to Week 12
Change in NPI [INVESTIGATOR_32005] ( PartD Depression/Dysphoria) fro m baseline to Week 12
Change in QUIP score from baseline to Week 12
Whereappropriate, these results will be investigated in more depth .
Exploratory DigitalBiomarker Analysis:  Data from digital biomarkers (Lilly  Trial app and 
Actigraphy watch) from baseline to Week [ADDRESS_1143237] 1 dose of LY3154207will be evaluated for safet y and toxicity.
Safety parameters (AEs, l aboratory  analytes, vi tal signs, ECGs) and number of subjects who 
meet the potentially clinically  significant vi tal signs criteria at 3 consecut ive time po ints at 
I7S-MC-HBEH(b) Clinical Protocol Page 72
LY3154207Visit3 (Day 1 stoppi[INVESTIGATOR_004]) will be summarized using descript ive statist ics for continuous 
variables and frequencies alo ng with percentages for categorical variables during the treatment 
period.
Comparisons between 3doses of LY3154207 and placebowill be made using an MMRM model 
for the in-clinic BP, pulse rate, and HBPM measureme nts during the treatment period.   No 
adjustments for multiple comparisons will be made.
The PWC -20 endpoint will be analyzed using an ANCOVA model wit h a covariate for baseline 
score.The primary analyses will be a change fro m baseline (Visit 11) to the in person fo llow up 
visit (Visit 801).
[IP_ADDRESS]. Adverse Events
Treatment -emergent adverse events will be defined as events that first occurred or worsened on
or after randomizat ion (Visit3). Should there be insufficient data for AEstart date,stop date, 
and time, the AEwill be considered treatment emergent.
Treatment -emergent adverse events will be calculated based on AEidentifier and coded 
according to established Medical Dict ionary for Regulatory Activities (MedDRA) terms and 
summarized by  [CONTACT_824364] (SOC) and Preferred Term .  Adverse event terms 
and severit y grades will be assigned by [CONTACT_824365] , version4.0.
An overview of AEs, including the number and percentage of subjects who died, suffered serious 
adverse events ( SAEs), discontinued due to AEs, and who suffered TEAEs, will be provided.
Summaries of AEs by [CONTACT_142538] o f Preferred Term within SOC will be provided for
the following:
preexisting condit ions
TEAEs
TEAEs by  [CONTACT_764]
TEAEs occurring in greater than 1% of subjects by [CONTACT_9560]
SAEs
AEs reported as reason for discont inuation
These summaries will include number and percentages of subjects wi th TEAEs
A summary  of TEAEs by  [CONTACT_824366].
Preexisting condit ions, TEAEs, SAEs, and discontinuat ions due to AEs will be listed.
[IP_ADDRESS]. Suicidal Ideation and Behavior
Suicide-related thoughts and behaviors, based on the C -SSRS, will be listed by [CONTACT_824367].  
Only subjects whoshow suicidal ideat ion/behavior will be displayed ( i.e.if a subject’s answers 
are all “no” for the C -SSRS, then that subjectwill not be displayed). However, if a subject
reported any  ideation or behavior at any  time point, then all their ideat ion and behavior will be 
displayed, even if not posit ive.
I7S-MC-HBEH(b) Clinical Protocol Page 73
LY315420710.3.4.3. Vital Signs and Weight
Vital sign measurements and weight will be analyzed ascontinuous data (change from baseline
to each visit) and the treatment-emergent abnormalit ies as categorical data.
If there are mult iple records of vital sign or weight measurements at baseline or postbaseline
visits, the last record will be used. The except ion is for the orthostatic BP and pulse rat e taken as 
part of the vital sign assessments at Visit1, Visit4, Visit5, Visit6, Visit 7, Visit 9, Visit10, 
unscheduled visit ,and ET/DC visit , and the initial measurement at time 0 of the in-clinic BPand 
pulse rate monitoring.  At these visits, 3 BP/pulse rate measurements will be taken in the seated 
position and the m ean of these will be ut ilized for analysis purposes .  Orthostatic changes will be 
calculated by [CONTACT_824368] 3BPand pulse rate measurements taken in the seated 
position to the value of the single BPand pulse rate measurement taken in the standing position .
Summary  statistics will be presented for observed values at baseline and for change fro m 
baseline results at each scheduled postbaseline visit. Systolic and diastolic BPand pulse 
(collected in sitt ing position), orthostatic SBP, orthostatic diastolic and orthostatic pulse 
(measurement after 5 minutes in the seatedposition minus that after 3minutes in the standing 
position), temperature, and weight will be summarize d by [CONTACT_824369].
The incidence of treatment -emergent abnor mal high or low vital signs will bepresented by  
[CONTACT_6982]. Treatment -emergent vital sign evaluat ions are defined for evaluations 
collected after the init iation of study  medication. Any vital sign meet ing the criteria will be 
considered abnormal .  For each vital sign at each postbaseline visit, only  subjects who had a 
baseline result and had a non-missing result at that postbaseline vis it will be included in the 
denominator when co mputingthe proporti on of subjects wi th treatment-emergent high, low, or 
abnormal values.
Summary  statisticsof change from  baseline in weight will be provided. Body mass index at 
baseline will be summarized by [CONTACT_3148] .
A listing of treatment -emergent abnorm al vital signs will  also be presented.
Day1 (Visit3) in-clinic BPand pulse ratechange post first dose
Change in in-clinic BPand pulse rate fro m [ADDRESS_1143238] 
day of study drug dosing will be analyzed using a nMMRM analysis wit h baseline value, 
treatment, time postdose (h ours),and the relevant interaction terms.  Two baselines will 
be considered: the Visit3 pretreatm ent value (time0) and the time -matched baselines 
from Visit 2 (hourly value 0 to 6hours). For the second of these, there is no 
time-matched value for the 7- and 8-hour time points of Visit3, so the 6 -hour time point 
of Visit2 will be used as their baseline value.  A separate change from baseline analysis 
will be co mpleted for each baseline approach.
Change in in -clinic BP and pulse rate from baseline (Visit 2, predrug) up to Week 12 
(V11)
I7S-MC-HBEH(b) Clinical Protocol Page 74
LY3154207Change in i n-clinic BPand pulse rate measured at Visit 2 (daily average 0to 6 hours) to 
the in-clinic BPand pulse rate measured at Week6/Visit8 and Week12/Visit11 (daily 
average 0 to 6hours) will be analyzed by a nMMRM m odel with baseline value, 
treatment, and the rel evant interaction terms. Analysis at 6 weeks will help to evaluate 
any significant ch anges (if any ) in BP and pulse rate earlier than 12 weeks (end of study ) 
and if they  accommodate by 6weeks.
Daily average change in ho me BP measurements and pulse rate from baseline to 
Week12.
[IP_ADDRESS]. Laboratory Analyses
Laboratory  measurements will be analyzed ascontinuous data (change from baseline) measured 
as International System Units or as categorical data (proportion of treatment -emergent 
abnormalities).
If there are mult iple records of laboratory  measurements at baseline or postbaseline visits, the
lastrecord will be used.
Change from baseline to postbaseline visit s at which laboratory  measurements are taken will be
summarized using descript ive statist ics.
For all laboratory  analytes, frequencies of subjects with notable changes ( i.e.increases or
decreases of a prespecified amount unique to each analyte) fro m baseline to each postbaseline
visit will also be summarized for all subjects and stratified by  [CONTACT_6398], norm al, or high at baseline.
[IP_ADDRESS]. Electrocardiograms
The ECG m easurements will be analyzed ascontinuous data (change fro m baseline) or as 
categorical data (proportion of treatment -emergent abnormalit ies).
Electrocardiogram is measured in triplicates andthe average of triplicates will be used at 
baseline and each double -blind period visit.  If th ere are multiple records after averaging ECG 
triplicates wi thin a visit, the last record of averages will be used.
All ECG parameter s change fro m baseline to each postbaseline visit at which ECG 
measurements are taken will be summarized.
Incidence of treat ment-emergent abnormal ECGs will be also be summarized.
10.3.5.Pharmacokinetic/Pharmacodynamic Analyses
LY3154207 concentrations will be illustrated graphically and summarized descript ively. If 
warranted and based on availabilit y of data, the exposure –response r elationship of plasma 
LY3154207 concentrations to efficacy endpo ints and/or safety  endpoints m ay be explored.  
Subjectand healthy subject data, including but not limited to plasma LY3154207 concentrations, 
from other clinical studies evaluat ing LY3154207 may be combined wit h data from this study  to 
support addi tional analyses. A model-based approach may be implemented using nonlinear 
mixed effects modeling (NONMEM) or other appropriate software to estimate PK or 
pharmacodynamic parameters.
I7S-MC-HBEH(b) Clinical Protocol Page 75
LY315420710.3.6.Other Analyses
[IP_ADDRESS]. Subgroup Analyses
The CDR-CCBCoA and its co mponentscores will be assessedbased on the fo llowing 
subgroups: concomitant PD therapy, conco mitant AChEI therapy ,PDD orDLB, and GDS (less 
than or equal to 6 ).All subgroup analyses will be considered exploratory  andadditional 
subgroup analyses may  be perform ed as suggested by  [CONTACT_26739].
10.3.7.Interim Analyses
A limited number of pre -identified individuals may gain access to the limited unblinded data, as 
specified in the unblinding pl an.  Information that may unblind the study  during the analyses will 
not be reported to study  sites or blinded study  team until the study  has been unblinded.
The efficacy and safet y interim analyses will be completed and reviewed by [CONTACT_824370].
Study sites will receive informat ion about interim results ONLY if they need to know for the 
safety of their subjects.
Safety interims will be conducted on the number of subjects on each treatment who met the 
potentially clinically significant vital s igns criteria at 3 consecut ive time po ints at Visit 3 (Day1 
stoppi[INVESTIGATOR_004]).  This will be done after 50, 100, and [ADDRESS_1143239] had 
the opportunit y to complete Visit 11 (Week 12) assessments.   The statist ical analysis will include 
all 170subjects in the interim analysis, which will evaluate both the efficacy and the safet y.  In 
addition, the PK data m ay be reviewed .  An addit ional interim analysis o f efficacy and safet y 
may be conducted prior to study  completion for internal decisio n making.Whileall potential
efficacy analyses may be used for internal decisio n making, theyarenot planned to stop the 
study for efficacy  or futility because this is an exploratory  study and there are other key  
endpoints being assessed, not just the primary endpoint.
Unblinding details are specified in the unblinding plan sect ion of the SAP or a separate 
unblinding plan document .
CCI
I7S-MC-HBEH(b) Clinical Protocol Page 76
LY315420711.References
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh- Sørensen P.  Prevalence and characteristics 
of dementia in Parkinson disease: an 8-year prospective study .Arch 
Neurol.2003;60(3):[ADDRESS_1143240] CG, Halliday G. Are Parkinson ’s disease with dement ia and dement ia with 
Lewy bodies the same ent ity?J Geriatr Psychiatry Neurol. 2004;17(3):[ADDRESS_1143241] C. Neuropathology of dement ia in 
Parkinson’s disease: a prospective, co mmunity-based study . Ann Neurol . 2005 
Nov;58(5):773 –776.
American Psychiatric Associat ion. Diagnostic and statist ical manual of mental disorders .5th ed. 
Washingto n, DC; 2013.
Arnsten AFT, Girgis RR, Gray  DL, Mailman RB. Novel dopamine therapeutics for cognit ive 
deficits in schizophrenia. Biol Psychiatry. 2017;81(1):[ADDRESS_1143242] C , Ziabreva I, Perry  R, Larsen JP, O ’Brien J, McKeit h I, Perry E, Aarsland D.
Differences in neuropathol ogic characterist ics across the Lewy body dement ia spectrum.
Neurology . 2006;67(11):1931 -1934.
Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday  GM, Hardy  J, 
Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl 
G.Time to redefine PD? Introductory statement of the MDS Task Force on the definit ion of 
Parkinson's disease .Mov Disord. 2014;29(4):454-462.
Brennan L, Siderowf A, Rubright JD, Rick J, Dahodwala N, Duda JE, Hurtig H, Stern M , Xie 
SX, Rennert L, Karlawish J, Shea JA, Trojanowski JQ, Weintraub D. Development and init ial 
testing of the Penn Parkinson’ s Daily Activities Questionnaire. Mov Disord. 
2016a;31(1):126 -134.
Brennan L, Siderowf A, Rubright JD, Rick J, Dahodwala N, Duda J E, Hurtig H, Stern M, Xi e 
SX, Rennert L, Karlawish J, Shea JA, Trojanowski JQ, Weintraub D. The Penn Parkinson ’s 
Daily Act ivities Questionnaire-15: Psychometric properti es of a brief assessment of cognit ive 
instrumental activities of daily living in Parkin son’s disease. Parkinsonism Relat Disord . 
2016b;25:21 -26.
Biundo R, Weis L, Bostantjopoulou S, Stefanova E, Falup -Pecurariu C, Kramberger MG, et al. 
MMSE and MoCA in Parkinson's disease and dement ia with Lewy bodies: a mult icenter 1-
year follow-up study. JNeural Transm (Vienna). 2016;123(4):431 -8.
Beyer K, Domingo -Sàbat M, Ariza A. Molecular pathology  of Lewy body  diseases. Int J Mol 
Sci. 2009 Mar;10(3):724 –745. 
Chou KL, Amick MM, Brandt J, Camicio li R, Frei K, Gitelman D, Goldman J, Growdon J, 
Hurtig HI, Levin B, Lit van I, Marsh L, Simuni T, Tröster AI, Uc EY; Parkinson Study  Group 
Cognitive/Psychiatric Working Group. A recommended scale for cognit ive screening in 
clinical trials o f Parkinson ’s disease. Mov Disord. 2010;25(15):2501-2507.
I7S-MC-HBEH(b) Clinical Protocol Page 77
LY3154207Colloby [CONTACT_112914], McParland S, O’Brien JT, Attems J. Neuropathological correlates of dopaminergic 
imaging in Alzheimer’s disease and Lewy Body Dementia. Brain J Neurol . 2012 Sep;135(Pt 
9):2798–2808.
Colloby [CONTACT_112914], McKeit h IG, Burn DJ, Wy per DJ, O’Bri en JT, Taylor J -P. Cholinergic and perfusio n 
brain networks in Parkinson disease dement ia. Neurology . 2016 Jul  12;87(2):178 –185. 
Cools R, D ’Esposito M.Inverted-U-shaped dopamine act ions on human working memory  and 
cognitive control. Biol Psychiatry. 2011;69(12):e113 -e125.
Cummings JL. The Neuropsy chiatric Inventory : assessing psychopathology  in dementia 
participants. Neurology . 1997;48([ADDRESS_1143243] 6):S10-6.
Cummings JL, Mega M, Gray  K, Rosenberg -Thompson S, Carusi DA, Gornbein J. The 
Neuropsychiatric Inventory : comprehensive assessment of psychopathology  in dementia. 
Neurology . 1994;44(12):2308-2314.
Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer 
TR, KirwanJ, Keenan R, Wells S, Porter RJ, Watts R, Anderson TJ. The MoCA: well -suited 
screen for cognit ive impairment in Parkinson disease. Neurology . 2010;75(19):1717-1725.
Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Funct ion System (D-KEFS). San 
Antonio, TX: The Psychological Corporation ; 2001.
Emre M, Aarsland D, Albanese A, By [CONTACT_324069], Deuschl G, De Deyn PP, Durif F, Kulisevsky J, 
van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wo lters E, Quarg P, Tekin S, Lane R. 
Rivastigmine for dement ia associated with Parkinson's disease. N Engl J Med . 
2004;351(24):2509 -2518.
Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, 
Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, 
McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical 
diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord Off J Mov 
Disord Soc . 2007 Sep 15;22(12):1689 –1707; quiz 1837.
[FDA] [LOCATION_002] Food and Drug Administration. Guid ance for Industry . Suicide ideat ion and 
behavior: prospective assessment of occurrence in clinical trials [draft guidance]. August 
2012. Available at: http://www .fda.gov/downl oads/Drugs/Guidances/UCM225130.pdf.  
Accessed February 21, 2017.
Freitas S, Sim oes MR, Alves L, Santana I. Montreal cognit ive assessment: Influence o f 
sociodemographic and heal th variables.Arch Clin Neuropsychol , 2012;27(2):165 -175.
Friedman JH. Dement ia with Lewy Bodies and Parkinson Disease Dement ia: It is the Same 
Disease! Parkinsonism Relat Disord . 2018 Jan;[ADDRESS_1143244] 1:S6 –S9.
Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognit ive assessment as a screening 
tool for cognitive impairment in Parkinson's disease. Mov Disord. 2008;23(7):[ADDRESS_1143245] er Society-sponsored revisio n of the Unified Parkinson’s 
I7S-MC-HBEH(b) Clinical Protocol Page 78
LY3154207Disease Rating Scale (MDS -UPDRS): process, format, and clinimetric testing plan. Mov 
Disord. 2007;22(1):[ADDRESS_1143246] B, Goetz CG, Stebbins GT. Dissociations amo ng 
daytime sleepi[INVESTIGATOR_008], nighttime sleep, and cognit ive status in Parkinson ’s disease. Parkinsonism 
Relat Disord. 2013;19(9):806 -811.
Gomperts SN. Lewy Body Dement ia: Dementia With Lewy Bodies and Parkinson Disease 
Dementia. Continuum (Minneap Minn). 2016;22(2 De mentia):435-63.
Gulwadi AG, Korpi[INVESTIGATOR_824323], Mailman RB, Nicho ls DE, Sit S -Y, Taber MT. Dinapsoline: 
characterizat ion of a D1 dopamine receptor agonist in a rat model of Parkinson’s disease. J 
Pharmacol Exp Ther. 2001;296(2):338 -344.
Harding AJ, Halliday GM. C ortical Lewy body  pathology in the diagnosis of dement ia. 
ActaNeuropathol (Berl) . [ADDRESS_1143247];102(4):355–363.
Hoddes E, Zarcone V, Smy the H, Phillips R, and Dement WC. Quantificat ion of sleepi[INVESTIGATOR_008]: a 
new approach. Psychophysiol . 1973;10:431-436.
Hoehn MM, Y ahr MD. Parkinsonism: onset, progressio n, and mortalit y. Neurology . 
1967;17:427 –442.
Högl B, Arnulf I, Com ella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, 
Sampaio C, Stebbins GT, Schrag A, Goetz CG. Scales to assess sleep impairmen t in 
Parkinson ’s disease: crit ique and recommendat ions.Mov Disord. 2010;25(16):2704 -2716.
Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D. Validit y of the 
MoCA and MMSE in the detection of MCI and dement ia in Parkinson disease. Neurology . 
2009;73(21):1738 -1745.
Jellinger KA. Dement ia with Lewy bodies and Parkinson’s disease -dementia: current concepts 
and controversies. J Neural Transm Vienna Austria 1996 . 2018 Apr;125(4):615–650. 
Jellinger KA, Korczyn AD. Are dement ia with Lewy bodies and Parkinson’s disease dement ia 
the same disease? BMC Med . 2018 06;16(1):34.
Johansen KK, White LR, Sando SB, Aasly JO. Biomarkers: Parkinson disease wit h dementia and 
dementia with Lewy bodies. Parkinsonism Relat Disord. 2010;16(5):307 -315.
Johns MW. A new method for measuring day time sleepi[INVESTIGATOR_008]: the Epworth sleepi[INVESTIGATOR_50526]. 
Sleep.1991;14:540 –545.
Kehagia AA, Barker RA, Robbins TW. Cognit ive impairment in Parkinson ’s disease: the dual 
syndrome hypothesis. Neurodegener Dis . 2013;11(2):79 -92.
Kish SJ, Shannak K, Horny kiewicz O. Uneven pattern of dopamine loss in the striatum of 
patients with idiopathic Parkinson’s disease. N Engl J Med . 1998;318:876 -880.
Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, Baudrexel S, Diederich 
NJ,Heiss WD, Hilker R. Neurotransmitter changes in dementia with Lewy bodies and 
Parkinson disease dementia in vivo. Neurology . 2010 Mar 16;74(11):885–892.
Lippa CF, Duda JE, Grossm an M, Hurti g HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, 
Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, 
I7S-MC-HBEH(b) Clinical Protocol Page 79
LY3154207Gwinn-Hardy KA, Hardy  J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah 
E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, 
Trojanowski JQ, Wszolek ZK; DLB/PDD Working Group. DLB and PDD boundary issues: 
diagnosis, treatm ent, molecular pathology , and biomarkers. Neurology . 2007;68(11):812-819.
Litvan I, Gol dman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, 
Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky  J, Rodriguez-Oroz MC, 
Burn DJ, Barker RA, Emre M. Diagnost ic criteria for mild cognit ive impairment in 
Parkinson ’s disease: Movement Disorder Societ y Task Force guidelines. Mov Disord. 
2012;27(3):349 -356.
McKeith I,Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin -Sain A, Ferrara R, Spi [INVESTIGATOR_16614] 
R. Efficacy  of rivastigmine in dement ia with Lewy bodies: a rando mised, double -blind, 
placebo-controlled internat ional study. Lancet 2000; 356(9247):2031-6
McKeith IG, Dickson DW, Lowe J, Emre M, O ’Brien JT, Feldman H, Cummings J, Duda JE, 
Lippa C, Perry  EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, 
Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez -Tortosa E, Halliday G, Hansen LA, 
Hardy J, Iwatsubo T , Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, 
Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, 
Mukaetova -Ladinska EB, Pasquier F, Perry  RH, Schulz JB, Troj anowski JQ, Yamada M; 
Consortium on DLB. Diagnosis and m anagement of dement ia with Lewy bodies: third report 
of the DLB Consorti um.Neurology . 2005;65(12):1863-1872.
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and 
management of dement ia with Lewy bodies: Fourth consensus re port of the DLB Consortium. 
Neurology . 2017;89(1):88 -100.Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang 
AE. Practice parameter: Init iation of treatment for Parkinson’s disease: an evidence -based 
review: report of the Qualit y Standards Subcommittee of the Ameri can Academy  of 
Neurology. Neurology. 2002;58:11–17.
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, et al. Diagnosis and management 
of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 
2017; 89(1):88-100
Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner -Fisman G, Anderson K, Shulman LM, 
Gronseth G, Weiner WJ; Qualit y Standards Subcommittee of the American Academy of 
Neurology. Practice Parameter: evaluat ion and treatment of depressio n, psychos is, and 
dementia in Parkinson disease (an evidence -based review): report of the Qualit y Standards 
Subcommittee of the American Academy of Neurology. Neurology .2006;66(7):996 -1002.
Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas 
L, Geldmacher D, Cl ark C, Thal  LJ. Development of cognit ive instruments for use in clinical 
trials of antidementia drugs: addit ions to the Alzheimer ’s Disease Assessment Scale that 
broaden its scope. The Alzheimer ’s Disease Cooperative Study .Alzheimer Dis Assoc Disord . 
1997;11 (suppl 2):S13-21.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, 
Chertkow H. The Montreal Cognit ive Assessment, MoCA: a brief screening tool for mild 
cognitive impairment. J Am Geriatr Soc. 2005;53(4):695 -699.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143248] TT, Colcher A, Horn SS, Moberg PJ, Wilkinso n JR, 
Hurtig HI, Stern MB, Weintraub D. Mon treal cognitive assessment performance in 
participants wi th Parkinson ’s disease with “normal”global cognition according to 
mini-mental state examinat ion score. J Am Geriatr Soc . 2009;57(2):304 -308.
Olson RA, Iverson GL, Carolan H, Parkinson M, Brooks BL, McKenzie M. Prospective 
comparison of two cognit ive screening tests: diagnostic accuracy and correlat ion with 
communit y integration and qualit y of life. J Neurooncol . 2011;105(2):337 -344.
Pagonabarraga J, Kulisevsky J. Cognit ive impairment and dementia in Parkinson ’s disease.
Neurobiol Dis . 2012;46(3):590 -596.
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classificat ion Algorithm o f 
Suicide Assessment (C -CASA): classificat ion of suicidal events in the FDA’s pediatric 
suicidal risk analysis of ant idepressants. Am J Psychiatry . 2007;164(7):1035-1043.
Postuma RB, Gagnon JF, Vendette M, Montp laisir JY. Idiopathic REM sleep behavior disorder 
in the transit ion to degenerative disease. Mov Disord. 2009;24(15):2225 -2232.
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, 
Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, 
Deuschl G. MDS clinical diagnostic criteria for Parkinson’ s disease. Mov Disord. 
2015;30(12):[ADDRESS_1143249] (PWC -20). 
J Clin Psychopharmacol . 2008;28(4):447 -51.
Rickels K, Schweizer E, Case WG, Greenblatt DJ . Long-term therapeuti c use of 
benzodiazepi[INVESTIGATOR_1651]. I. Effects of abrupt discont inuation.1990;Arch Gen Psychiatry . 47:899-907
Rosen WG, Mohs RC, Davis KL. A new rat ing scale for Alzheimer ’s disease. Am J 
Psychiatry. 1984;141(11):1356 -1364.
RowanE, McKeith IG, Saxby  [CONTACT_90145], O’Brien JT, Burn D, Mosimann U, Newby J, Daniel S, 
Sanders J, Wesnes K. Effects of donepezil on central processing speed and attentional 
measures in Parkinson’ s disease with dementia and dement ia with Lewy bodies. Dement 
Geriatr Cogn Disord. 2007;23:161 –167.
Schneider LS, Olin JT, Doody  RS, Clark CM, Morri s JC, Reisberg B, Schmitt FA, Grundman M, 
Thomas RG, Ferris SH . Validity and reliabilit y of the Alzheimer’s Disease Coopera tive 
Study-Clinical Glo bal Impression of Change: the Alzheimer’s Disease Cooperative Study . 
Alzheimer Dis Assoc Disord .1997;11(suppl2):S22-S32.
Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long -term therapeuti c use of 
benzodiazepi[INVESTIGATOR_1651]. II Effects of gr adual taper. 1990; Arch Gen Psychiatry . 47:908-915
SheikhJI, Yesavage JA . Geriatric Depressi on Scale (GDS): Recent evidence and development of 
a shorter version. ClinGerontologist .1986;5:165 -173.
Smith T, Gildeh N, Holmes C. The Montreal Cognit ive Assessment: validit y and utility in a 
memory clinic setting. Can J Psychiatry .2007;52(5):329 –332.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143250] C, Aarsland D. Cognit ive impairment in participants with 
Parkinson ’s disease: diagnosis, bio markers, and treatment. Lancet Neurol . 
2012;11(8):[ADDRESS_1143251], Nelson DL, Lucaites VL, Emkey  R, DeLapp NW, Wiernicki TR, Cramer JW, 
Yang CR, Bruns RF.  An allosteric potentiator of the dopamine D1 receptor increases 
locomotor activit y in human D1 knock- in mice without causing stereoty py or tachyphylaxis. J 
Pharmacol Exp Ther. 2017;360:117 –128.
Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ; Alzheimer’s Disease Neuroimaging 
Initiative.Relationship between the Montreal Cognit ive Assessment and Mini -mental State 
Examinat ion for assessment of mild cognit ive impairment in older adults. BMC Geriatr.
2015;15:107.
Thomas AJ, Taylor JP, McKeit h I, Bamford C, Burn D, Allan L, O’Brien J. Revisio n of 
assessment toolkits for improving the diagnosis of Lewy  body dementia: The DIAMOND 
Lewy study. Int J Geriatr Psychiatry . [ADDRESS_1143252];33(10):1293–1304.
Wang CS, Pai MC, Chen PL, Hou NT, Chien PF, Huang YC. Montreal Cognit ive Assessment 
and Mini-Mental State Examinat ion performance in patients wit h mild-to-moderate dement ia 
with Lewy bodi es, Alzheimer's disease, and normal participants in Taiwan. Int Psychogeriatr . 
2013;25(11):[ADDRESS_1143253] ionnaire for impulsive -compulsive disorders in Parkinson’ s disease. 
Mov Disord. 2009;24(10):1461-1467.
Weintraub D, Mamikonyan E, Papay  K, Shea JA, Xi e SX, Siderowf A. Questionnaire for 
Impulsive-Compulsive Disorders in Parkinson ’s Disease-Rating Scale. Mov Disord. 
2012;27(2):[ADDRESS_1143254] use with impulse co ntrol disorders in Parkinson 
disease. Arch Neurol . 2006;63(7):969 -973.
Wesnes KA. Assessing change in cognit ive function in dement ia: the relat ive utilities of the 
Alzheimer’s disease assessment scale –cognitive subscale and the cognitive drug research 
system. Neurodegenerative Dis . 2008;5:261-263.
Wesnes KA, McKeit h I, Edgar C, Emre M, Lane R. Benefit s of rivast igmine on attention in 
dementia associated with Parkinson disease. Neurol.2005;65:[ADDRESS_1143255] igmine on cognit ive function in dement ia with lewy bodies: a 
randomised placebo -controlled internat ional study using the cogni tive drug research 
computerised assessment sy stem. Dement Geriatr Cogn Disord .2002;13:183 –192.
I7S-MC-HBEH(b) Clinical Protocol Page 82
LY3154207Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M. , Leirer VO. Development and 
validation of a geriatric depressio n screening scale: A preliminary report. J Psychiatr Res . 
1983;17:37-49.
Zadikoff C, Fox SH, Tang -Wai DF, Thomsen T, de Bie RM, Wadia P, Miyasaki J, Duff- Canning 
S, Lang AE, Marras C. A comparison of the mini mental state exam to the Montreal cognit ive 
assessment in ident ifying cognit ive deficit s in Parkinson’ s disease. Mov Disord.
2008;23(2):297 -299.
I7S-MC-HBEH(b) Clinical Protocol Page 83
LY315420712.Appendices
I7S-MC-HBEH(b) Clinical Protocol Page 84
LY3154207Appendix 1. Abbreviations and Defin itions
Term Definition
AChEI acetylcholinesterase inhibitor
AD Alzheimer’s disease
ADAS-Cog13 Alzheimer’s Disease Assessment Scale –13-item Cognitive Subscale
ADAS-Cog11 Alzheimer’s Disease Assessment Scale –11-item Cognitive Subscale
ADCS-CGIC Alzheimer’s Disease Cooperative Study -Clinician Global Impression of Change
AE adverse event:  Any untoward medical occurrence in a subjector clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory find ing), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
blinding/masking A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the subjectis not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the subjectare not.
A double-blind study is one in which neither the subject nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.
Cmax maximum observed drug concentration
C-SSRS Columbia -Suicide Severity Rating Scale
CDR-CCB Cognitive Drug Research Computerized Cognition Battery
CI confidence interval
CIOMS CouncilforInternational Organizations ofMedicalSciences
CoA Continuity of Attention
Companion diagnostic An in vitro diagnostic device (assay or test) that provides information that is essential for 
the safe and effective use of a corresponding therapeutic product
I7S-MC-HBEH(b) Clinical Protocol Page 85
LY3154207complaint A complaint is any written, electronic, or oral communication th at alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related requirements, good clinical practice (GCP) requ irements, 
and applicable regulatory requirements.
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physi cian or other medical officer.
CSF cerebrospi[INVESTIGATOR_824324] P450
CYP3A4 cytochrome P450 3A4
D1PAM positive allosteric modulator of the dopamine D1 receptor
D-KEFS Delis–Kaplan Executive Function System
DLB dementia with Lewy bodies
EC25 effective concentration [ADDRESS_1143256]
ESS Epworth Sleepi[INVESTIGATOR_824325]-S Geriatric Depression Scale –Short Form
HEENT head, ear, eye, nose, and throat
HBPM home blood pressure monitoring
IB Investigator’s Brochure
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143257]’s decision to participate.  Informed consent is documented by [CONTACT_3553] a 
written, signed and dated informed consent form.
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational product A pharma ceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed prod ucts used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IWRS
LBDinteractive web -response sy stem
Lewy Body Dementia
MDS Movement Disorder Society
MDS-UPDRS Movement Disorder Society ’sUnited Parkinson’s Disease Rating Scale
MedDRA Medical Dictionary for Regulatory Activities
MMRM mixed-model repeated measures
MMSE Mini-Mental State Examination
MoCA Montreal Cognitive Assessment
NOAEL no-observed -adverse-effect level
NONMEM nonlinear mixed effects modeling
NPI [INVESTIGATOR_824326]’s disease
PDAQ-15 Penn Parkinson’s Daily Activities Questionnaire -15
PDD Parkinson’s disease dementia
PK pharmacokinetic(s)
I7S-MC-HBEH(b) Clinical Protocol Page 87
LY3154207PoA Power of Attention
PSG Parkinson Study Group
QD once a day
QTcF Fredericia ’s corrected QT interval on the ECG
QUIP Questionnaire for Impulsive -Compulsive Disorders in Parkinson’s Disease
REM rapid eye movement
SAE serious adverse event
SAP statistical analysis plan
SBP systolic blood pressure
Screen The act of determining if an individual meets requirements for participation in a clinical 
study. 
SD standard deviation
SOC System Organ Class
S[LOCATION_003]R suspected unexpe cted serious adverse reaction
TBL total bilirubin
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship with 
this treatment.
ULN upper limit of normal
WOCBP womenof child-bearing potential
I7S-MC-HBEH(b) Clinical Protocol Page 88
LY3154207Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Tests
Hematology a,b Clinical Chemistry a,b,c
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocyte count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocytes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Glucose, nonfasting 
Urinalysis a,b Albumin
Specific gravity Cholesterol
pH Creatine kinase (CK)
Protein
Glucose
Ketones Serum FSH (females only)a,b,c,d
Blood
Urine leukocyte esterase
Abbreviations:  FSH = follicle -stimulating hormone; RBC = red blood cells; WBC = white blood cells.
aAssayed by [CONTACT_11008]-designated Central L aboratory .
bResults will be confirmed by [CONTACT_11008]-designated Central L aboratoryat the time of initial testing.
cRefer to the Schedule of Activities .
dRefer to inclusion criteria [12e] in Section 6.1.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143258] igator is responsible for:
ensuring that the subject/subject’s legal representative understands the nature of the 
study, the potenti al risks and benefi ts of participating in the study , and that thei r 
participation is voluntary.
ensuring that informed consent is given by [CONTACT_824371].  Thi s 
includes obtaining the appropriate signatures and dates on the informed consent form 
(ICF)prior to the performance of any  protocol procedures and prior to the administration 
of investigational product.
answering any qu estions the subject/subject’s legal representative may have throughout 
the study and sharing in a t imely manner any  new inform ation that may be relevant to 
the subjects/subject’s legal representative’s willingness to continue his or her 
participation in the study.
ensuring that a copy  of the ICF is provi ded to the subject or the subject’s legal 
representative and is kept on file.
ensuring that the medical record includes a statement that written informed consent was 
obtained before the subject was enrolled in the study and the date the written consent 
was obtained. The authorized person obtaining the informed consent must also sign the 
ICF.
Caregivers will also sign a separate informed consent. If it is not known that the caregiver will 
change, the new car egiver woul d need to si gn the ICF when he/she takes over the care for the 
subjectand study participat ion. The change in caregiver would also need to be documented on 
the eCRF.
As used in this protocol, the term “informed consent ” includes all consent and assent given by
[CONTACT_824372].
Appendix 3.1.[ADDRESS_1143259] ( ERB)was properly constituted and convened as required by [CONTACT_82410] (ICH)guidelines and other applicable laws and regulations.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143260] be provided to Lilly  before the 
study may begin at the investi gative site(s).  Lilly  or its representatives must approve the ICF, 
including any changes made by [CONTACT_41429], before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP).
The study  site’s ERB(s) shoul d be provided wi th the following:
the protocol and related amen dments and addenda, current Investigator 
Brochure ( IB)and updates during the course of the study
informed consent form
other relevant documents (e.g., curricula vitae , advertisements)
Appendix 3.1.4. Regulatory Considerations
This study  will be conducted in accordance wit h the protocol and with:
the consensus ethics principles derived fro m international ethics guidelines, 
including the Declarat ion of Helsinki and CouncilforInternational Organizat ions
ofMedicalSciences (CIOMS) Internati onal Ethical Guidelines
the applicable ICH GCP Guidelines
the applicable laws and regulat ions
Some of the obligat ions of the sponsor will be assigned to a third party.
Appendix 3.1.5. Investigator Information
Physicians with a specialt y inneurology, geriatric medicine ,and/or psy chiatry will participate as 
investigators in this clinical trial.
Appendix 3.1.6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accura tely describes the pl anned design and conduct of the 
study.
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 3.1.7. Final Report Signature
[CONTACT_314867](CSR)coordinating investigator [INVESTIGATOR_824327] , 
indicating agreement that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
The invest igator with the mostqualified subjectswill serve as the CSRcoordinat ing investigator.  
If this invest igator is unable to fulfill this funct ion, another invest igator will be chosen by [CONTACT_480793].
I7S-MC-HBEH(b) Clinical Protocol Page 91
LY3154207The sponsor’s responsible medical o fficer and statistician will approve the final CSRfor this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendi x 3.2.Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provide instructi onal materi al to the study  sites, as appropriate
sponsor investigator study  site trainings to instruct the invest igators and study 
coordinators.  This trainingwill give instructi on on the protocol, the complet ion 
of the eCRFs, and study  procedures .
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_129237], telephone, and/or fax
review and evaluate eCRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addition, Lilly or its representatives willperiodically check a sample of the subject data 
recorded against source documents at the study sit e.  The study  may be audited by [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice prior 
toan audit.
The invest igator will keep records of all original sour ce data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
documents.
Appendix 3.2. 1.Data Capture System
An electronic data capture sy stem will be used in this study .  The site maintains a separate source 
for the data entered by  [CONTACT_129238] -provided electronic data capture system.
Electronic Clinical Outcom e Assessment (eCOA) measures (e .g., a rating scale) are entered into 
an eCOAinstrument (at the time that the information is obtained ).  In these instances, where 
there is no prior written or electronic source data at the site, the eCOAinstrument record will 
serve as the source.
If eCOArecords are stored at a third- party site, investi gator sites will have continuous access to 
the source documents during the study  and will receive an archival copy  at the end of the study  
for retention.
Any data for whi ch the eCOAinstrument record will serve to collect source data will be 
identified and documented by [CONTACT_140842]’s study file .
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143261] data or electrocardiogram data, will be stored 
electronically in the central vendor’s database syst em.  Data will subsequent ly be transferred 
from the central vendor to the Lilly data warehouse .
Any data for which paper documentati on provided by [CONTACT_129241] i dentified and documented by  [CONTACT_129240]’sstudy file.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management system.
Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study site participation may be discont inuedif Lilly or its designee, the investigator, or the ERB 
of the study  sitejudges it necessary for medical, safety, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for medical, safet y, 
regulatory, or other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3.4. Publication Policy
The publicat ion policy for Study HBEHis described in the Clinical Trial Agreement.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143262]
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti-smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspi[INVESTIGATOR_82355]; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normali zed 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssayed by [CONTACT_11007] -designated laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I7S-MC-HBEH(b) Clinical Protocol Page 94
LY3154207Appendix 5. MDS Diagnostic Criteria for P arkinson’s 
Disease –Red Flags and Supportive 
Criteria
Postuma et al. 2015
ABSOLUTE EXCLUSION CRITERIA
1.unequivocal cerebellar abnormalit ies on exam;
2.downward vertical supranuclear gaze palsy or selective slowing of downward vert ical
saccades;
3.diagnosis of behavioral variant of frontotemporal dement ia or primary progressive 
aphasia within the first 5 years of disease;
4.parkinsonian features restricted to the lower limb for greater than 3 years;
5.treatment with a dopamine receptor blocker or dopamine deplet ing agent that temporally 
suggests drug- induced parkinsonism;
6.absence of observa ble response to high -dose levodopa therapy ;
7.unequivocal cortical sensor y loss, clear limb ideomotor apraxia , or progressive aphasia;
8.normal functional imaging of the presynapt ic dopaminergic system (PET or SPECT);
9.documentation of an alternative condit ion to account for parkinsonism or expert opi[INVESTIGATOR_3078] n 
thatan alternat ive diagnosis is more likely  than PD.
RED FLAGS
1.Rapid progressi on of gait impairment requiring regular use of wheelchair within 5 years
of onset.
2.A complete absence of progression o f motor symptoms or signs over 5 or more years 
unlessstability is related to treatment.
Note: This criterion is targeted at patients w ho may have been misdiagnosed w ith
parkinsonism. This must be defined based on observation (i .e.historical information 
cannot suffice). The absence of progression must be continuous over a minimu m of 
5years.
3.Early bulbar dy sfunction, defined as one of severe dy sphonia, dysarthria (speech 
unintelligible most of the time), or severe dysphagia (requiring soft food, NG tube, or 
gastrostomy  feeding) wi thin the first 5 y  of disease.
Note: Severity def initions are from the Movement Disorder Society’s –sponsored 
revision of the United Parkinson’s Disease Rating Scale ( MDS-UPDRS)(i.e.4 for 
dysarthria, ≥3 for dysphagia).
4.Inspi[INVESTIGATOR_824328].
5.Severeautonomic failure in the first 5 y  of disease.
This can include:
I7S-MC-HBEH(b) Clinical Protocol Page 95
LY3154207a.Orthostatic hypotension: orthostatic decrease o f blood pressure with in [ADDRESS_1143263] 5 y of disease (excluding 
longstanding low -volume stress incontinence in women), which is not simply  
functional incontinence (i.e., inability to get to the bathroom in a reasonable time). 
In men, urinary  retention must not be caused by  [CONTACT_824373], and thi s must be 
associated with erectile dysfunct ion.
Note: Autonomic dysfunction is a common feature of PD; how ever, this criterion is
intended to identify the severe autonomic dysfunction associated particularly with 
multiple system atrophy. If the patient has more than 5 years’disease duration at 
assessment, these features must have occurred within the first 5 years(documented 
either by [CONTACT_824374] a clear onset time on history 
for urinary incontinence).
6.Recurrent (>1/y ) falls because of impaired balance within 3 yearsof onset.
Note: For this criterion, falls are considered to be attributable to impaired balance, 
implying that falls attributable to loss of consciousness (syncope, seizure), or to 
situations during w hich persons with normal balance w ould also fall (athletic activities, 
violence, slippi[INVESTIGATOR_740490], and so forth) are not included. Clinical judgment is required to 
determine whether impaired balance played a key role in the fall.
7.Thepresence of disproportionate a nterocollis (dystonic in nature) or contractures of hand 
or feet wi thin the first 10 y .
8.Absenceof any of the commo n non-motor features of disease despi[INVESTIGATOR_040] 5 y  disease 
duration.  These include:
Sleep dysfunct ion: sleep-maintenance inso mnia, excessive dayt ime somnolence, 
symptoms of rapid eye movement sleep behavior disorder
Autonomic dysfunction: constipation, daytime urinary urgency (i .e., not simply 
nocturia),symptomatic orthostasis
Hyposmia
Psychiatric dysfunct ion: depression, anxiet y, or hallucinat ions
Note: This criterion is designed primarily to detect nonparkinsonian conditions 
mimicking PD (e.g., subjects w ithout evidence of dopaminergic deficit, dystonic 
tremor, essential tremor)
9.Otherwise unexplained py ramidal tract signs, defined as pyramidal weakness or cl ear 
pathologic hyperreflexia (excluding mild reflex asymmetry  in the more affected limb, and 
isolated extensor plantar response).
Note: Mild reflex asymmetry is excluded because it can commonly be seen in PD. 
Isolatedextensor plantar response is excluded because of the difficulty in differentiating 
this from a “striatal toe” (an occasional finding in PD), and the possibility that unrelated 
pathology (e.g., mild cervical myelopathy) can produce this finding.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143264] returned to normal or near -normal level of 
function. In the absence of clear documentation of init ial response (e.g. ,initial treatment 
with lower-efficacy agents or very  low dose), a dramat ic response also can be classified 
as:
a.Marked improvement with dose increases or marked worsening with dose 
decreases. Mildchanges wi th dose changes do not qualify. This canbe 
documented either objectively (defined as >30% in UPDRS III with change in 
treatment), orsubjectively with a clear history of marked changes provided by a 
reliable patient or caregiver.
b.Unequivocal and marked on/off fluctuations, which must have at some po int 
includedpredictable end-of-dose wear ing off.
Note:To meet this criterion, it is not sufficient to document some beneficial response to 
dopaminergic therapy; the response must be unequivocal and of large amplitude. If 
treatment response is of modest amplitude, the patient does not meet thi s criterion.  The 
requirement of predictable end- of-dose wearing off is to ensure that these are true 
dopaminergic fluctuations (as opposed to day -to-day variability, for example). The 
documentation of predictable end -of-dose wearing off can be from retrospective history 
(i.e., patients do not have to currently be experiencing predictable fluctuations).
2.Presence of levodopa -induced dyskinesia
3.Rest tremor of a limb, documented on clinical examinat ion (in the past, or on current 
examination).
Note: This is included primarily for tw o reasons: (1) rest tremor is less common in 
alternate conditions, and (2) rest tremor may occasionally be less responsive to therapy; 
if so, criterion [ADDRESS_1143265] having a specificit y greater than 
80% for different ial diagnosis of PD from  other parkinsonian condit ions. Currently 
available tests that meet this criterion include:
Olfactory  loss (in the anosmic or clearly hypos mic range, adjusted for age and sex)
Metaiodobenzylguanidine scint igraphy clearly docum enting cardiac sympathetic 
denervation
Note: To meet these criteria, the marker must have been demonstrated to provide more 
than 80% specificity in most studies (w ith aminimum of three studies from different 
centers).
I7S-MC-HBEH(b) Clinical Protocol Page 97
LY3154207Appendix 6. DLBDiagnostic Criteria
Core Clinical Features Indicative Biomarkers
Fluctuating cognit ion with pronounced 
variations in attention, and alertnessReduced dopamine transporter (DaT) uptake in 
basal gangli a via SPECT or PET
Recurrent visual hallucinat ions Abnormal 123iodine-MIBG my ocardial 
scintigraphy
REM Sleep behavior di sorder (RBD) Polysomnographic confirmat ion of REM sleep 
without atonia (RBD)
Spontaneous Parkinsonism (at least one of 
bradykinesia, rest tremor, or rigidity)
Probable DLB requires dement ia (Dement ia should predate, occur concurrent ly or within 1 year 
of Parkinsonism) plus 2 or more Core Clinical Features OR 1 Core Feature and 1 or more 
Indicative Biomarkers(McKeith et al, 2017 ).
I7S-MC-HBEH(b) Clinical Protocol Page 98
LY3154207Appendix 7. Protocol A mendment Summary
I7S-MC-HBEH(b)Effect of LY3154207 on Cognition in 
Mild-to-Moderate Dementia Due to Lewy Body Dementia
(LBD) Associated with Idiopathic Parkinson’s Disease 
(PD) or Dementia with Lew y Bodies (DLB) (The 
PRESENCE Study )
Overview
Protocol I7S-MC-HBEH(b) Effect of LY3154207 on Cognition in mild-to-moderate Dementia 
Due to Lewy  Body Dementia (LBD) Associated with Idiopathic Parkinson’s Disease (PD) or 
Dementia with Lewy Bodies (DLB) has been amended.  The new protocol is indicated by
[CONTACT_61504] ( b) and will be used to conduct the study  in place of any preceding version o f the 
protocol.
The overall changes and rationale for the specificchanges m ade to this protocol  are as follows:
Expanded the patient population to include those indivi duals with DLB with insufficient 
motor symptom s to meet MDS cri teria for PD.Previously only subjects with dement ia 
who met MDS criteria for PD were included, this allowed for patients with DLB to enroll 
as long as they  met the MDS cri teria for PD. This is reflected in changes to the tit le, 
background and inclusion criteria to allow all patients with dement ia associated with 
LBD(PD or DLB) to be enro lled.
A secondary  safety objective and endpo int are added to evaluate the effect of LY3154207 
on physical withdrawal symptoms by [CONTACT_824375] -[ADDRESS_1143266]. Understanding the 
symptoms associated with study  drug withdrawal will  help inform  drug discont inuation 
strategies.
The addit ion of a telephone visit 111 (2 day s after v11) to Schedule of act ivities will 
allow for the assessment of early  withdrawal symptom svia PWC-20(approximately 
5half-lives after last drug dose) when withdrawal symptoms may be maximum with 
minimal addit ional participant burden.
Eliminate GDS score of ≤[ADDRESS_1143267] of LY3154207 on mood and the 
relationship between mood and cognition .
Changes to the duration of stabilit y requirement for certain concomitant medications to 
ensure consistency across medicat ion classes and improve protocol compliance.
The visit 1duration was updated to [ADDRESS_1143268] feedback 
from sites on the actual  time to conductthe visit.
Inclusion and exclusio n criteriaupdated to improve compliance and reduce areas of 
confusion.
Editorial changesthroughout docum entto improve clarit y.
I7S-MC-HBEH(b) Clinical Protocol Page 99
LY3154207Amendment Summary for Protocol I7S-MC-HBEH Amendment ( b)
Section # and Name [CONTACT_19523] 1. Synopsis and Section 4. 
(Objective(s)/Endpoints )A secondary safety objective and 
endpoint are added.
Objective:  To evaluate the effect of 
LY3154207 on physical withdrawal 
symptoms
Endpoint:  Change in the PWC-[ADDRESS_1143269] of LY3154207 on physical 
withdrawal symptoms
Section 1. Synopsis ( Summary of 
Study Design )A telephone visit 111 (2 days after 
V11) is added to the schedule of 
activities to assess withdrawal 
symptoms using the PWC -20.The addition of a telephone visit 
will allow for the assessment of 
early withdrawal sy mptoms 
(approximately [ADDRESS_1143270] 
drug dose) ,when withdrawal 
symptoms may  be maximum with 
minimal additional participant 
burden. 
Section 1. Synopsis ( Number of 
subjects)Approximate number of subjects to be 
screened changed from 400 to 750Compared with a predicted screen 
failure rate of 15%, t he observed 
rate is approximately 55%.The 
numbers have been adjus ted 
accordingly.
Section 1. Synopsis ( Withdrawal )Assessment of withdrawal symptoms 
usingthe PWC-20 was added at 
visit11 Understanding the symptoms 
associated with study drug 
withdrawal will help inform drug 
discontinuation strategies.
Section 1. Synopsis ( Interim 
Analysis)Added language to allow for 
additional efficacy interim analy ses,
as deemed necessary for internal 
decision making only.Modified text to allowflexibility in 
the timing and number of additional 
efficacy interim s.
Section 2 Sc hedule of Activities Modified to account for additional 
assesments and visits Added to provide instruction
Section 5.1.1. Screening Period 
(Visit 1)Visit1 is expected to be of a duration 
of approximately [ADDRESS_1143271] feedback from sites on the 
actual time for conducting the visit.
Section [IP_ADDRESS].Screening 
ProceduresScreening procedures are updated.
Added CDR -CBB training and 
Clinical diagnostic criteria for PDD 
and DLBAs the primary outcome, it is 
critical to ensure that all subjects 
can complete the CDR, in addition, 
the training reduces practice effects.
6.1. Inclusion Criteria [2] Meet diagnostic criteria for PD 
(Postuma et al. 2015) or DLB 
(McKeith et al. 2017) ( See 
Appendix 5 and 6 for details)Revised to define expanded patient 
population.
I7S-MC-HBEH(b) Clinical Protocol Page 100
LY3154207Section # and Name [CONTACT_23688]
6.2.1. Rationale for Exclusion of 
Certain Study CandidatesCNS diseases and other 
neuropsychiatric disorders (e.g., 
active psychosis, substance abuse) 
that can affect performance on 
cognitive tasks and compliance with 
the protocol are also excluded.Clarification and modification based 
on changes to inclusion criteria (e.g. 
GDS>6 removed).
9.4.5. Physician Withdrawal 
ChecklistThe Penn Physician Withdrawal 
Checklist (PWC-20) is a 20-item 
checklist originally developed to 
assess the severity of withdrawal 
symptoms in anxiolytic medication 
discontinuation (Rickels et al. 2008 ).
The PWC -[ADDRESS_1143272] 
(Schweizer et al. 1990; Rickels et al. 
1990).  The [ADDRESS_1143273]’s level of symptoms on a 
variety of withdrawal symptoms since 
last visit.  Each of the 20 items are 
scored as 0 (not present), 1 (mild), 
2(moderate), 3 (severe)Descriptio n of PWC -20,added per 
previous rationale.
I7S-MC-HBEH(b) Clinical Protocol Page 101
LY3154207Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Additions have been identified by  [CONTACT_58002] .
1. Synopsis
Title of Study:
Effect of LY3154207 on c ognition in mild-to-moderate dementia due to Lewy Body Parkinson ’s
Disease Dementias (PDDLBD)associated with idiopathic Parkinson’s disease (PD) or dement ia 
with Lewy bodi es (DLB).
Rationale: 
Eli Lilly and Company  (Lilly) is developi[INVESTIGATOR_90721]3154207, an orally available, selective posit ive 
allosteric modulator (PAM, also called “potentiator”) of the dopamine D1 receptor subt ype 
(D1PAM). By [CONTACT_395514] y of dopamine for the D1 receptor, a D1PAM is 
hypothesized to amplify respons e to endogenous dopamine, thereby [CONTACT_30212] D1 tone at the 
site of dopamine release, and represents a novel mechanism o f action.  By [CONTACT_824337] (or administered levodopa) in subjects wi th
insufficient physio logic dopamine such as those with LBD(PDD orDLB)PDD and DLB , a 
D1PAM should improve cognit ive performance.  In addit ion, a D1PAM should have a positive 
impact on other domains affected by  [CONTACT_824338](PDD orDLB)PDD and DLB including motor 
deficits, mood, apathy , and daytime sleepi[INVESTIGATOR_008].
 
Study I7S-MC-HBEH (HBEH) is a mult icenter, rando mized, double -blind, parallel -group, 
placebo-controlled, fixe d-dosage, Phase 2 astudy comparing 3 dosages of LY3154207 (10, 30, or 
75 mg administered orally [or 50 mg based on interim analysis] once a day [QD]) with placebo 
over 12 weeks in subjects wi th mild-to-moderate dem entiaassociated withLBD(PDD or 
DLB)PDD.Study HBEH will test the hypothesis that LY3154207 administered at 10 mg, 
30mg, and/or 75 mg daily (or 50 mg based on interim analysis) (QD) oral dosing for [ADDRESS_1143274] s with mild -to-moderateLBD
(PDD orDLB)PDDcompared with placebo.Important secondary  outcomes will assess the 
effect of LY3154207 on funct ion, parkinsonism, sleep and mood/behavior .
 
 
CCI
CCI
I7S-MC-HBEH(b) Clinical Protocol Page 102
LY3154207Objective(s)/Endpoints:
Objectives Endpoints
Primary
To test the hypothesis that LY3154207 administered at 
10mg, 30mg,and/or 75mgdaily (or 50mg based on 
interim analysis) ( QD) oral dosing for 12 weeks will 
result in a significant improvement in cognition in 
subjects with mild-to -moderate LBD(PDD orDLB)
PDD compared with placebo.Change in the CoA composite score of the CDR-CCB
from baseline to Week 12.
Secondary
Safety:
To evaluate the effect of LY3154207 on acute changes 
of vital signs on the first day of dosingNumber of subjects who met the potentially clinically 
significant vital signs criteria at 3 consecutive time 
points at Visit 3 (Day1 stoppi[INVESTIGATOR_004]).
To evaluate the effect of LY3154207 on SBP on the first 
day of dosingChange in in -clinic SBP from [ADDRESS_1143275] of LY3154207 on SBPfrom 
baseline to Week 12Change in in -clinic mean SBP at baseline to mean SBP 
at Week12
Change in in -clinic mean pulse rate at baseline to mean 
pulse rate at Week 12
Change in the PWC-20 total score from Week 12 to in-
clinic follow -up visit
Change in totalMDSUPDRS (sum of Part I III) and
individual subscales nonmotor experiences of daily
living (Part I), motor experiences of daily living
(Part II),motor exam (Part III) , and motor complications
(Part IV) s ubscalesfrom baseline to Week [ADDRESS_1143276] day of study drug dosing
Change in in -clinic mean SBPat baseline to mean SBP
at Week12
I7S-MC-HBEH(b) Clinical Protocol Page 103
LY3154207Abbreviations:  ADAS -Cog11= 11-item Alzheimer’s Disease Assessment Scale –Cognitive subscale;
ADAS-Cog 13= 13-item Alzheimer’s Disease Assessment Scale –Cognitive subscale; CDR -CCB = Cognitive 
Drug Research Computerized Cognition Battery; ADCS –-CGIC = Alzheimer’s Disease Cooperative Study –
Clinician Global I mpression of Change; CoA = Continuity of Attention; D -KEFS = Delis –Kaplan Executive 
Function System ; DLB = dementia with Lewy bodies; ESS = Epworth Sleepi[INVESTIGATOR_7110]; LBD = Lewy Body 
Dementia ; HBPM = home blood pressure monitoring; MDS -UPDRS = Movement Dis order Society’s Unified 
Parkinson’s Disease Rating Scale; MoCA = Montreal Cognitive Assessment; NPI = Neuropsychiatric Inventory; 
PDD = Parkinson’s disease dementia; PDAQ -15 = Penn Parkinson’s Daily Activities Questionnaire -15;
PK = pharmacokinetics; PoA = Power of Attention; PWC -20 = physician withdraw al checklist -20; QD = once a 
day; QUIP = Questionnaire for ’Impulsive -Compulsive Disorders in Parkinson’s Disease; SBP = systolic blood 
pressure.
Summary of Study Design:   Study I7S-MC-HBEH (HBEH)is a multicenter, randomized, 
double-blind, parallel -group, placebo-controlled, fixed- dosage, Phase 2a 2 study comparing 3 
dosages of LY3154207 (10, or 30, or 75 mg administered orally [or 50mg based on interim 
analysis]once a day[QD]) with placebo ove r 12weeks in subjects with mild-to-moderate LBD
(PDD or DLB)PDD.  The study  includes a Screening Period (Visits 1 to 2) of a minimum o f 
7days and up to 14 days, a Pretreatment Period of a minimum of 11 days and up to 17 days
(Visits2 to 3), a 12 -week Treatment Period (Visits 3 to 11), and a 14 -day Safety Fo llow-Up 
Period (Visits11 to 801 or early terminat ion [ET]/discontinuat ion [DC] visit to Visit 801)that 
includes one telephone visit (Visit 111) .  Subjects who meet entry  criteria will be rando mizedin 
a 1:1:1:1 ratio to LY3154207 (10 or 30 or 75 mg QD) or placebo.  The primary objective of the 
study is to test the hypothesis that LY3154207 administration for 12 weeks will result in a 
significant improvement in cognit ion as measured by [CONTACT_735514] m baseline to Week 12 in the 
Continuit y of Attention (CoA) com posite score of the Cogni tive Drug Research Computerized 
Cognition Battery  (CDRCCB), in subjects with mildtomoderate PDD, compared to placebo.
The CoA has demonstrated a significant treatmen t effect in previous tri als in subjects with PDD 
(Wesnes et al. 2005; Rowan et al. 2007).
Number of subjects:   Approximately [ADDRESS_1143277] imated total of 85 evaluable subjects per treatment group.
Withdrawal: Withdrawal symptom  analyses will be conducted on subjects who completed at 
least one pre -withdrawal and one post -withdrawal PWC -[ADDRESS_1143278].  Week 12/Visit 11 will be 
considered baseline in the change fro m baseline analyses; Visit [ADDRESS_1143279] 
baseline assessment. This will be examined using an analysis o f covariance (ANCOVA) m odel 
with treatment arm as an independent factor and baseline value as a covariate in the model. This 
will allow us to assess the withdrawal symptoms between tr eatments and groups.
Interim Analysis :  Safety interim analyses will be conducted on the number of subjects on each 
treatment who m et the potentially clinically significant vital signs criteria ( TableHBEH.3) at 
3consecutive time points at Visit3 (Day1 stoppi[INVESTIGATOR_004]) .  This will be done after 50, 100, and 
[ADDRESS_1143280] co mpleted Visit3.  
 
 Those 
CCI
I7S-MC-HBEH(b) Clinical Protocol Page 104
LY3154207already on 75 -mg dose and passed the Day 1 stoppi[INVESTIGATOR_824329] 75 mg.  In the event 
of an unacceptable rate of subjects meeting Day 1 stoppi[INVESTIGATOR_824330], a djustments to 
doses may  be made for subsequently randomized subjects at the discretion of the Internal 
Assessment Committee (IAC).   Additional efficacy analyses may be conducted at the time of 
these safety interim analyses. A safety and efficacy  interim analysis will be conducted when 
170randomized subjects have complete dVisit11 (Week 12) assessments and may also be 
conducted at other timepoints prior to study  completion.  All potential efficacy analysesmay be 
used for internal decisio n making, but arenot planned to stop the study .
I7S-MC-HBEH(b) Clinical Protocol Page 105
LY3154207Procedure aScreening Pretreatment Double-Blind Treatment Follow-upUnscheduled
VisitET/DC 
Visitd,t
Study DayMin 7 days; 
max 
14days 
prior to V2Min 11 days; 
max 17 days 
prior to V37 
days14 
days21 
days28 
days42 
days56 
days70 
days84 
days2 days 
after V11u14 days 
from 
V11or 
ET/DC
Tolerance Interval for 
Visit (Days)Baseline VisitRandomi
zation±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3+1
±3
eCRF Visit No.: V1b,d V2b,d V3bV4dV5 V6 V7 V8 b,dV9V10 V11 b,dV111dV801 V997 c
Informed Consent(s) 
Signed (before 
procedures/tests)X
Register subject in 
IWRS -Subject 
number assignedX
Complete IWRS X X X X X X X X X X X X X X
Demographics X
Prior/concomitant 
treatmentX X X X X X X X X X X X X X
Inclusion/exclusion 
criteriaX X X
Modified Hoehn and 
Yahr ScaleX
Medical History X
Physical Examination eX X X X X
Height X
Weight X X X X
Orthostatic BP/pulse 
ratefX X XdX X X X X X X X X X X
In-clinic BP/Pulse rate 
monitoring gX X X X XTableHBEH.1. Schedule of A ctivities for Protocol I7S -MC-HBEH
I7S-MC-HBEH(b) Clinical Protocol Page 106
LY3154207Procedure aScreening Pretreatment Double-Blind Treatment Follow-upUnscheduled
VisitET/DC 
Visitd,t
Study DayMin 7 days; 
max 
14days 
prior to V2Min 11 days; 
max 17 days 
prior to V37 
days14 
days21 
days28 
days42 
days56 
days70 
days84 
days2 days 
after V11u14 days 
from 
V11or 
ET/DC
Tolerance Interval for 
Visit (Days)Baseline VisitRandomi
zation±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3+1
±3
eCRF Visit No.: V1b,d V2b,d V3bV4dV5 V6 V7 V8 b,dV9V10 V11 b,dV111dV801 V997 c
Temperature X X X X X
12-Lead ECG X X X X X X X c X
Review HBPM
instructionshX X X X X X
HBPM device returned 
to siteX X
Hematology X X X X X X X c X
Urinalysis X X X X X X X c X
Clinical Chemistry X X X X X X X c X
Serum FSH i X
PGx sampling X
Collection of dose 
administration timing 
(date and time)X X X X X X X X X X
PK Sampling j XjXjXj Xj Xj Xj
Randomization X
Study drug dosing at 
siteX Xk Xk
Dispense 
Investigational ProductX X X X X X X X
Return Investigational 
ProductX X X X X X X X X
Adverse Events X X X X X X X X X X X X X
Review Lilly Trial app (if 
available) instructions lX X X X X X X X X X
I7S-MC-HBEH(b) Clinical Protocol Page 107
LY3154207Procedure aScreening Pretreatment Double-Blind Treatment Follow-upUnscheduled
VisitET/DC 
Visitd,t
Study DayMin 7 days; 
max 
14days 
prior to V2Min 11 days; 
max 17 days 
prior to V37 
days14 
days21 
days28 
days42 
days56 
days70 
days84 
days2 days 
after V11u14 days 
from 
V11or 
ET/DC
Tolerance Interval for 
Visit (Days)Baseline VisitRandomi
zation±1 ±1 ±1 ±1 ±3 ±3 ±3 ±3+1
±3
eCRF Visit No.: V1b,d V2b,d V3bV4dV5 V6 V7 V8 b,dV9V10 V11 b,dV111dV801 V997 c
Actigraphy watch
provided to subjects (if 
available) mX X X
Return of Actigraphy 
watch (if available) nX X X
CDR-CCBo,p X X X X X X X X X X X X X
Alzheimer’s Disease 
Cooperative Study –
Structured Clinical Global 
Impression interview dX X X X
ADCS-CGICd X X X
ADAS-Cog13p X X X X
D-KEFSp X X X X
MoCAp X X X X
PDAQ-15d X X X X
MDS-UPDRSd,p X X X X X
NPId X X X X
ESSd X X X X X X
QUIPd X X X X
GDS-Sd X X X
PWC-20(Subject) X X X X
PWC-20d(Caregiver) X X X X
C-SSRS –Children’s 
Version and Self -Harm 
Supplement Form sXq Xr XrXrXrXrXrXrXrXrXr Xr Xr Xr
I7S-MC-HBEH(b) Clinical Protocol Page 108
LY3154207Abbreviations:  ADAS -Cog13= Alzheimer’s Disease Assessment Scale –13-Item Cognitive Subscale; ADCS-CGIC = Alzheimer’s Disease Cooperative 
Study -Clinician Global Impression of Change ; BP = blood pressure; CDR-CCB= Cognitive Drug Research Computerized Cognition Battery ;
C-SSRS = Columbia -Suicide Severity Rating Scale; DC = discontinuation; D -KEFS= Delis–Kaplan Executive Function System; ECG = electrocardiogram; 
eCOA = electronic Clinical Outcome Assessment; eCRF =electronic case report form; ED = early discontinuation; ESS = Epworth Sleepi[INVESTIGATOR_7110] ;
ET=earlytermination; FSH = follicle -stimulating hormone; GDS -S = Geriatric Depression Scale –Short Form;HBPM = home blood pressure monitoring; 
HCG = human chorio nic gonadotropin; HEENT = head, ear, eye, nose, and throat; IWRS = interactive web -response sy stem; MDS-UPDRS = Movement 
Disorder Society’s Unified Parkinson’s Disease Rating Scale ; MoCA=Montreal Cognitive Assessment; NPI = Neuropsychiatric Inventory; PDAQ-15= P enn 
Parkinson Daily Activities Questionnaire -15; PGx =pharmacogenomic(s); PK = pharmacokinetic(s); PWC-20 = physician withdraw al checklist -20;
QUIP = Questionnaire for Impulsive -Compulsive Disorders in Parkinson’s Disease; V = visit .
Note:  Be sure that the visit allowance period takes into account the required washout duration needed for medications that are not allowed by [CONTACT_760].
aEvery effort should be made for visits to occur on designated study days.  The overall treatment period in the protocol should be maintained (visits should be 
scheduled based on the randomization visit).  Procedures and assessments should be done in the order described in the Operati ons Manual.
bVisit1 may be splitover 2days.In exceptional circumstances, if the clinical assessments cannot be completed within 1 day atV1,V2, V3, V8, and/or V11, 
those clinical assessments may be completed the next day.  The Orthostatic Blood pressure measurements, in -Clinic Blood pressure measurements, the CDR -
CCB, and the laboratory procedures including PK have to be completed on Day 1 of that visit. The visit interval will start from Day 1.
cECGs or samples for clinical laboratory tests (hematology, clinical chemistry, and urinalysis) will only be collected if a re test is needed.  All other procedures 
are required for each unscheduled visit.
dThe caregiver is required to attend Visit1 at the clinic to sign the informed consent and be informed about the study details.  Caregiver’s attendance will also 
be required at Visit2, Visit4, Visit8, Visit 11, Visit801, and the ET/DC visit to provide inputs for the PDAQ -15, ADCS-CGIC,GDS-S, MDS-UPDRS, NPI, 
ESS, and QUIP scales. The caregiver is required at Visit 11, andVisit 111 and Visit 801 to provide input for the PWC -20.
eMedical history should include timing of onset of cognitive symptoms relative toand of motor symptoms (less or equal to 1 yea r).
feThe physical examination should include HEENT, cardiac, lung, abdomen, extremity, skin, and neurological examinations.
gfOrthostatic BP/pulse rate will be measured as part of the vital sign assessments at every visit. At Visit2, Visit3, Visit 8,Visit11, and Visit 801, these
measurements will be collected at time 0 of the in-clinic BP/pulse rate monitoring .  Subjects will have 3BP/pulse rate measurements taken in the seated 
position approximately 1minuteapart followed by 1BP/pulse rate measurement taken in the standing position . Subjects should be seated for at least 
5minutes and stand for at least [ADDRESS_1143281]’s orthostatic BP and pulse rate measurements must meet inclusion criteria [6] for the subject to proceed with dosing at Visit 3.  Subjects not 
fulfilling inclusion criteria [6] can have their BP/pulse rate re evaluated within 3 days of Visit3.  If inclusion criteria [6] is subsequently met (within 3 days of 
Visit3), the subject may proceed with dosing.  If inclusion criteria [6] is subsequently not met (within 3 days of Visit 3), the subject must be discontinued 
from the study.
I7S-MC-HBEH(b) Clinical Protocol Page 109
LY3154207igIn-clinic BP a nd pulse rate monitoring will be done at Visit 2, Visit3, Visit8, Visit 11,and Visit 801.  The BP and pulse rate measurements will occur at 
time0 and every 60minutes thereafter at Visit2, Visit8, and Visit 11, in-clinic BP and pulse rate will be monitored for up to 6 hours; at Visit 3,  for up to 
8hours and at Visit 801 for up to 2 hours..    The initial measurement , time0of the in-clinic BP and pulse rate monitoring, will be done as an orthostatic 
BP/pulse rate (refer to footnote cabove), and subsequent BP and pulse rate measurements will be done in the seated position only.  Time [ADDRESS_1143282] meets 
inclusion criteria [6].  At Visit2, Visit8, and Visit 11, inclinic BP and pulse rat e will be monitored for up to 6 hours; at Visit 3,  for up to [ADDRESS_1143283] should be given the HBPM device at Visit 2.  Home BP will be measured twice daily in the seated position using the HBPMequipment provided 
by [CONTACT_105410] (Lilly).  Home BP measurements will should be conducted for a minimum of 7 days between Visit 2 and Visit 3, for 3weeks 
between Visit 3 and Visit 6, and for a minimum of 7 days between Visit 10 and Visit 11, and Visit11 andVisit 801.  Home BP will should be measured twice 
in the morning (approximately 1 minute apart) (e .g., 8AM) immediately following study medication dosing and twice in the evening, approximately 12 hours 
later (approximately 1 minute apart) (e.g., 8PM).
kThe subject should return the HBPM device at Visit 801 or at ET/DC visit, if subject is discontinued early.
lLaboratory tests to be performed by [CONTACT_112726].
miRefer to inclusion criteria [12e] in Section 6.1.
njPK sampling. At Visit3, a PK sample is to be collected within 1 to 3hoursafter the drug is administered at the site.  At Visit 4, Visit5, Visit 8,and ET/DC
visit, the PK sample can be collected at any time during the visit.  At Visit 11, the PK sample should be colle cted prior to the drug being administered at the 
site.  The date and time of the PK sample collection as well as the date and time of the dose administration immediately preceding th e PK sampl ingshouldbe
enteredin theeCRF.
oFirst dose to be administered at the clinic on the morning of Visit3 following the Time 0 inclinic BP/pulse rate measurements.  The subject’s initial in clinic 
BP/pulse rate measurements taken in the seated position must meet inclusion criteria [6] for the subject to pro ceed with dosing.  Subjects not fulfilling 
inclusion criteria [6] can have their BP/pulse rate re evaluated within 3 days of Visit 3.  If inclusion criteria [6] is subsequently met (within 3 days of Visit 3), 
the subject may proceed with dosing.  If inclus ion criteria [6] is subsequently not met (within 3 days of Visit3), the subject must be discontinued from the 
study.
pkStudy drug dos etobe administered at the clinic on the morning of Visit 8 and Visit 11following the Time0 in-clinic BP/pulse rate measurement s.
qlAn iPad®configured with the Lilly Trial application (Lilly Trial app) will be provided to the subjects at Visit 2 (if available).  Subjects will should complete 
assessments from 2 weeks prior to dosing (starting the day following Visit2), throughout the dosing period, and for 2 weeks after the conclusion of the 
treatment period (until Visit 801).  This assessment will should be done up to twice daily. Subjects will self -select for this optional component of the protocol 
at Visit1.  Subjects can decide to opt out at any time during the study .In case of opt -out or ET, the subject should return the iPad to the site at the visit 
following the subject opt -out or at the ET/DC visit.  For subjects who complete the Lilly trial application assessments throughout the study, the iPad should be 
returned at Visit 801.  Refer to the Operations Manual for details about Opt -in and Opt -out process.
rmThe actigraphy device (if available) will should be worn on the wrist , similar to a watch, beginnin g at Visit 2, for 3 separate 2 -week periods of time:  Visit 2to
Visit3, Visit8toVisit9,and Visit [ADDRESS_1143284] will should bring the device back to the site at the next scheduled visit (Visit 3, Visit9,or Visit801).
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143285]-CCB:  At least 2training sessions are required at Visit 1. At each visit, the CDR -CCB should be assessedafter the study drug has been dosed. At 
Visit4, Visit5, Visit6, Visit 7, Visit9,and Visit 10, if a subject has ’not taken the study drug prior tothe study visit, the subject must take study drug at the 
site prior tothe CDR-CCBis assessed .
upThe CDR -CCB, MoCA, ADAS -Cog13, MDS-UPDRS (Part III), and D-KEFS scales shouldbe conducted in the practically defined medication “on” state at 
all visits.  The “on” state is defined as the individual best motor function as determined by [CONTACT_824376] 1hour after the dose of 
dopaminergic therapy.   Every attempt should be made to conduct these assessments in the “on” state.  In the exceptional circumstance that this is no t possible, 
the assessments could be done in the “off” state.  The “on/off” state should be confirmed prior t o completion of the respective scales listed above.  This 
information will be collected in the eCOA or the eCRF. If any portion of an assessment is done in the “off” state, then that subject should be rated as in the 
“off” state for the whole assessment .If the subject is not on dopaminergic therapy the assessment should be documented as “on”.
vqThe C-SSRS “Baseline” version will be used at the Screening visit (Visit 1).
wrThe C-SSRS “Since Last Visit” scale will be administered at each subsequent visit.
xsIf, based on administration of the C -SSRS, it is determined that suicide -related behaviors have occurred, then the Lilly Self -Harm Follow -Up form will be 
used to collect additional information to allow for a more complete assessment of these beha viors.
ytAll subjects who discontinue study treatment prior toa scheduled visit should have an ET/ DCvisit and procedures/assessments performed as soon as possible.
zu  If the visit window falls on a weekend/holiday then the visit should be conducted at the next possible day.
I7S-MC-HBEH(b) Clinical Protocol Page 111
LY31542073.2. Background
Lewy Body Dementia (LBD), including Parkinson’s disease dementia (PDD) and DLB, is a
progressive neurodegenerat ive disorder associated with alpha -synuclein deposit ion, Lewy body 
pathology, and degenerat ion of nigro -striatal dopaminergic neurons.  According to the 
Parkinson’s Disease Foundation, Parkinson’s disease (PD) affects approximately 1 million 
people in the [LOCATION_002] (U .S.) and 7 to 10 million people worldwide (Statist ics on 
Parkinson’s). It is estimated that up to 78% of of patients with PD will develop dement ia (PDD) 
in their lifet ime (Aarsland et al.2005).  DLB is the second most commo n dementia after 
Alzheimer’s disease (AD) and affects 1.4 millio n individuals in the U.S., represent ing an 
estimated 15 -20% of all dementia cases worldwide (Lewy  Body Dementia Associat ion 
[https://www.lbda.org/go/10- things-you-should-know-about-lbd).  
LBDispathologically characteri zed by [CONTACT_824339], a major component of which is misfo lded aggregated 
α-synuclein (Beyer et al. 2009).  Lewy  body formation and propagati on is accom panied by 
[CONTACT_824340], particularly affect ing the dopa minergic and cho linergic 
neurons (Harding and Halliday  2001; Klein et al . 2010; Coll oby [CONTACT_2297]. 2012).  These 
neuropathological findings are largely indist inguishable between DLB and PDD and have thus 
led the field to consider them the same disease. 
The cognitive impairments of PDD and DLB also overlap. Progressive executive dysfunct ion 
and visual -spatial abnormalit ies are noted in both, but memory  remains relat ively intact early in 
the course of disease (Lippa et al. 2007).   Prodromal and non -motor features are similar for both 
conditions and incl ude REM sl eep behavi or disorder, hy posmia, prominent visual hallucinat ions, 
fluctuations in arousal, autonomic dysfunct ion, and depression/anxiet y.  They share 
neuroimaging characteristics with overlappi[INVESTIGATOR_136677] s of atrophy , glucose utilizat ion, and 
neurotransmitter changes ( cortical cholinergic defici ts [Colloby [CONTACT_2297]. 2016]and striatal/cortical 
dopaminergic deficit s [Klein et al. 2010]).  Although once considered as two separate entit ies,
the constellat ion of supportive pathological, clinical, imaging, and neurochemical data suggest 
PDD and DLB fall wit hin a spectrum of the same disease (Berg et al . 2014; Gom perts 2016; 
Friedman 2018; Jellinger 2018; Jellinger and Korczyn 2018) . 
Because of the dopaminergic fronto -striatal dysfuncti on and cho linergic deficit s associated with 
LBD[Klein et al. 2010], LY3154207, a D1PAM, is a hypothesized mechanism to treat the 
cognitive deficits of the disorder.LY3154207 increases the affinity of dopamine f or the D1 
receptor, thus amplifying the response to endogenous dopamine and increasing D1 tone when 
and where dopamine is released.  By  [CONTACT_824341]
(or administered L -DOPA), a D1 PAM should improve cognit ive performance through enhancing 
frontal dopaminergic neurotransmissio n.  In addition to facilitating dopamine neurotransmissio n, 
LY3154207 may be effect ive in improving cognit ive dysfunct ion through activation of cortical 
neurons, markers of synaptic plasticit y, and D1 medi ated enhanced acet ylcholine 
neurotransmitter release.  Other potential effects such as reduced dayt ime sleepi[INVESTIGATOR_008], enhanced 
motor function, improved mood, and goal- directedbehaviors leading to reduced apathy  (via 
activation of cortical and st riatal D1receptors) would also be beneficial in LBD.  
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143286] the hypothesis that LY3154207 administered at 
10mg, 30mg,and/or 75mgdaily (or 50mg based on 
interim analysis) (QD)oral dosing for 12 weeks will 
result in a significant improvement in cognition in 
subjects with mild-to -moderate LBD(PDD or 
DLB)PDDcompared with placebo .
Pharmacokinetics
To assess the PK of LY3154207 in a population of 
subjects with mild tomoderate de mentia due to 
Parkinson’s diseaseChange in the CoA composite score of theCDR-CCB
from baselineto Week12
Steady-state trough plasma concentrations of 
LY3154207 at Week12
Secondary
Safety:
To evaluate the effect of LY3154207 on physical 
withdrawal symptoms Change in the PWC-20 total score from Week 12 to in -
clinic follow -up visit
Abbreviations: DLB = dementia with Lewy bodies; LBD = Lewy Body Dementia ; PWC-20 = physician withdraw al 
checklist-20
5.1 Overall Design
Study HBEHis a multicenter, randomized, double -blind, parallel-group, placebo-controlled , 
fixed-dosage, Phase2astudy comparing 3 dosages of LY3154207 (10, 30, or 75 mg 
administered orally [ or 50mg based on interim analys is]once a day[QD]) with placebo over
12weeksin subjects with mild-to-moderate dementia associated withLBD(PDD and 
DLB)PDD.  The study  includes a Screening Period (Visits1 to 2)of a minimum  of 7daysand 
up to 14days, a Pretreatment Period of a minimum of 11 days and up to 17 days (Visits2 to 3), a 
12-week Treatment Period (Visits3 to 11), and a 14-daySafety Follow-UpPeriodincluding a 
telephone visit (Visit 11 + 2 day s) and Visit 801 or early termination [ET]/discontinuation [DC]
(Visits 11 to 801) .Subjects who meet entry  criteria will be rando mized in a 1:1:1:1 ratio to 
LY3154207 ( 10 or 30or 75mg QD) or placebo.  The primary objective of this study  is to test the 
hypothesis that LY3154207 administration for 12 weeks will result in a significant improvement 
in cognition as measured by  [CONTACT_824377] 12 on the Continuit y of Attention 
(CoA) composite score of the Cognit ive Drug Research Co mputerized Cognit ion Battery 
(CDR-CCB), in subjects with mild-to-moderate dementia associated withLBD(PDD and 
DLB)PDD,compared to pl acebo.  Treatment effects with acet ylcholinesterase inhibitors in LBD
(PDD and DLB) subjects have been demonstrated using the CDR (Wesnes et al . 2005; Rowan et 
al. 2007, McKeith et al 2000).The Continuit y of Attention (CoA) has demo nstrated a significant 
treatment effect in previous trials in subjects with PDD and is resistant to lear ning and placebo 
effects.
I7S-MC-HBEH(b) Clinical Protocol Page 113
LY31542075.1.1.1.Screening Procedures
Screening, entry  and administrative procedures, cognit ive and physical assessments, vitals, safety  
assessments, and laboratory  assessments (see Schedule of Act ivities) are to be performed at 
Visit 1.For subjects treated with dopaminergic treatment for parkinsonism symptoms, the 
CDR-CCB and MoCA should be conduc ted in the practically  defined medicat ion “on” state.  
The “on” state is defined as the individual’s best motor funct ion as determined by [CONTACT_824344] [ADDRESS_1143287] these assessments in the “on” state.  In the except ional circumstance 
that this is not possible, the assessments could be done in the “off” state.  The “on/o ff” state 
should be confirmed pri or to com pletion of the respective scales listed above.  This information 
will be co llected in the electronic Clinical Outcome Assessment (eCOA) or the electronic case 
report form (eCRF).  If any portion of an assessment is done in the “o ff” state, then that subject 
should be rated as in the “off” state for the whole assessment. Subjects NOT on dopaminergic 
therapy should be recorded as being in the “on” state for the purpose of analysis.
Medical history  should include the di agnosis, whether PDD or DLB , and the timing of onset of 
dementia and Parkinson’s symptoms and date of diagnosis if applicable. Additionally, the 
relationship of the onset of dementia relat ive ofto motor symptom s will be assessed. Subjects 
without motor symptoms shoul d report thei r dementia as occurring prior to motor symptoms.
The physical exami nation should include head, ear, ey e, nose, and throat (HEENT), cardiac, 
lung, abdo men, extremit y, skin, and neurological examinat ions.
[IP_ADDRESS].1. BP and Pulse Rate
Subjects should have a BP or pul se rate at Visit 1 and Visit 3 (time 0), as determined by  
3sequential BP/pulse rate measurements in the seated posit ion:
Subjects <60 years old:
oa mean systolic blood pressure (SBP) less than or equal to 
140mmHg, a mean diastolic BP less than or equal to 90 mmHg, 
and a mean pulse rate less than or equal to 90 beats/min in the 
seated posit ion.
oeach of the [ADDRESS_1143288] be less than 180 mmHg.
Subjects ≥60years old:
oa mean SBP l ess than or equal to 150 mmHg, a mean diastolic BP 
less than or equal to 90 mmHg, and a mean pulse rate less than or 
equal to 90beats/min in the seated posit ion.
oeach of the [ADDRESS_1143289] be less than 180 mmHg.
[IP_ADDRESS].2. CDR-CBB
At Visit 1, two training sessio ns of the CDR -CBB will be administered to familiarize subjects 
with the instrum ent and to minimize practice effects . Subjects must be able to complete both 
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143290] -CCB at V1 
will not be included in the analysis unless the baseline (V2) scores are inco mplete or missing and 
then V1 scores may  be used for cal culation of the baseline. 
[IP_ADDRESS].3.Modified Hoehn and Yahr Scale
Enrolled individuals must be Hoehn and Yahr Stage 1to Stage4 at screening .  The Hoehn and 
Yahr Scale (Hoehn and Yahr 1967) is used to describe the symptom progression of PD.  The 
scale was originally described in 1967 and included Stages 1 through 5.  It has since been 
modified wit h the addit ion of Stages 1.5 and 2.5 to account for the intermediate course of PD.  
The modified Hoehn and Yahr scale is as fo llows:
Stage 0:  No signs of disease
Stage 1:  Unilateral disease
Stage 1.5:  Unilateral plus axial invo lvement
Stage 2:  Bilateral disease, without impairment of balance
Stage 2.5:  Mild bilateral disease, with recovery  on pull test
Stage 3:  Mild- to-moderate bilateral disea se; some postural instabilit y; physically 
independent
Stage 4:  Severe disabilit y; still able to walk or stand unassisted
Stage 5:  Wheelchair bound or bedridden unless aided
[IP_ADDRESS].4. Clinical Diagnostic Criteria for PD and DLB
Subjects must meet diagnost ic criteria for either PD or DLB. 
PD Criteria: Subjects shoul d meet MDS cri teria for clinically probable PD (Postuma et al. 
2015) as detailed in Appendix [ADDRESS_1143291] tremor and/or rigidit y.  Subjects must not have any abso lute 
exclusion criteria.  Subjects must not have greater than 2 red flags; if [ADDRESS_1143292] of abso lute exclusio n 
criteria, red flags and supportive criteria.
DLB Criteria:   Subjects should meet the Fourth consensus report of the DLB Consorti um 
diagnostic criteria for probable DLB (McKeit h et al. 2017) as detailed in Appendix [ADDRESS_1143293] 2or more of the 4 core clinical features of DLB 
(fluctuation in cognit ion, visual hallucinat ions, REM sleep behavior diso rder and/or 
parkinsonism).  Subjects with [ADDRESS_1143294] of core features and indicative bio markers.
I7S-MC-HBEH(b) Clinical Protocol Page 115
LY3154207Section [IP_ADDRESS]. 5Montreal Cognitive Assessment Scale
TheMoCA will be administ ered to subj ects inVisit [ADDRESS_1143295] a MoCA score of 10 to 23 at screening to 
be eligible for the study .  The MoCA, included here as a screening cognit ive assessment, is 
described in detail in Section [IP_ADDRESS].5.
Section [IP_ADDRESS]. 6.Geriatric Depression Scale Short Form
Enrolled individuals must have a Geriatric Depressio n Scale Short Form (GDS S) score of ≤6 
at screening.  The GDS is a site-administer ed questio nnaireof depressio n in older adults 
(Yesavage et al. 1983).  Users respond in a “Yes/No” format.  Originally developed as a 30 -item 
scale (Long Form), it has since been shortened to a 15- item scale (Short Form ), which can be 
completed in approxi mately 5 to 7 minutes (Sheikh and Yesavage 1986).  Of the 15 items, 10 are 
indicative of depressio n when answered “Yes” and 5 are indicative of depressio n when answered 
“No.”Caregiver’s input may be needed at Visit 1 for the Geriatric Depressio n Scale – Short form 
(GDS-S).
Section [IP_ADDRESS]. 7.Columbia -Suicide Severity Rating Scale –Children’s Version
The C-SSRS is a scale that captures the occurrence, severit y, and frequency  of suicide-related 
thoughts and behaviors during the corresponding assessment period.  The C-SSRS, included here 
as a screening assessment, is described in detail in Section9.4.4.   The C-SSRS “Baseline” 
version will be used at screening , and the findings will const itute the baseline assessment.
The C-SSRS will be administered to the patient with the study  partner/study  informant present or 
available by  [CONTACT_756], after the cognit ive and functional assessments. Responses from both the 
study partner/study  informant and patient will be considered when administering the scale. Ifa 
suicide-related though t or behavior is ident ified at any time during the study , a thorough 
evaluation will be performed by a study  physician, and appropriate medical care will be 
provided. 
The Lilly Self -Harm Supplement shoul d be completed every  time the C -SSRS is administered.  
If, based on administration of the C -SSRS, it is determined that suicide -related behaviors have 
occurred, then the Lilly Self -Harm Follow-Up form will be used to col lect additional information 
to allow for a more complete assessment of these behaviors. The CSSRS will be administered to 
the subject after the cognit ive and funct ional assessments.  Responses fro m subject will be 
considered when administering the scale.  If it is determined that the subject has suicidal ideat ion 
or behavior at this baseline assessment, then the subject will not be rando mized and will be 
discontinued fro m the study.
I7S-MC-HBEH(b) Clinical Protocol Page 116
LY3154207FigureHBEH.1. Illustration of study design for Clinical Protocol I7S-MC-HBEH (b).
[IP_ADDRESS] Blood Pressure and Pulse Rate Measures
Orthostati c BP/pulse rate measurements will be collected at time 0 of the in-clinic BP/pulse rate 
monitoring.  Subjects will have 3BP/pulse rate measurements taken in the seated posit ion 
approximately  1minuteapart followed by 1BP/pulse rate measurement taken in the standing 
position.  Subjects shoul d be seated for at l east 5minutes and stand for at least [ADDRESS_1143296] feels unabl e to stand, vi tal signs only in the 
seated position will be recorded.
In-clinic BPand pulse rate measurements will occur at time 0 and every  60minutes thereafter up 
to 8hours. The initial measurement, time 0 of the in-clinic BPand pulse rate monitoring, will be 
done as an orthostatic BP/pulse rate (refer to orthostatic BP/pulse rate above), and subsequent BP
and pulse rate measurements will be done in theseated posi tion only.
[IP_ADDRESS].Cognitive, Motor, and Functional Assessmen ts
For subjects treated with dopaminergic therapy for parkinsonism symptoms, The following 
assessments ( CDR-CCB, Alzheimer’s Disease Assessment Scale –13-Item Cognit ive Subscale
[ADAS-Cog13], Movement Disorder Societ y’s Unified Parkinson’s Disease Rat ing Scale 
[MDS-UPDRS] [PartIII])and Delis–Kaplan Executive Funct ion System (D-KEFS) 
assessments )shouldbe conducted in the practically defined medicat ion “on” state.  The “on” 

I7S-MC-HBEH(b) Clinical Protocol Page 117
LY3154207state is defined as the individual ’sbest motor function as determined by  [CONTACT_824378]  1hour after the dose of dopaminergic therapy .  Every attempt should be made to 
conduct these assessment sin the “on” state.  In the except ional circumstance that thi s isnot 
possible, the assessmentscould be done in the “off” state.   The “on/o ff” state should be 
confirmed prior to complet ion of the respect ive scales listed above.   This informat ion will be 
collected in the eCOA or the eCRF.  If any portion of an assessment is done in t he “off” state, 
then that subject should be rated as in the “o ff” state for the who le assessment. Subjects NOT on 
dopaminergic therapy  should be recorded as being in the “on” state for the purpose of analysis.
[IP_ADDRESS] Actigraphy and iPAD Device
The actigr aphy device , similar to a watch, will be placed on the wri st of the subject at Visit 2(if 
available and if consented ),similar to a watch for the 2-week peri odsof timeuntilVisit 3(see 
Section9.8.1.2and the Operations Manual) .
An iPad configured wi th the Lilly Tri al application (Lilly Tri al app) will  be provided to the 
subjects (if available and if consented )(see Section9.8.1.1and the Operations Manual) .  
Subjects should completeassessments starting the day  following Visi t2, throughout the dosing 
period, and for 2 weeks after the conclusio n of the treatm ent period (until Visit801).  Thi s 
assessment should be done up to twice daily.
[IP_ADDRESS] Home Blood Pressure Monitoring
The subject should be given the ho me blood pressure monitoring (HBPM) device at Visit 2 and 
instructed to measure Home BPtwice daily in the seated posit ion using the HBPM equipment 
provided by [CONTACT_242936] a minimum of 7 days between Visit 2 and Visit 3.  Home BP will should be 
measured twice in the morning (approximately 1 minute apart) (e .g., 8AM) immediately 
following study  medication dosing and twice in the evening, approximately 12 hours later 
(approximately 1 minute apart) (e .g., 8PM).
An iPad configured wi th the Lilly Trial application (Lilly Trial app) will be provided to the 
subjects (if available) (see Section9.8.1.1and the Operations Manual) .  Subjects will complete 
assessments starting the day  following Visi t2, throughout the dosing period, and for 2 weeks 
after the concl usion of the treatm ent period (until Vi sit801).  This assessment will be done up to 
twice daily.
5.1.3. Double -Blind Period (Visit 3 through Visit 11)
All study procedures for the respective visits are should to be completed within 1 day.  In 
exceptional circumstances, if the clinical assessments cannot be completed within 1 day at V3, 
V8, and/or V11, those clinical assessments may be completed on the next day .  The orthostati c 
blood pressure measurements, in -clinic blood pressure m easurements, the CDR -CCB, and the 
laboratory  procedures including PK have tomustbe completed on Day1the first dayof that visit.  
The visit interval will start from Day1the first day of visit .
I7S-MC-HBEH(b) Clinical Protocol Page 118
LY3154207Visit3 (Day1 of dosing) -
[IP_ADDRESS] Orthos tatic BP/Pulse Rate Measurements
Prior to dosing, O
orthostatic BP/pulse rate measurements will be collected at time 0 of the 
in-clinic BP/pulse rate m onitoring.  Subj ects will have 3BP/pulse rate measurements taken in the 
seated posi tion approximately  1minuteapart follo wed by 1BP/pulse rate measurement taken in 
the standing posit ion.  Subjects shoul d be seated for at l east 5minutes and stand for at least 
3minutes prior to taking the respect ive measurements.  If the subject feels unable to stand, vital
signs only in the seated posit ion will be recorded.
The mean should be calculated from of the 3 initial in-clinic BP/pulse rate measurements taken 
in the seated position , andmust meet inclusio n criteria [6] in order to proceed with dosing
(TableHBEH.4).  At Visit 3, Ssubjects not fulfilling inclusio n criteria [6] at their time 0 
BP/pulse rate measurements can have their BP/pulse rate re -evaluated within 3 days.  If inclusio n 
criteria [6] is subsequent ly met (within 3days of Visit3), subject may proceed with dosing.  If 
inclusion criteria [6] is subsequent ly not met (within 3days of Visit3), the subject must be 
discontinued.  Subjects who continue to meet entry cri teria will be rando mized to LY3154207 
(10, 30,or 75mg QD) or placeboimmediately fo llowing confirmat ion that subject meet s
inclusion criteria [6].  Subjects should be dosed immediately after randomization.
The time 0 mean BP and pulse rate will be used for the baseline measurement to assess the 
change thresho ld for the development of potentially clinically significant BP/pulse rate. 
After time 0, in-clinic BPand pulse rate measurements will be takenevery 60minutes in the 
seated posi tion only for up to 8 hours.  Subjects who meet p otentially clinically significant 
BP/pulse rate measu rement (Table HBEH.3 )at 3 consecut ive timepo ints (Day 1 stoppi[INVESTIGATOR_37660]) 
should be discont inued from the study. 
TableHBEH.3.Potentially Clinically Significant Vital Sign Criteria

I7S-MC-HBEH(b) Clinical Protocol Page 119
LY3154207TableHBEH.4.Vital Sign Inclusion Criteria[6]for Subjects at Visit 1 and Visit 3 
(time 0)
Subjects <60 Years Subjects ≥60 Years
Mean Systolic BPa(mm Hg) ≤140 ≤150
Mean Diastolic BP (mm Hg) ≤90 ≤90
Mean Pulse Rate (bpm) ≤90 ≤[ADDRESS_1143297] be less than 180 mmHg
[IP_ADDRESS].PK Sample
A PK sample is to be collected within 1 to 3 hours after the drug is administered at the site.  The 
date and time of the PK sample co llection as well as the date and time of the dose administration 
immediately  preceding the PK sampling w ill be entered in the eCRF recorded.
[IP_ADDRESS].Home Blood Pressure Monitoring
The subject should be instructed to take Home BPmeasurements twice daily in the seated 
position using the HBPMequipment provided by [CONTACT_824379] a minimum o f 7days between Visit 3
and Visit 4.  Home BP shouldwillbe taken twice in the morning (approximately 1 minute apart) 
(e.g., 8AM) immediately fo llowing study  medication dosing and twice in the evening, 
approximately  12hours later (approximately 1 minuteapart) (e.g., 8PM).
Appointments should be made for all remaining visits and should be scheduled as close as 
possible to the target date, relat ive to Visit 3.
[IP_ADDRESS]. Visit 4 to Visit 11
During the double blind period, v Visits will occur at weekly intervals (7 days ± 1day) for Visit 4
through Visit 7, and will occur at biweekly intervals (14 days ± 3days) for Visit8 through 
Visit 11.
Study drug is to be administered at the clinic on the morning of Visit 8 and Visit 11 following 
the Time0in-clinic BP/pulse rate m easurements .
In-clinic BP/pulse rate monitoring at Visit [ADDRESS_1143298]-CCB assessment .  
MoCA, ADAS -Cog13, MDS -UPDRS [Part III], and D -KEFS will be performed according to the 
Study Schedule.  
I7S-MC-HBEH(b) Clinical Protocol Page 120
LY3154207Caregiver’s inputs will be needed at Visit 4, Visit8, Visit11, or ET/ DC for the PDAQ-15, 
Alzheimer’s Disease Cooperative Study  –Clinician Global Impressio n of Change 
(ADCS-CGIC), MDS-UPDRS, NPI, ESS, GDS-S,and/or QUIP scales.  Caregiver’s input, 
separate from the subject, will be needed at Visit 10 (in person or via telephone) and Visit 11, 
Visit 111 and Visi t 801 for the PWC -20 early termination.
5.1.4.Telephone Visit (Visit 111)
A telephone visit will be conducted [ADDRESS_1143299] and caregiver , separately, at this telephone visit.
5.1.5. Follow-Up Period (Visit 801)
A follow-up visit will be perform ed at Visi t801, which will occur 14 days ± 3daysfollowing 
the subject’s last dose of study  medication.
Visit 801 is expected to be of a duration of approximately 2 hours.
Caregiver’s inputs will be needed at Visit 801for MDS-UPDRS, PWC-20, and ESS.
See the Schedule o f Activities (Section2)for the timing of events and the measures to be 
assessedduring the fo llow-up period.
The CDRCCB assessment should be conducted in the practically defined medicat ion “on” state.  
The “on” state is defined as the individual’s best motor funct ion as determined by [CONTACT_824380] [ADDRESS_1143300] this assessment in the “on” state.  In the except ional circumstance 
that this is not possible, the assessment could be done in the “off” state.  The “on/o ff” state 
should be confirmed pri or to assessment complet ion of the respect ive scale listed above.  This 
information will be co llected in the eCOA or the eCRF.  If any portion of the assessment is done 
in the “off” state, then that subject should be rated as in the “off” state for the who le assessment.
5.2. Number of Subjects
Approximately  [ADDRESS_1143301] scheduled procedure shown in the Schedule o f 
Activities(Section2)for the last subject.
5.4. Scientific Rationale for Study Design
StudyHBEH will include subjects who meet the revised MDS criteria for PD (Postuma et al. 
2015) or those whomeet the revised criteria for DLB ,and all who have mild-to-moderate 
dementiaas defined by a decline in cognit ive functio n, which in the opi[INVESTIGATOR_3078] n of the invest igator 
has resulted in functional impairment and a MoCA score between 10 and 23 (Trzepacz et al. 
2015).  Per the revised MDS criteria, PDD can be diagnosed in the presence of dement ia, 
regardless of the timing o f dementia onset relative to PD diagnosis.  Subjects diagnosed with 
I7S-MC-HBEH(b) Clinical Protocol Page 121
LY3154207dementia with Lewy bodies (DLBs) should be considered as also having PD if they meet the 
MDS PD criteria.  Therefore, subjects may have dement ia prior to, at the time of, or subsequent 
to the diagnosis of PD.  Unlike registration trials of symptomat ic therapi[INVESTIGATOR_824331] (Emre et al. 
2004), the current study  will include so me subjects who would otherwise have met the tradit ional 
criteria (dem entia prior to or within 1 year of motor onset) for DLB based on the timing of their 
dementia (Mckeit h et al. 2005).  Th is criterion was that the dement ia occurs prior toor within 
1year of Parkinson’s symptoms.  The 1 year rule is arbitrary and based on the historical belief 
that PD was not associated with dement ia; however, there is increasing controversy  about the 
validity of this tradi tional approach to splitt ing the diagnoses (Berg et al. 2014).  In support of 
the proposed approach, both disorders share a variety  of clinical, genetic, and patho logical 
features (Lippa et al. 2007; Postuma et al. 2009; Johansen et al. 20 10).  Both DLB and PDD are 
associated with similar impairments in cognit ion with predominant visuoperceptual 
abnormalities, improvement in memory  with cues, and so on.  Both are associated with 
prominent psychosis, neurolept ic sensitivity, and alterat ions in arousal.  Prodromal features (e.g., 
rapid eye movement [REM] sl eep behavior disorder, olfactory  loss) are the same in both 
conditions.  Non motor symptom s with depression, anxiet y, autonomic dysfunct ion and sleep 
disturbances occur with similar relative frequency  in both.  The same genetic mutations 
(alphasynuclein duplicat ions, glucocerebrosidase mutations) are associated with the 
development of either condit ion.  Finally, they  have a shared pathology  with alphasynuclein and 
Lewy body formation in thebrain stem  and cortex.  Therefore, The inclusio n of LBD(PDD or
DLB)both PDD and DLB the StudyinHBEH m eets current thinking about LBDPDD and DLB
that, apart fro m the timing of cognit ive impairment, PDD and DLB are clinically and 
pathologically indistinguishable and would likely  respond to similar therapeutic approaches 
(Aarsland et al. 2004; Ballard et al. 2006).
6.1. Inclusion Criteria
Study HBEH will include men and wo men aged 40 to 85 years with mild tomoderate PDD.  
Subjects are eligible to be included in the study  only if they meet all of the following criteria
(note that inclusio n criteria [6] to [10]must be met orat anadditional visits):
Type of Subjectand Disease Characteristi cs
[1]Male and female subjects aged 40 to 85 years (inclusive).
[45]Meet diagnostic criteria for PD (Postuma et al. 2015) or DLB (McKeit h et al. 
2017) (See Appendix 5 and 6 for details)
[2]Have idiopathic PD per MDS criteria (Postuma et al. 2015) wi th at least 
2years of PD symptoms.
[5]Are Modified Hoehn and Yahr Stages 1 0 to 4.
[6]Have a BP or pulse rate at Visit 1 and Visit 3 (time 0) , as determined by 3
sequential BP/pulse rate measurements in theseated posit ion:
I7S-MC-HBEH(b) Clinical Protocol Page 122
LY3154207[7]If onanti-parkinsonian agents , subjects m ust be on stable dosage for at least 4
3 weeks prior to Visit1 2,andit is anticipated that no changes will be 
neededshould remain on stable doses duringthe course of the study.
[8]If on medications affect ing cognit ion (rivastigmine, galantamine, donepezil, 
memantine), subjects must be on stabledosagefor at least 8 3weeks prior t o 
Visit 2 1and expected to shouldremain ata stable dosage during the course of 
the study.
[9]If on antidepressant medicat ions, subjects m ustbe on stabledosagefor at least 
8 3weeks prior to Visit2 1 and expected to shouldremain at a stabl e dosage 
during the course of the study .
[10]If on clozapi[INVESTIGATOR_050], queti api[INVESTIGATOR_050],and pi[INVESTIGATOR_824307]- induced or 
disease-related psy chosis, subjects must be on stabledosagefor 34weeks 
prior to Visit 12and expected toremain at a stable dosage during the course 
of the study .
[11]If on antihypertensive medications, subjects must be on stable dosage for at 
least 3months3weeksprior to Visit 1.
[12c] Men with pregnant partners should use condoms during intercourse for the
duration ofthe study and until the end of estimated relevant potential exposure 
in WOCBP (below the NOAEL/10) plus 903daysfollowing the last dose of 
study drug).
[12d] Men should refrain fro m sperm donation for the duration of the study and
until theirplasma concentrati ons are below the level that could result in a
relevantpotentialexposure to a possible fetus, predicted to be 930days
following the last dose of study  drug(below the NOAEL/10) plus 90 days.
[13]In the investigator’s opi[INVESTIGATOR_3078] n is able to comply wit h all appo intments for clinic
visits,tests, and procedures, including venipuncture, computerized 
assessments and examinat ions required by [CONTACT_760].
[16] All subjectsmust have a reliable caregiver who is in frequent contact [CONTACT_824346](defined as at least 10 hours per week) and will acco mpany the subject
toVisit1, Visit2, Visit4, Visit8, Visit11, Visit 111 (telephone only) and 
Visit 801.
6.2. Exclusion Criteria
[21]Have significant central nervou s system or psychiatric disease, other than PD
or DLB, that in the invest igator’s opi[INVESTIGATOR_3078] n may affect cognition or the abilit y to 
complete the study .may affect cognit ion or the abilit y to complete the study , 
including but not limited to other dement ias (e.g., Alzheimer’s disease [AD]).
[27]Have a current or any  previous diagnosis of bipolar disorder, schizophrenia, or 
other primary  psychotic di sorder. Exclusion criterion [27] has been deleted.
I7S-MC-HBEH(b) Clinical Protocol Page 123
LY3154207[28]Have poorly  controlled psychosis (hallucinat ions or delusio ns) that in the 
opi[INVESTIGATOR_824332] h the subject’s abilit y to be 
compliant with the study  protocol.Exclusion criterion [28] has been deleted.
[29]Have any other psychiatric disorder that, in the judgment of the investigator, 
would interfere wi th compliance wi th the study  protocol.Exclusion criterion 
[29] has been deleted.
[31]Have a GDS S score of >6 at Visit 1.Exclusion criterion [31] has been 
deleted.
[32]Have a serious or unstable medical illness, other than idiopathic LBD(PDD or
DLB)PDD, including cardio vascular, hepat ic, respi[INVESTIGATOR_696], hematologic, 
endocrino logic, neurologic, or renal disease, or clinically significant 
laboratory  or electrocardi ogram (ECG) abnorm ality as determined by  [CONTACT_1275].
[36]Have used anticholienergics trihexyphenidyl and benztropi[INVESTIGATOR_231423] 4 weeks 
prior to screening (Visit 1) and at any  time during the course of the study .
[38]Are current ly takingHave taken any medicat ions or food, herbal or dietary  
supplements that are inhibitors (e.g. , ketoconazole, grapefruit juice), or 
strong/moderate inducers of cy tochrome P450 3A4 (CYP3A4) (e.g., 
rifampi[INVESTIGATOR_2513])or are unable or unwilling to discont inue usage of them 4 weeks 
prior to Visit 3. If subjects are willing and able to discontinue use of CYP3 A4 
inhibitors or strong/moderate inducers at least [ADDRESS_1143302] of 
inhibitors and inducers of CYP3A4.
[43]Are Lilly employees, employees of Quintiles IMSIQVIA, or employees of a 
third party organization involved in the conduct of the study .
[44]Are unwilling or unable (e.g., visually  impaired or physically unable) to 
comply with the use of a data collect ion device (e.g., HBPM, eCOA, 
CDRCCB) to di rectly record data from the subject. Exclusion criterion [44] 
has been deleted.
6.2.1. Rationale for Exclusion of Certain Study Candidates
CNS diseases and Depression affects approximately  50% of subjects wi th PD and can affect 
cognitive perform ance that m ay confound the a nalysis of cognitive outcom es.  Therefore, 
subjects wi th active depressio n will be excluded.  O other neuropsy chiatric disorders (e .g., active 
psychosis, substance abuse) that can affect performance on cognit ive tasks and compliance with 
the protocol are al so excluded.
Medications that negatively affect cognit ion (e.g., certain anticholinergics, exclusio n criteria 
#36) and motor function (e.g., certain antipsychotics, exclusio n criteria #35) will be excluded, 
given the potential of these medicat ions to confound clinically relevant outcomes.
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143303] dose (below the NOAEL/10) plus [ADDRESS_1143304] 
dose of LY3154207 .
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m aybe 
rescreened once.  The interval between the initial screening and the re screen should be at least 
4weeks.  When the subject is rescreened, the subject must sign a new ICF , and be assigned a 
new subject identification number , and undergo all screening procedures .
7.2 Method of Treatment Assignment
Selection and Timing of Doses
The doses willshouldbe administered at approximately the same time each day in the morning.   
At Visit3, Visit8, and Visit11, the dose will be administered at the clinic.   The actual date and 
time of thedose administrations on the day  of Visit3, Visit4, Visit5, Visit8, Visit11, and 
ET/DC vi sit will be recorded in the subject’s eCRF.
7.3.Blinding
If an invest igator, site personnel performing assessments, or subjectisunblinded, the subject
must be discont inued from thestudy.  In cases where there are ethical reasons to have the subject 
remain in the study , the investigator must obtain specific approval fro m a Lilly clinical research 
physician (CRP) for the subject to continue in the study .
In case of an emergency , the invest igator has the sole responsibilit y ofdetermining if unblinding 
of a subject’s treatment assignment is warranted for medical management of the event.  The 
subject’s safet y must always be the first consideratio n in making such a determinat ion.Every 
effort should be made to notify  Lilly Medical  representati ve prior to unblinding if feasible. If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
promptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
7.6. Treatment Compliance
Subjectcompliancewith study medication will be assessed at each visit.  Compliance will be 
assessed by  [CONTACT_433676].   Deviation(s) from the prescribed Capsules dis pendsed 
and returned dosage regimen should be recorded in the CRF.
7.7.Concomitant Therapy
Concomitant medicat ions to treat the underlying PD (known as ant iparkinsonian agents) are 
permitted, provided the subjecthas been on a stable dos ageregimen for at least 4 3weeks prior 
toVisit1 2, and is expected to shouldremain on a stabl e dosage for the duration of the study .  
I7S-MC-HBEH(b) Clinical Protocol Page 125
LY3154207Routine medicat ions taken PRN are allowed.  However, if in the investigator ’s opi[INVESTIGATOR_824333] ,the 
reason for change in medication should be recorded as an AE and the concomitant medication 
eCRF page updated accordingly . In addition, the study  sponsor shoul d be notified as soon as 
feasible an d a notificat ion generated.
In addition to medications for PD, drugs for common conditions in an older population, such as 
hypertensio n,hypercholesterolemia, and ischemic heart disease ,are acceptable at stable dosages . 
Specifically , antihypertensive medicat ions should be stable for 3 months prior to screening (V1) 3
weeks prior to V 1.During the course of the study , antihypertensive medicat ions may be 
adjusted for m edical need.  The concomitant medication eCRF page shou ld be updated 
accordingly and if applicable the reason for change in medicat ion should be recorded as an AE.
Concomitant medicat ions to treat cognition ( rivastigmine, galantamine, donepezil, memantine )
and depression are permitted ,if subjects havebeen ona stable dosageregimen for at least 
8 3weeks prior to Visit 2 1 and is expected to shouldremain on a stabl e dosage for the duration 
of the study .  Concomi tant medications to treat psychosis (clozapi[INVESTIGATOR_050], queti api[INVESTIGATOR_050],and 
pi[INVESTIGATOR_4256]) are permitted, provided the subject has been on a stable dosage regimen for at 
least [ADDRESS_1143305] be contact[CONTACT_479031] t o determine whether the subjectshould continue in the study .
Subjects and their caregiver will should be instructed to consult the investigator or other withthe 
appropriate study  personnel at the site prior toinitiation of any new medicat ions orsupplements 
and prior tochanging dose or discontinuing fro mof any currentconcomitant medicat ions or 
supplements.
TableHBEH.4.Prohibited Concomitant Medications and Supplements
Drug ClassAllowed 
as 
NeededChronic 
Use 
AllowedConditions for Use
All inhibitors of CYP3A4 N N Topi[INVESTIGATOR_824334]/moderate inducers of CYP3A4 N N Topi[INVESTIGATOR_824335] (except clozapi[INVESTIGATOR_050] ,quetiapi[INVESTIGATOR_050], and
pi[INVESTIGATOR_4256] )N N
Trihexyphenidyl and benztropi[INVESTIGATOR_050] N N
Illicit use of any drugs of abuse N N
Abbreviations: CYP3A4 = cytochrome P450 3A4;N = No.
Additional information about concomitant medicatio ns is provided in the Operat ions Manual A 
complete list of prohibited concomitant medicat ions and supplements is included in the 
Operations Manual .
I7S-MC-HBEH(b) Clinical Protocol Page 126
LY31542078.1.1. Permanent Discontinuation from Study Treatment
Possible reasons leading to permanent discontinuatio n of study  treatment:
Subject Decisio n
othe subject or the subject’s designee , for example, parents or legal guardian ,
requests to discont inue the investigational product.
Day 1 stoppi[INVESTIGATOR_004] -Discontinuation due to change in acute vital signs on –Day1 
(Visit3) (Day 1 stoppi[INVESTIGATOR_37660])
(Day1 of dosing)
If during Day 1 (Visit3) and following of study drug dosing, any  of the potenti ally 
clinically significant vital signs criteria ( Table HBEH.3 )are met at [ADDRESS_1143306] should be discont inued from 
the study drug.  The relative value o f the potentially clinically significant vital sign 
criteria is calculated by [CONTACT_824381] 3 seated blood pressure and pulse 
rate at Time 0 of Visit3 (baseline).
TableHBEH.5.Potentially Clinically Significant Vital Sign Criteria
For vital sign measurements that meet the criteria for potentially  clinically significant 
vital signs (Table HBEH.3 )after Visit3, management will be left to the discret ion of the 
investigator and may include discont inuation of study  drug.  Prior to study  drug 
discontinuation after Vi sit3, theTheinvestigator should consult wi th the Lilly CRP or 
designee.
Discontinuati on due to a hepati c event or liver test abnormalit y
Subjects who are discontinued from the studydue to a hepatic event or liver test abnormalit y 
should have addi tional hepatic safety data collected via CRF/electronic data entry eCRF.
Subjects di scontinuing fro m the study treatment prem aturely for any reason shoul d complete an 
early terminati on visit and safety follow-up (V801) to complete AEand other fo llow-up 

I7S-MC-HBEH(b) Clinical Protocol Page 127
LY3154207procedures per Section2(Schedule of Act ivities), Section 9.2(Adverse Events) and Section 9.4
(Safety).
8.1.2. Temporary Discontinuation from Study Treatment
Temporary discontinuation from study drug treatment is allowed if a short -term treatment of an 
excluded medicat ion is necessary, secondary  to hospi[INVESTIGATOR_059], personal  circumstances ,or to 
evaluate the study  drug impact on an uncertain AE. Study drug may be restarted at the 
investigator ’s discretion. If temporary discontinuation is due to an AE, it should be reported to 
the LillyCRP or their representative .Temporary treatment discont inuation and restarting should 
be docum entedin the eCRF . Restarting treatment after a discont inuation period that is greater 
than [ADDRESS_1143307] should co mplete an early terminat ion 
visit and safet y follow-up (V801) to complete safety follow-up as outlined in Section2
(Schedule of Act ivities), Section9.2(Adverse Events), and Section 9.4(Safety).
8.2 Discontinuation from the Study
Subjects discontinuing fro m the study prematurely for any  reason should complete an early 
termination visit and safet y follow-up (V801) ,to completemust completeAE and other safet y 
follow-up per Section 2(Schedule of Act ivities), Section 9.2(Adverse Events), and Section 9.4
(Safety).
9.1.1. Primary Efficacy Assessments
The CoA component of the CDR -CCB has been selected as the primary endpo int for this study  
because it measures the ability to sustain concentration and has demonstrated a significant 
treatment effect in previous trials in subjects with LBD(PDD orDLB)within the time frame of 
the current study (Wesnes et al . 2005; Rowan et al. 2007).  The battery  is a simple “yes/no” 
computerized assessment that is feasible across a range o f PD motor impairment, and as the CoA 
score is based on accuracy  but not speed of response, it is resistant to con founding due to motor 
impairment (Wesnes et al. 2002).  The CDR- CCB is not dependent on skill o f a rater, and hence 
there is less inter -rater variability; learning effects can be minimized wit h training and it targets 
I7S-MC-HBEH(b) Clinical Protocol Page 128
LY3154207domains relevant to subjects with LBD(PDD and DLB). The CDRCCB, described below , has 
been widely used in dement ia research for more than 25 years.  The CoA component of the 
CDRCCB, which includes attention, concentration, and vigilance assessments, will be used as 
the primary  efficacy measu re in this study .  Treatment effects with acet ylcholinesterase 
inhibitors in LBD(PDD and DLB) subjects have been demo nstrated using the CDR (Wesnes et 
al. 2005; Rowan et al. 2007, McKeit h et al 2000)The CoA composite score reflects the abilit y to 
sustain concentration and has demo nstrated a significant treatment effect in previous trials in 
PDDsimilar populat ions subjects (Wesnes et al. 2005; Rowan et al. 2007) .  The CoA is 
calculated from the CDR -CCB by [CONTACT_824382] t ime tasks and then subtracting the number of digit vigilance false 
alarms.
The CDR CCBshould be assessed in the practically defined medicat ion “on” state at all visits.  
The “on” state is defined as the individual best motor funct ion as determined by [CONTACT_824383]  1hour after the dose of dopaminergic therapy .  Every attempt should be made 
to conduct this assessment in the “on” state.  In the except ional circumstance that thi s is not 
possible, the assessment could be done in the “o ff” state.  The “on/off” state should be confirmed 
prior to assessment complet ion of the respective scales listed above.  This information will be 
collected in the eCOA or the eCRF .  If any portion of the assessment is done in the “off” state, 
then that subject should be rated as in the “o ff” state for the who le assessment.
[IP_ADDRESS].3. Alzheimer’s Disease A ssessment Scale –13-Item Cognitive Subscale
The ADAS Cog13should be conducte d in the practi cally defined medicat ion “on” state at all 
visits.  The “on” state is defined as the individual’s best motor funct ion as determined by [CONTACT_824344] [ADDRESS_1143308] this assessment in the “on” state.  In the except ional circumstance 
that this is not possible, the assessment could be done in the “off” state.  The “on/o ff” state 
should be confirmed pri or to assessment complet ion of the respect ive scales listed above.  This 
information will be co llected in the eCOA or the eCRF.  If any portion of the assessment is done 
in the “off” state, then that subject should be rated as in the “o ff” state for the who le assessment.
[IP_ADDRESS].4. Delis -Kaplan Executive Function System
The D-KEFSverbal fluency has shown a significant response (p<.001) to rivastigminetherapy in 
a 24-week randomized controlled trial in subjects with PDD (Em re et al. 2004).  The D-KEFS 
verbal fluency test is preferred as a measure of execu tive funct ion in PDD because it is not 
confounded by [CONTACT_542699] .  This specific measure of execut ive function, a domain commonly 
affected in LBD(PDD and DLB) PDD, will complement other m easures of cognit ion included in 
Study HBEH thatdo not adequately assess this domain.
The DKEFS should be conducted in the practically defined medicat ion “on” state at all visits.  
The “on” state is defined as the individual best motor funct ion as determined by [CONTACT_824383]  1hourafter the dose of dopaminergic therapy .  Every attempt should be made 
to conduct this assessment in the “on” state.  In the except ional circumstance that thi s is not 
possible, the assessment could be done in the “o ff” state.  The “on/o ff” state should be confirmed 
I7S-MC-HBEH(b) Clinical Protocol Page 129
LY3154207prior to assessment complet ion of the respective scales listed above.  This information will be 
collected in the eCOA or the eCRF.  If any portion of the assessment is done in the “off” state, 
then that subject should be rated as in the “o ff” state for the who le assessment.
[IP_ADDRESS].5. Montreal Cognitive Assessment Scale
The MoCA (available at www.mocatest.org) was developed as a brief screening instrument for 
mild cognit ive impairment and mild AD to address limitat ions of the Mini-Mental State 
Examination (MMSE)(Nasreddine et al. 2005).  The MoCA has been ident ified as a suitable 
screening instrument for the detection of cognit ive impairment in PD (Hoops et al. 2009) and 
DLB (McKeith et al. 2017).  Since development, it has been increasingly ut ilized to detect 
cognitive impairment in subjects with PD.The MoCA is divided into 7 subscores (maximum
possible subscore):
Use of MoCA in the context of PD to screen for subjects with cognit ive impairment is consistent 
with the Parkinson Study  Group (PSG) Cognitive/Psychiatric Working Group and MDS 
recommendat ions; although, due to limitat ions of data for the MoCA on change over time or 
change with treatment, the PSG only reviewed the scale in the context of trials where execut ive 
functioning was not a prim ary outcome (Chou et al. 2010; Litvan et al. 2012).  The MoCA has 
consistent ly demonstrated higher sensit ivity than the MMSE for the detection of mild cognit ive 
impairment in various subjectpopulations including PD and DLB (Nasreddine et al. 2005; 
Smith et al. 2007, Zadi koff et al. 2008; Ol son et al. 2011; Freitas et al. 2012 ; Biundoet al. 2016; 
Wang et al . 2013).  Using a cut -off score of less than or equal to 26 as a predictor of cognit ive 
impairment, results fro m the MoCA i dentified from 52% to 83% of subjects wi th PD who had 
already been i dentified as having mild cognit ive impairment (Smith et al. 2007; Hoops et al. 
2009; Nazem et al. 2009).  A MoCA score of 26 or less has also provided excellent 
discriminat ion between subjects who had mild cognit ive impairment and those who did not 
(receiver operating characterist ic curve analyses 78% to 90%; sensit ivity 90%; specificit y 75% 
(Dalrymple-Alford et al . 2010).  Sati sfactory test–retest reliabilit y and inter-rater reliabilit y have 
been demo nstrated (interc lass correlat ion coefficients 0.79 and 0.81, respectively ) (Gill et al. 
2008).  Addit ionally, good correl ation between the MoCA and a neuropsycho logical battery  
(assessing the domains of memory  and execut ive function) was observed (coefficient of 0.72 )
(Gill et al. 2008).
The MoCA should be conducted in the practically defined medicat ion “on” state at all visit s.  
The “on” state is defined as the individual best motor funct ion as determined by [CONTACT_824383]  1hour after the dose of dopam inergic therapy.  Every attempt should be made 
to conduct this assessment in the “on” state.  In the except ional circumstance that thi s is not 
possible, the assessment could be done in the “o ff” state.  The “on/off” state should be confirmed 
prior to com pletion of the respect ive scales listed above.  This informat ion will be co llected in 
the eCOA or the eCRF.  If any portion of the assessment is done in the “off” state, then that 
subject should be rated as in the “o ff” state for the who le assessment.
I7S-MC-HBEH(b) Clinical Protocol Page 130
LY31542079.[IP_ADDRESS]. Penn Parkinson’s Daily A ctivities Questionnaire -[ADDRESS_1143309] ivities of daily living (IADL) that is 
impacted by  [CONTACT_824357].  The PDAQ -[ADDRESS_1143310] –retest reliabilit y, construct validit y, 
sensitivity,and specifi city to PD cogni tive impairment (Brennan et al. 2016a , 2016b), and the 
questionnaire iscompleted by [CONTACT_18629]. The score range is [ADDRESS_1143311]–retest reliabilit y and construct validit y,and is both sensit ive and specific in PD cognit ive 
impairment.  The PDAQ -15 demonstrates abili ty to discriminate between cognit ively normal, 
mild cognit ive impairment ,and dement ia in PD, and correlateswith global measures of 
cognition (dementia rating scale) and perfor mance-based funct ional measures.The PDAQ -[ADDRESS_1143312] of LY 3154207 on cognitive IADL in 
order to understand the relationship between change in cognit ion and change in IADL in PDD
and DLB.
[IP_ADDRESS].1. Movement Disorder Society’s United Parkinson’s Disease Rating Scale
The MDS UPDRS (Part III) should be conducted in the practically defined medicat ion “on” state 
at all visit s.  The “on” state is defined as the individual best motor funct ion as determined by [CONTACT_824344] [ADDRESS_1143313] this assessment in the “on” state.  In the except ional circumstance 
that this is not possible, the assessment could be done in the “off” state.  The “on/o ff” state 
should be confirmed pri or to com pletion of the respective scal es listed above.  This informat ion 
will be co llected in the eCOA or the eCRF.  If any portion of the assessment is done in the “o ff” 
state, then that subject should be rated as in the “o ff” state for the who le assessment.
[IP_ADDRESS]. Measures of Behavioral Symptoms Associated with Parkinson’s Disease 
Dementia
The following measures will serve as tools to assess the impact of LY3154207 on behavioral 
symptoms associated with LBD(PDD and DLB) PDDaswell as the effects on motor funct ions.
[IP_ADDRESS].1. Neuropsychiatric Inventory
The NPI [INVESTIGATOR_824336] .
9.1.3. Appropriateness of Efficacy Assessments
As previously stated, the CoA has demo nstrated a significant treatment effect in previous trials in 
PDD subjects similar popul ations(Wesnes et al. 2005; Rowan et al.2007).  The CoA is a 
parameter calculated using the CDR-CCB,which has been widely used in dement ia research for 
more than [ADDRESS_1143314] demonstrated an abilit y to 
minimize learning effects up to 8 weeks (Wesnes, personal co mmunicat ion).  The CDR -CCB 
system also has a l arge norm ative database of over 6000 healthy vo lunteers from 18 to 87 years 
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143315] of treatment on cognit ive changes (Wesnes 2008).
The secondary  efficacy measures described in Section9.1.2are also established measures of 
cognitive function and related outcom es, as well as behavioral symptoms associated with PD 
dementiaand DLB, and considered appropriate assessments for the mildtomoderate PD 
dementia populationthis popul ation.
9.2.1. Serious A dverse Events
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the patient’s final study  dispositionsubjectsummary
CRF has been co mpleted).  However, if the investigator learns of any SAE, including a death, at 
any time after a subject has been discharged from the study , and he/she considers the event 
reasonably  possibly related to the study  treatment or study  participation, the investigator must 
promptly notify Lilly .
9.3. Treatment of Overdose
For this study, any dose of invest igational product greater than twice participant’s assigned daily  
dose within a 24-hour time period will be considered an overdose.
In the eve nt of an overdose, the invest igator or treating physician shoulduse supportive therapy  
as necessary  and contact [CONTACT_824360] (or designee) immediately .
Decisions regarding dose interruptions or modifications will be made by [CONTACT_32844] h the CRPbased on the clinical evaluat ion of the participant.
Refer to the LY3154207 IB.
9.4.1. Electrocardiograms
Electrocardiograms willinitiallybe interpreted by  a qualified physician healthcare provider (the 
investigator or qualified designee) at the site as soon after the time of ECG collect ion as possible, 
and ideally  while the subjectis still present to determine whether the subjectmeets entry criteria
atthe relevant visit(s) and for immediate subjectmanagement, should any clinically rel evant 
findings be ident ified.
9.4.5. Physician Withdrawal Checklist
The Penn Physician Wit hdrawal Checklist (PWC -20) is a 20-item checklist that will be used to 
assess the presence and severit y of withdrawal symptom s.  The PWC -[ADDRESS_1143316] and caregiver, separately.  The scale was originally developed to assess the severit y 
of withdrawal symptom s in anxio lytic medication discontinua tion (Rickels et al . 2008).  The 
PWC-[ADDRESS_1143317] ( Schweizer et al. 1990; Rickels et al. 1990).  
The [ADDRESS_1143318]’s level of symptoms on a variet y of withdrawal symptoms since 
last visit.  Each of the 20 i tems are scored as 0 (not present), 1 (mild), 2 (moderate), 3 (sev ere).
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143319] ivities (Section2),venous blood samples
will be collected to determine the plasma concentrations of LY3154207.  Instructions for the 
collection and handling of blood samp les will be provided by [CONTACT_456] .  At Visit3, a PK 
sample is to be collected within 1 to 3 hours after the drug is administered at the site.  At Visit 4, 
Visit5, Visit 8,and ET/DC, the PK sample can be collected at any t ime during the visit.  At 
Visit11, the PK sample should be collected prior to the drug being administered at the site.  The 
date and time (24-hour clock time ) of the PK sample collect ion as well as the da te and time of 
the dose administration immediately preceding the PK sampl ingwill be entered in the 
eCRFrecorded.
9.7.1. Whole Blood Sample for Pharmacogenetic Research
The collection and storage of samples for genetic studies (including samples for 
pharmacogenetic studies) is to continue our ongoing efforts to understand the correlat ion 
between the clinical outcome wit h the drug(s) under study  in the clinical trial and the genet ic 
makeup of the subject.  DNA extracted from the who le blood samples co llectedfrom the subjects 
maybe used to generate genetic data on a genome genoty pi[INVESTIGATOR_362337] . The genoty pe data maybe 
used to perform a targeted genetic analysis of the genes of interest to understand potential safet y 
and efficacy  concerns shoul d they arise either during this trial, future trials for this drug, or if the 
drug is launched and on the market. For example, genet ic variations in well-known 
drug-metabolizing enzymes, such as cytochro me P450 (CYP), including CYP3A4, CYP1A2, and 
so on, could be a potential set of genes of interest to answer any  safety concerns.
Samples will notbe used to conduct unspecified disease or populat ion genetic research either 
now or in the future.  Samples maybe used to investigate variable response to LY3154207 and to 
investigate genet ic variants though t to play a role in PDLBD.  Assessment of variable response 
may include evaluation o f AEs or differences in efficacy.
10.1. Sample Size Determination
Approximately  [ADDRESS_1143320] size for LY3154207 rel ative to placebo on the CoA is 0.4 with the sample size of 340there 
will be over80% probabilit y of passing this criterion. A 20% discont inuation rate by [CONTACT_10585] 12 
has been accounted for in the sample size determination .
10.2. Populations for Analyses
Population Description
EnteredEnrolled All subjects who sign informed consent
CCI
I7S-MC-HBEH(b) Clinical Protocol Page 133
LY315420710.3.2.4. Concomitant Therapy
Prior medicat ions are defined as those that stop before randomizat ion (Visit32). Concomitant
medications are defined as those being taken on or after randomizat ion (Visit 32).  A summary  of
concomitant medicat ions will be presented as frequencies and percentages for each treatment
group. If the start or stop dates of therapi[INVESTIGATOR_824322], the therapy will 
be deemed conco mitant.
[IP_ADDRESS] Secondary Efficacy Analyses
The secondary  efficacy outcom es (ADCS-CGIC, PDAQ- 15, ADAS -Cog13, CDR-CCB PoA, 
D-KEFS, MoCA, NPI, ESS, and MDS -UPDRS) will be assesse d at the 12 -week time po intas 
the primary  analysis.  Each of these secondary  endpoints will be analyzed using a nMMRM 
model,which will include terms for: baseline value, treatment, visit, and the relevant interaction 
terms.  Further covariates may be in cluded such as age, site, and the severit y of PD motor 
function as well as severit y of dementia at baseline as appropriate.  The change of the score from 
baseline will be the dependent variable.  If subscores for a particular scale are deemed clinically  
relevant to analysis, it will be completed as an exploratory  analysis.
[IP_ADDRESS]. Tertiary/Exploratory Efficacy A nalyses
The following exploratory  efficacy endpoints will be analyzed using MMRM model.
Change in total MDS-UPDRS (sum of PartsI to III) and individual subscales –
non-motor experiences o f daily living ( PartI), motor experiences of daily  living 
(PartII), motor exam (Part III), and motor complications ( Part IV) subscales from 
baseline to Week 12
Change in GDS -S score from  screening to Week 12
Change in QUIP score from baseline to Week 12
Exploratory Digital Biomarker Analysis:  Data from digital bio markers (Lilly  Trial app and 
Actigraphy watch) from baseline to Week [ADDRESS_1143321].  The data may also be used to explore the 
validity and reliabilit y of these assays in PDD LBD subjects.  If applicable, potential predictive 
biomarkers associated with interpretable clinical benefit may further be examined wit h biological 
evidence.
[IP_ADDRESS].Vital Signs and Weight
Day1 (Visit3) in-clinic BP and pulse rate change post first dose
I7S-MC-HBEH(b) Clinical Protocol Page [ADDRESS_1143322] 
day of study drug dosing will be analyzed using an MMRM analysis wit h baseline value, 
treatment, time postdose (hours), and the relevant interaction terms.  Two baselines will 
be considered:  the Visit 3 pretreatment value (time0) and the time -matched baselines 
from Visit2 (hourly value 0 to 6 hours).  For the second of these, there is no 
time-matched value for the 7- and 8-hour time points of Visit 3, so the 6 -hour time point 
of Visit2 will be used as th eir baseline value.  A separate change from baseline analysis 
will be co mpleted for each baseline approach.
Change in in -clinic BP and pulse rate from baseline (Visit 2, predrug) up to Week 12 
(V11)
Change in in -clinic BP and pulse rate measured at Visit2 (daily average 0 to 6 hours) to 
the in-clinic BP and pulse rate measured at Week 6/Visit8 and Week 12/Visit11 (daily 
average 0 to 6 hours) will be analyzed by [CONTACT_824384], 
treatment, and the rel evant interaction terms.  Anal ysis at 6weeks will help to evaluate 
any significant changes (if any ) in BP and pulse rate earlier than 12 weeks (end of study ) 
and if they  accommodate by 6weeks.
Daily average change in ho me BP measurements and pulse rate from baseline to 
Week12.
10.3.4.Safety A nalyses
The PWC -20 endpoint will be analyzed using an ANCOVA model wit h a covariate for baseline 
score.The primary analyses will be a change fro m baseline (Visit 11) to the in person fo llow up 
visit (Visit 801).
[IP_ADDRESS]. Subgroup A nalyses
The CDR-CCBCoA and its co mponentscores will be assessedbased on the fo llowing 
subgroups: concomitant PD therapy, conco mitant AChEI therapy , Land timing of dementia 
onset (less or equal  to 1year versus greater than 1 year relat ive to onset of motor symptomsLBD
(PDD orDLB), and GDS (less than or equal to 6)). All subgroup analyses will be considered 
exploratory  andadditional subgroup analyses may  be perform ed as suggested by  [CONTACT_26739].
10.3.7 Interim Analyses
A limited number of pre -identified individuals may gain access to the limited unblinded data, as 
specified in the unblinding plan .  Information that may unblind the study  during the analyses will 
not be reported to study  sites or blinded study  team until the study  has been unblinded.
The efficacy and safet y interim analyses will be completed and reviewed by [CONTACT_824370].
I7S-MC-HBEH(b) Clinical Protocol Page 135
LY3154207Only the IAC is authorized to evaluate unblinded interim efficacy and safety  analyses.   Study 
sites will receive information about interim results ONLY if they need to know for the safet y of 
their subjects.
Safety interims will be conducted on the number of subjects on each treatment who met the 
potentially clinically significant vital signs criteria at 3 consecut ive time po ints at Visit 3 (Day1 
stoppi[INVESTIGATOR_004]).  This will be done after 50, 100, and [ADDRESS_1143323] had 
the opportunit y to complete Visit 11 (Week 12) assessments.   The statist ical analysis will include 
all 170subjects in the interim analysis, which will evaluate both the efficacy  and the safet y.  In 
addition, the PK data m ay be reviewed .  An addit ional interim analysis o f efficacy and safet y 
may be conducted prior to study  completion for internal decisio n making. While Aall potential
efficacy analyses may be used for internal decisio n making, but theyare not planned to stop the 
study for efficacy  or futility because this is an exploratory  study and there are other key  
endpoints being assessed, not just the primary endpoint.
CCI
Leo Document ID = cfa0b6c1-d553-4c3f-9316-73c00b4eef9a
Approver: 
Approval Date & Time: 25-Jan-2019 16:25:11 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 25-Jan-2019 21:17:45 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]